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Amyotrophic Lateral Sclerosis (ALS) is the most common adult motor neuron 
disease. The majority of ALS cases are sporadic (SALS), but 10% of patients have a familial 
form of ALS (FALS). Mutations in Fused in Sarcoma (FUS) occur in approximately 4% of 
FALS and less than 1% of SALS. A hallmark feature of ALS is the degeneration of upper and 
lower motor neurons in the brain and spinal cord; however, the mechanism underlying 
this loss is not known. Studies of degenerative mechanisms have been impeded by the 
inaccessibility of human neural tissue. A possible solution is to use induced pluripotent 
stem cells (iPSCs) derived from patients, which may be differentiated into the cell types 
affected by disease. 
To test whether patient-specific stem cells can be used to model aspects of ALS 
pathogenesis, iPSC lines were generated from a patient carrying the pathogenic FUS 
R521C mutation. FUS iPSCs derived from patient fibroblasts and WT iPSCs derived from 
fibroblasts from two healthy controls were differentiated into neural progenitors and 
motor neurons. FUS iPSC-derived neuronal cells recapitulate key aspects of FUS-
associated ALS, including mislocalisation of FUS protein, the redistribution of FUS protein 
into cytoplasmic stress granules, and increased apoptotic cell death. 
The second study uses this iPSC model to investigate the effects of mutant FUS on 
dendritic morphology and synaptic regulation. FUS iPSC-derived neurons display 
abnormal dendritic morphology, such as reduced neurite outgrowth and reduced density 
of dendritic protrusions. FUS iPSC-derived neurons also show differences in the 
localisation of synaptic proteins. This study suggests that physiological levels of mutant 
FUS protein affect the morphology and synaptic structure of human neurons. 
These studies validate the stem cell approach to disease modelling and provide 
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1.1 MOTOR NEURONE DISEASE  
1.1.1 ALS 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative condition 
characterised by the selective loss of upper and lower motor neurons. Muscle weakness 
usually begins in one limb, or the throat, but gradually spreads to affect all skeletal 
muscles such that patients are unable to walk, talk, dress or toilet themselves. Death, 
usually due to respiratory failure, typically occurs 2-5 years from symptom onset. The 
relentless accumulation of disabilities and progressive loss of autonomy engenders a 
feeling of hopelessness. ALS is the most common reason that people seek Euthanasia, 
where the physician acts directly to end the patient’s life. In the Netherlands where 
“physician assisted suicide” is legal, 20% of ALS patients choose to die this way, where the 
physician provides the means for death, most often with a prescription, but the patient 
ultimately administers the lethal medication (Veldink et al. 2002). 
ALS has a prevalence of 3 to 6 per 100.000 and an incidence of 1 to 3 per 100,000 
(Chiò et al. 2013). The onset of the disease usually occurs in late-adulthood, although 
juvenile onset (< 25 years) and early-onset ALS (< 45 years)occurs in about 10% of all 
cases (Turner et al. 2012). The clinical symptoms include fasciculations, muscle wasting 
and/or spasticity leading to progressive paralysis. There is currently no cure, and the sole 
disease-modifying treatment, riluzole, has only a modest effect on survival.  
ALS is now recognised as being a part of a disease spectrum that is linked to 
frontotemporal dementia (FTD) due to overlap in the pathology and common genetic 
origins for these two neurodegenerative conditions. FTD is the second most common form 
of early-onset dementia, after Alzheimer's disease. It is characterised by the loss of 
neurons in the frontal and temporal cortices. This results in behaviour and personality 
changes, and the loss of language skills. Some ALS cases demonstrate cognitive 





There is no definitive test to diagnosis ALS. Instead, the diagnosis is made through 
a clinical examination and a series of tests to rule out diseases that have the same 
symptoms as ALS, according to the El Escorial criteria (Brooks et al. 2000). The diagnostic 
tests include electromyography, nerve conduction velocity, magnetic resonance imaging 
and muscle or nerve biopsy. Post mortem pathological examination may be done to 
confirm the clinical diagnosis of ALS. 
 
1.1.3 Genetics 
Most ALS cases are sporadic, but approximately 5-10% have a family history 
(Byrne et al. 2011; Chiò et al. 2013). Although sporadic cases are classically defined as 
those with a lack of clear genetic association, mutations in C9ORF72, TARDBP and SOD1 
have also been observed in sporadic cases (Chio et al., 2008; DeJesus-Hernandez et al., 
2011; Kabashi et al., 2008; Renton et al., 2011; . In addition, de novo mutations have 
recently been reported in sporadic ALS patients (Chesi et al., 2013). This may arise from a 
lack of clinical information from the patient’s family, as increased risk has been reported 
in relatives of people with SALS (Hanby et al., 2011). 
Familial ALS (FALS) cases mainly exhibit autosomal dominant inheritance with 
incomplete penetrance, but autosomal recessive (where both copies of the gene in each 
cell have mutations; Andersen et al., 1996) and X-linked inheritance (where the gene is 
located on the X chromosome; Deng et al., 2011) have previously been reported. For 
instance, incomplete penetrance has been reported for the C9ORF72 expansion, where the 
expansion has been observed in controls (Smith et al., 2013).  
50% of familial ALS cases are associated with mutations in four genes, SOD1, 
C9ORF72, FUS and TARDBP in descending order of frequency of occurrence (Fig. 1.1) (Ling 
et al. 2013). TARDBP and FUS mutations are rarely observed in FTD, whereas the most 
common mutation in ALS and FTD is a massive expansion of a hexanucleotide repeat in 
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the first intron of C9ORF72 (DeJesus-Hernandez et al. 2011; Renton et al. 2011).  A 
summary of the genes linked to ALS is shown in Table 1.1. Some of the recent genetic 
discoveries will be discussed below. 
 
 
Figure 1.1 Proportion of ALS explained by each gene in European populations. (Figure 
adapted from (Renton et al. 2014)  
 
Table 1.1 Genes implicated in the pathogenesis of ALS (genes in bold delineate causative 
genes, other genes delineate risk factors). 
Function Gene Name Location Reference 
Oxidative 
stress 
SOD1 Superoxide dismutase 1 21q22 (Rosen et al. 1993) 
PON1-3 Paraoxonase 1-3 7q21 (Saeed et al. 2006; 
Slowik et al. 2006) 





ANG Angiogenin 14q11 (Greenway et al. 2004) 
SETX Senataxin 9q34 (Chen et al. 2004) 
TARDBP TAR DNA binding 
protein 
1p36 (Kabashi et al. 2008; 
Sreedharan et al. 2008) 
FUS Fused in sarcoma 16p11 (Kwiatkowski et al. 
2009; Vance et al. 
2009) 
ELP3 Elongation protein 3 
homolog 
8p21 (Simpson et al. 2009) 
ATXN2 Ataxin 2 12q24 (Elden et al. 2010) 
TAF15 TATA box binding 
protein (TBP)-
associated factor 
17q11 (Couthouis et al. 2011) 
C9ORF72 Chromosome 9 open 
reading frame 72 
9p21 (DeJesus-Hernandez et 
al. 2011; Renton et al. 
2011) 
HNRNPA2B1 Heterogeneous nuclear 
ribonucleoprotein 
A2/B1 
7p15 (Kim et al. 2013) 
HNRNPA1 Heterogeneous nuclear 
ribonucleoprotein A1 
12q13 (Kim et al. 2013) 





associated protein B and 
C 
20q13 (Nishimura et al. 2004) 




FIG4 SAC domain-containing 
protein gene family 
6q21 (Chow et al. 2009) 




9p13 (Johnson et al. 2010) 
SQSTM1 Sequestosome 1 5q35 (Fecto et al. 2011) 




NEFH Neurofilament heavy 
polypeptide 
22q12 (Figlewicz et al. 1994) 
DCTN1 Dynactin 1 2p13 (Münch et al. 2004) 
NTE Neuropathy target 
esterase 
19p13 (Rainier et al. 2008) 
KIFAP3 Kinesin-associated 
protein 3 
1q24 (Landers et al. 2009) 
PFN1 Profilin 1 17p13 (Wu et al. 2012) 
Other or 
unknown 
ALS2 Alsin 2q33 (Hadano et al. 2001) 
SPG11 Spatacsin 15q14 (Orlacchio et al. 2010) 
SIGMAR1 Sigma non-opioid 
intracellular receptor 1 
9p13 (Al-Saif et al. 2011) 
 
 
1.1.3.1 Principal genes 
SOD1 
The first locus associated with ALS was identified on Chromosome 21 by linkage 
analysis (Siddique et al., 1991). The mutated gene was subsequently identified as the gene 
encoding the antioxidant enzyme copper-zinc superoxide dismutase (SOD1) (Rosen et al. 
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1993). Rosen et al. (1993) originally identified 11 missense mutations in FALS. 177 
missense and nonsense mutations have since been reported (ALS Online database, ALSoD; 
(Abel et al. 2012).  
Most SOD1 mutations result in single amino acid substitutions and occur 
throughout the entire protein, with some clustering in exons four and five (Shaw et al. 
1998). Mutations in SOD1 occur in 20% of FALS and 1% of SALS (Shaw et al. 1998; Renton 
et al. 2014). SOD1 cases generally have a lower age of onset compared with the familial 
ALS cases without SOD1 mutations (Cudkowicz et al. 1997). SOD1 cases demonstrate 
heterogeneous phenotypes, with some mutations, such as Ala4Val, giving rise to an 
aggressive phenotype, while others are associated with a milder phenotype, such as 
Asp90Val. SOD1 cases have predominantly lower motor neuron features, without 
cognitive impairment (Wicks et al. 2009). The pathology of SOD1-associated ALS appears 
to be distinct from other types of ALS. While protein aggregates containing SOD1 may be 
seen in FALS patients with SOD1 mutations (Watanabe et al. 2001), this feature is not 
always present (Shaw et al. 1997) and is rarely observed in most sporadic cases.  
Observations from cellular and animal models suggest that mutant SOD1 causes 
ALS by a toxic gain of function. SOD1 functions as an enzyme to catalyse the dismutation of 
superoxide anions and the production of free radicals with hydrogen peroxide as a 
substrate. Different ALS mutant forms of SOD1 have a wide range of dismutation activity 
(from nil to normal) and enhanced radical-generating function compared to WT SOD1 
(Yim et al. 1996), suggesting that mutant SOD1 may play a modifying role in ALS (Saccon 
et al., 2013), but does not cause ALS by a loss of function. Rather, mutant SOD1 and 
oxidised WT SOD1 are misfolded and aggregate, potentially causing dysfunction of many 
cellular processes, including axonal transport (Bosco et al. 2010), suggesting a gain of toxic 
function may arise from both mutant and oxidised WT SOD1. Injection of mutant SOD1 in 
motor neuron cultures induces aggregation of SOD1 and motor neuron death mediated by 
glutamate stimulation (Roy et al. 1998). There is a strong link between mutant SOD1 and 
excitotoxicity as a pathogenic mechanism underlying motor neuron degeneration. Spinal 
26 
 
motor neurons from mutant SOD1 mice are characterised by persistent Na+ current and 
enhanced neuronal excitability, which could be reduced by riluzole, the sole available 
treatment for ALS (Kuo et al. 2005).  
 
TARDBP 
In 2006, TDP-43 was identified as the major protein of pathological inclusions of 
postmortem tissue in 90% of ALS patients, 60% of FTD patients, as well as other 
neurodegenerative diseases (Neumann et al. 2006). Subsequently, three independent 
candidate gene studies reported the mutations in the gene encoding TDP-43, (TAR DNA-
binding protein, TARDBP), in familial and sporadic ALS patients (Gitcho et al. 2008; 
Kabashi et al. 2008; Sreedharan et al. 2008). Sreedharan et al. (2008) showed that mutant 
TDP-43 protein underwent fragmentation and was neurotoxic in vivo. 50 mutations in 
TARDBP have now been observed (ALSoD), accounting for 4% of familial and 1% of 
sporadic cases (Renton et al. 2014). 
All mutations identified reside in the carboxylate terminal (C-terminal) of the 
protein, with the exception of the D169G mutation. FALS cases with TARDBP mutations 
have pathology that is indistinguishable from SALS cases; the majority of cases are 
characterised by TDP-43-positive ubiquitinated inclusions in affected neurons and glia of 
the motor system (Van Deerlin et al. 2008). Most TDP-43 cases are associated with 
classical ALS symptoms and signs but have a lower age of onset and a slower disease 
course compared to non-familial cases (Corcia et al. 2012), whereas others are 
concomitant with dementia and Parkinsonism (Lattante et al. 2013). TDP-43 inclusions 
have also been observed in a number of other diseases, including FTD, Alzheimer’s 
disease, Down syndrome and Parkinson’s disease (Lagier-Tourenne et al. 2010).  
TDP-43 is a 43-kDa protein that is ubiquitously expressed in various human 
tissues, including the brain and spinal cord. It was originally discovered in 1995 as a 
transcriptional repressor of the transactive response DNA binding element of the HIV1 
virus (Ou et al. 1995). TDP-43 shuttles between the nucleus and cytoplasm, interacting 
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with other hnRNPs to bind RNA and function as a translational activator and repressor 
(Ayala et al. 2008; D'Ambrogio et al. 2009).  
It remains unclear whether mutant TDP-43 causes ALS via a gain or loss of 
function. Nuclear clearing of TDP-43, accompanied by the accumulation of TDP-43 in the 
cytoplasm, is often observed in surviving neurons in patients with TARDBP mutations 
(Van Deerlin et al. 2008), suggesting that loss of nuclear function of TDP-43 as a 
component of the disease process. The loss of TDP-43 in mice results in embryonic 
lethality, whereas heterozygous TARDBP mice exhibit motor defects despite a lack of 
neurodegeneration or motor atrophy (Kraemer et al. 2010) . The selective removal of 
TDP-43 from motor neurons leads to progressive weight loss and motor impairment in 
mice, along with degeneration of motor axons and skeletal muscle and denervation in the 
neuromuscular junction (NMJ) (Iguchi et al. 2013). However, the mortality of these mice 
were not different from control mice (Iguchi et al. 2013).  Therefore, loss of TDP-43 
function may contribute to the development and progression of disease, but it does not 
appear to be sufficient to lead to fatal motor neuron disease. 
The expression of WT TDP-43 in C. elegans results in neurodegeneration, 
locomotor deficits, and reduced lifespan (Ash et al. 2010). This study showed that the 
locomotor deficit correlated with the levels of endogenous protein, suggesting that 
neurotoxicity may result from excess TDP-43 function (Ash et al. 2010). The expression of 
either human WT or mutant TDP-43 in mice has also been shown to cause degeneration of 
motor neurons and the development of ALS-related motor dysfunction (Wils et al. 2010; 
Igaz et al. 2011; Arnold et al. 2013).  However, the overexpression of human TDP-43 in 
mice is accompanied by a reduction in endogenous TDP-43 (Arnold et al. 2013),  making it 
difficult to differentiate between a gain or loss of function mechanism in TDP-43 
transgenic mice. Similarly, both overexpression of human TDP-43 and knockdown of 
endogenous tardbp in zebrafish causes a motor phenotype and motor neuron toxicity 
(Kabashi et al. 2010) . Thus, there is evidence to suggest that both mechanisms may be 
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Shortly after the identification of TARDBP mutations in ALS, mutations in FUS, 
another gene encoding a DNA/RNA-binding protein, were reported by two independent 
groups in 2009 (Kwiatkowski et al. 2009; Vance et al. 2009). This locus on Chromosome 
16q had previously been linked to ALS (Abalkhail et al. 2003; Ruddy et al. 2003; Sapp et al. 
2003). Vance et al. (2009) demonstrated in transfected cells that the mutations reduced 
the nuclear import of FUS leading to cytoplasmic accumulation. They also detected large 
FUS-immunoreactive inclusions in spinal cord and motor neurons.  
The prevalence of FUS mutations is ~4% in FALS and 1% in SALS and so far, 77 
FUS mutations have been identified (ALSoD). Most FUS mutations are missense mutations; 
however two nonsense mutations have also been reported, in addition to insertion and 
deletion mutations. Similar to the TARDBP mutation spectrum, most mutations are 
clustered within the 12 amino acids of the C-terminal that contains the nuclear localizing 
signal (Lagier-Tourenne et al. 2010).  Unlike TARDBP, a number of amino terminal (N-
terminal) mutations have also been identified. Whereas the C-terminal mutations are 
mostly associated with familial cases, the N-terminal mutations are more commonly 
sporadic. The finding that mutations identified in sporadic cases are localized in the 
glycine-rich region suggests several possibilities, that SALS patients with FUS patients may 
represent sporadic cases due to the lack of information about affected relatives or that N-
terminal FUS mutations may represent low penetrance FUS variations (Corrado et al., 
2010). Missense variants in the N-terminus of FUS have also been reported in controls 
(Corrado et al., 2010; Merner et al., 2012); therefore, further studies using functional 
assays are required to determine the involvement of these mutations in ALS pathogenesis. 
A different set of mutations in FUS has been reported in essential tremor, which is 
a fairly benign slowly progressive and non-fatal movement disorder (Rajput et al. 2013). 
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Some FUS mutations are associated with an earlier onset and aggressive disease 
progression (Conte et al. 2012; Sproviero et al. 2012). FUS cases often present with signs 
of lower motor neuron degeneration and display limited upper motor neuron involvement 
(Blair et al. 2010). The only biochemical feature of FUS inclusions to date is decreased 
solubility (Kwiatkowski et al. 2009), in contrast to other proteins implicated in 
neurodegenerative diseases, such as Amyloid-beta (Aβ), TDP-43 and α-synuclein, which 
show abnormal cleavage and/or phosphorylation (Baba et al. 1998; Neumann et al. 2006).  
FUS-immunoreactive inclusions are also a common feature of rare and atypical 
forms of FTD, such as neuronal intermediate filament inclusion disease and basophilic 
inclusion body disease (Munoz et al. 2009; Urwin et al. 2010). However, FUS mutations are 
rarely observed in FTD patients, and dementia is rare in FUS-mediated ALS (Lagier-
Tourenne and Cleveland 2009; Blair et al. 2010; Groen et al. 2013). FUS inclusions have 
also been reported in polyglutamine disease, such as Huntington’s disease, spinocerebellar 
ataxia and dentatorubral-pallidoluysian atrophy (Lagier-Tourenne et al. 2010). The 
functions this protein and the implications of mutations in this gene will be discussed 
further in Section 1.2.  
 
C9ORF72 
Another major breakthrough in ALS and FTD research came in 2011 with the 
identification of a large GGGGCC hexanucleotide repeat expansion in a noncoding region of 
the C9ORF72 gene (DeJesus-Hernandez et al. 2011; Renton et al. 2011).  This repeat 
expansion is the most common cause of ALS and FTD, accounting for up to 80% of familial 
ALS-FTD, 20-50% of familial ALS and 10-30% of FTD (Ling et al. 2013; Smith et al. 2013). 
In healthy individuals, this hexanucleotide is repeated 2-5 times. In ALS patients, the 
length of the expansion may contain hundreds or thousands of repeats. 
C9ORF72 cases show combined upper and lower motor neuron degeneration and 
classical ALS pathology with TDP-43 inclusions in spinal motor neurons (Cooper-Knock et 
al. 2012). In addition, p62- and ubiquitin-positive, TDP-43 negative neuronal and glial 
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cytoplasmic inclusions containing dipeptide-repeat proteins are prevalent in non-motor 
regions of C9ORF72 cases (Mackenzie et al. 2014). Another unique feature of C9ORF72 
cases is the formation of nuclear RNA foci in the frontal cortex, hippocampus and 
cerebellum (DeJesus-Hernandez et al. 2011; Mackenzie et al. 2014).  
Symptoms and signs of FTD or mild cognitive impairment are often present in 
C9ORF72 ALS cases (Cooper-Knock et al. 2012). In addition, these cases often have a 
family history of other neurodegenerative diseases being diagnosed, such as Parkinson’s 
disease, Huntington’s disease and Charcot-Marie-Tooth disease (Cooper-Knock et al. 
2012), which may be coincidental or due to phenotypic variation. The molecular 
mechanism by which the repeat expansion causes ALS or FTD is highly controversial. 
Three different pathogenic mechanisms have been proposed. Loss of function 
(haploinsufficiency) arising from failure of the mutant transcript to be translated into 
C9ORF72 protein seems unlikely as no other mutations in the gene have been identified 
and homozygosity of the mutant does not cause a more severe phenotype (Fratta et al. 
2013). Gain of function may either be due to direct toxicity from the accumulation of sense 
(GGGGCC)- and antisense (GGCCCC)- containing RNA forming RNAse resistant foci that 
sequester RNA binding proteins (Lee et al. 2013; Mori et al. 2013; Xu et al. 2013; Zu et al., 
2013) or repeat RNA-mediated toxicity or protein-mediated toxicity due to repeat-
associated non-ATG translation of dipeptides from forward (GP, GA, GR) and antisense (PR 
and PA) RNA strands (Ash et al. 2013; Mori et al. 2013). 
 
1.1.3.2 Genes involved in protein homeostasis 
Ubiquilin 2 (UBQLN2) 
In 2011, mutations in UBQLN2 were shown to cause X-linked ALS and ALS-FTD 
(Deng et al. 2011). UBQLN2 mutations are rarely observed in FALS and SALS, likely 
accounting for less than 1% of both (Daoud and Rouleau 2011). ALS patients carrying 
UBQLN2 mutations are associated with an early age of onset, especially in male patients 
with disease progression ranging from 6 months to 5 years (Deng et al. 2011; Gellera et al. 
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2013). UBQLN2 cases are characterised by widespread upper motor neuron signs, and 
often also present with dementia (Deng et al. 2011; Gellera et al. 2013). The pathology of 
FALS patients with UBQLN2 mutations and SALS patients are typified by the presence of 
ubiquilin-2 and ubiquitin-positive inclusions, which also contain TDP-43, FUS and 
optineurin (Deng et al. 2011; Williams et al. 2012). This suggests that mutations in 
UBQLN2 lead to an impairment of protein degradation via the ubiquitin proteasome 
system (UPS) (Deng et al. 2011). 
 
Sequestosome 1 (SQSTM1) 
Mutations in SQSTM1 were identified in FALS and SALS in a candidate gene study 
(Fecto et al. 2011). These mutations occur throughout the protein and correspond to 
about 1.1% in FALS and 4% in SALS (Fecto et al. 2011; Teyssou et al. 2013). SQSTM1 
encodes the ubiquitin-binding adaptor protein p62, which enhances the formation and 
degradation of polyubiquitin-containing bodies by autophagy and the UPS. SQSTM1 
patients have p62- and TDP-43-positive inclusions and increased levels of p62 and TDP-43 
protein in the spinal cord (Teyssou et al. 2013). The mean age at onset of SQSTM1 patients 
was similar to those with SOD1, FUS or TARDBP mutations, whereas the duration of 
disease was relatively longer (Fecto et al. 2011). 
 
Optineurin (OPTN) 
OPTN mutations were first identified in Japanese FALS and SALS patients 
(Maruyama et al. 2010). Mutations in this gene had been previously linked to adult-onset 
open-angle glaucoma (Rezaie et al. 2002). Optineurin is involved in maintaining the Golgi 
complex, membrane and vesicle trafficking.  OPTN mutations account for about 1% of both 
FALS and SALS patients (Del Bo et al. 2011). The spinal cord of OPTN patients shows 
cytoplasmic inclusions immunopositive for OPTN, ubiquitin and TDP-43 (Maruyama et al. 
2010). Interestingly, Maruyama et al. (2010) also found that SOD1-positive inclusions 
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from SOD1 FALS cases also label positively for OPTN, suggesting that OPTN may be 
involved in the pathogenesis of ALS arising from several different origins.  
 
Valosin-containing protein (VCP) 
Mutations in the valosin containing protein (VCP) were identified in ALS using 
exome sequencing of two members of an Italian family (Johnson et al. 2010). VCP 
mutations are also causative of inclusion body myopathy, which may also be associated 
with Paget’s disease of bone and FTD (IBMFTD) (Watts et al. 2004). VCP is a protein that is 
involved in ubiquitin-dependent proteasome degradation and the pathology of ALS 
patients with VCP mutations includes cytoplasmic neuronal inclusions in the spinal cord 
and frontal cortex. VCP patients have a classical ALS phenotype along with some degree of 
cognitive impairment and mutations account for 1-2% of FALS (Johnson et al. 2010). VCP 
mutations are associated with a more rapidly progressive disease course and age of onset 
similar to SOD1, FUS or TARDBP mutations (Johnson et al. 2010; Koppers et al. 2012). 
 
Chromatin-modifying protein 2B (CHMP2B) 
CHMP2B mutations were first identified in a large Danish kindred with FTD 
(Skibinski et al. 2005), and later found in ALS (Parkinson et al. 2006). CHMP2B mutations 
may account for about 1% of FALS cases (Cox et al. 2010). This gene encodes a protein 
involved in endosome-lysosome-autophagy function. CHMP2B patients show 
neuropathology consistent with ALS/FTD, such as p62- and TDP-43-positive inclusions in 
oligodendroglia, as well as upper motor neuron degeneration typical of primary lateral 
sclerosis (Parkinson et al. 2006; Cox et al. 2010). CHMP2B patients with ALS show a 
variable age of onset and a typical disease progression (Cox et al. 2010). 
 
Polyphosphoinsoitide phosphatase (FIG4) 
Mutations in FIG4 were reported in about 2% of ALS and primary lateral sclerosis 
patients with a typical age of onset but a longer disease duration of 9 years (Chow et al. 
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2009). FIG4 mutations are also found in Charcot-Marie-Tooth disease (Chow et al. 2007). 
FIG4 is involved in the trafficking of endosomal vesicles to the Golgi network. Kon et al. 
(2014) reported that FIG4 is not localised in TDP-43 inclusions in SALS or FTD, but is 
observed in inclusions in other neurodegenerative diseases, such as Pick’s disease, 
Parkinson’s disease and dementia with Lewy bodies (Kon et al. 2014). 
 
Vesicle-associated membrane protein-associated protein B/C (VAPB) 
In 2004, a missense mutation in VAPB was found in a large kindred with adult 
spinal muscular atrophy (SMA) where two individuals had an ALS phenotype (Nishimura 
et al. 2004). Symptom onset occurs from 25-55 years and the disease course ranges from 
2-60 years. VAPB encodes a membrane protein involved in the unfolded protein response 
and vesicle trafficking. Mutations in VAPB were shown to disrupt its subcellular 
distribution, leading to intracellular aggregation of the protein (Nishimura et al. 2004; 
Landers et al. 2008).  
 
1.1.3.3 Genes involved in RNA metabolism 
Elongator protein 3 (ELP3) 
ELP3 variants were observed in ALS in an association study of UK, USA and Belgian 
populations (Simpson et al. 2009). ELP3 is implicated in axonal biology and synaptic 
development in animal models. Simpson et al. (2009) showed that the expression of ELP3 
was decreased in ALS patients carrying risk-associated alleles. The mechanism through 
which ELP3 leads to motor neuron degeneration remains unknown, but it appears that 
variants in this gene modulates risk for susceptibility to SALS. 
 
Senataxin (SETX) 
Autosomal dominant mutations in SETX (ALS4) are found in a juvenile-onset, 
slowly progressive non-fatal form of spastic paraplegia with some lower motor neuron 
degeneration causing distal muscle weakness with absence of bulbar and respiratory 
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symptoms (Chen et al. 2004). Symptom onset occurs before 25 years and individuals with 
ALS4 have a normal life span (Chen et al. 2004). SETX likely encodes a DNA/RNA helicase 
that functions in DNA repair and the production of RNA. SETX mutations are also 
associated with ataxia with oculomotor apraxia (Moreira et al. 2004). 
 
Ataxin-2 (ATXN2) 
Ataxin-2 is a polyglutamine protein that is mutated in spinocerebellar ataxia type 2 
(SCA2). A CAG trinucleotide repeat is expanded to >33 repeats in patients with SCA2 (Pulst 
et al. 1996). Elden et al. (2010) showed that ataxin-2 interacts with TDP-43 and is a 
modifier of TDP-43 toxicity in yeast and animal models. These findings led to an 
investigation of CAG repeat length in ALS. Elden et al. (2010) found Intermediate-length 
expansions of 27-33 in ataxin-2 occur in 4.7% of ALS cases and are significantly associated 
with susceptibility to ALS. ALS patients with intermediate-length ataxin-2 repeats have an 
earlier age of onset, and ataxin-2 accumulates in the cytoplasm in the spinal cord of ALS 
patients (Elden et al. 2010). 
 
HNRNPA2B1 and HNRNPA1 
Mutations in HNRNPA2B1 and HNRNPA1 were found in families with IBMPFD and 
ALS (Kim et al. 2013). Muscle biopsies from patients with these mutations show 
hnRNPA2B1/hnRNPA1-positive cytoplasmic inclusions and TDP-43 pathology (Kim et al. 
2013). This study showed that disease mutations are centred within prion-like domains 
and enhance the fibrillisation of the protein and its incorporation into stress granules and 
cytoplasmic inclusions (Kim et al. 2013). 
 
TAF15 
Several variants were found in a screening of TAF15 and EWS, two proteins 
structurally related to FUS, in FALS patients (Ticozzi et al. 2011). The pathogenicity of 
these variants is unclear. They appear to occur at a low frequency or may represent rare, 
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benign single nucleotide polymorphisms. Further studies are needed to determine 
whether mutations in TAF15 are indeed a rare cause of ALS. 
 
Matrin3 (MATR3) 
Mutations in MATR3 were recently found in FALS and SALS in an exome 
sequencing study and are likely a rare cause of FALS (Johnson et al. 2014). MATR3 cases 
demonstrate heterogeneous phenotypes including myopathic features; one mutation is 
associated with slowly progressive ALS, while another presented with typical, rapidly 
progressive ALS. MATR3 encodes a nuclear matrix DNA/RNA-binding protein that 
interacts with TDP-43. MATR3 is localised in the nuclei of motor neurons in control 
subjects, but is occasionally in the cytoplasm in ALS patients, and rarely observed in 
cytoplasmic inclusions (Johnson et al. 2014).  
 
1.1.3.4 Other genetic factors 
Profilin 1 (PFN1) 
Mutations in PFN1 were reported in FALS in 2012 in an exome sequencing study 
and account for 1-2% of familial cases (Wu et al. 2012). PFN1 regulates the polymerisation 
of actin filaments and cells transfected with PFN1 mutants develop abnormal actin levels 
and axon outgrowth which may contribute to ALS pathogenesis by affecting the 
cytoskeleton. ALS cases with PFN1 mutations have classical ALS pathology including 
ubiquintinated, insoluble TDP-43 aggregates (Wu et al. 2012). PFN1 patients have a 




SPG11 mutations were also identified in an exome sequencing study (Daoud et al. 
2012). SPG11 mutations are associated with juvenile onset ALS and long-term survival 
(Orlacchio et al. 2010; Daoud et al. 2012). Individuals with SPG11 mutations show upper 
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and lower motor neuron symptoms (Orlacchio et al. 2010). SPG11 encodes spatacsin, a 
predicted transmembrane protein involved in DNA damage. Mutations in SPG11 are a 
common cause of autosomal recessive hereditary spastic paraplegia (Stevanin et al. 2007).  
 
ALS2 
Mutations in ALS2 are observed in a juvenile-onset autosomal recessive form of 
ALS (Hadano et al. 2001). This form of ALS (ALS2) is rare and is characterised by slowly 
progressive spasticity of limbs and facial muscles. Symptom onset occurs in the first or 
second decade of life. ALS2 encodes a guanine nucleotide exchange factor, which activates 
GTPases to regulate endosomal trafficking (Otomo et al. 2003). ALS2 mutations are 
predicted to cause ALS through a loss of protein function. 
 
1.1.4 Mechanisms of ALS pathogenesis 
The study of the genetic aetiology of ALS has enabled the generation of animal and 
cellular models. This has provided some insight into the processes underlying ALS 
pathogenesis. It is believed that ALS is a complex disease that manifests as a result of 
defects in a multitude of cellular processes (Fig. 1.2). Some of the putative mechanisms 





Figure 1.2 Molecular mechanisms underlying motor neuron degeneration in ALS (Figure 
from Vucic et al., 2014). 
 
1.1.4.1 Failure of proteostasis 
 As with most neurodegenerative conditions, a hallmark feature of ALS is the 
presence of pathological protein aggregates. This, along with disease-linked mutations in 
multiple genes involved in protein degradation and maintenance of protein homeostasis, 
indicates failure of proteostasis as a key pathogenic mechanism. 
 The aggregation of mutant proteins in ALS is well-documented. Mutant SOD1 has 
been shown to misfold and adopt a conformation to prevent ubiquitylation-mediated 
degradation (Niwa et al. 2007). Mutant SOD1 forms toxic oligomers (Urushitani et al. 
2002), which further accumulates as aggregates to induce a stress response in cells (Atkin 
et al. 2006). The oxidation of WT SOD1 also leads to misfolding and aggregation of the 
protein, similar to mutant SOD1. Aggregation of SOD1 has toxic effects on two major 
protein degradation pathways, the UPS and autophagy. 
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 Similarly, TDP-43 and FUS have been observed in protein aggregates in ALS as well 
as other neurodegenerative disorders. Mutant TDP-43 and FUS are recruited into 
cytoplasmic stress granules upon stress. Stress granules are normally resolved by 
disaggregases and chaperones; however, it is thought that mutant TDP-43 and mutant FUS 
aggregates with stress granule components in an irreversible manner to give rise to 
pathological inclusions. This may be mediated by mislocalisation of the mutant protein 
and the prion-like domain within the protein structure of TDP-43 and FUS. 
 A characteristic feature of C9ORF72-linked ALS cases is the presence of neuronal 
cytoplasmic inclusions in the hippocampus, cerebellum and neocortex that are 
immunoreactive for p62, an adaptor protein that facilitates clearance of misfolded 
proteins by autophagy and UPS (Al-Sarraj et al. 2011). Several studies subsequently 
demonstrated that this unique protein pathology arose from unconventional repeat-
associated non-ATG-initiated translation of sense and antisense transcripts of the 
expanded hexanucleotide repeat (Mori et al. 2013). TDP-43 inclusions are also present 
and are abundant in the tissues that most commonly undergo neurodegenration (Stewart 
et al. 2012; Mann et al. 2013) 
 
1.1.4.2 Aberrant RNA metabolism 
The first link between alterations in RNA processing and motor neuron 
degeneration was described more than a decade ago. In experimental models, chronic loss 
of glutamate transport has been shown to produce motor neuron degeneration and may 
contribute to disease. The astroglial glutamate transporter EAAT2 (excitatory amino acid 
transporter 2) protein is severely decreased in the motor cortex and spinal cord of ALS 
patients (Rothstein et al., 2004). Aberrant EAAT2 mRNA species, due to intron-retention 
and exon-skipping, have been shown to occur in SALS and its presence correlated with the 
selective loss of EAAT2 protein in ALS (Lin et al., 1998). In addition, the expression of a 
neurofilament transgene was found to affect binding of ribonucleoprotein to the 
neurofilament mRNA and lead to the degeneration of enteric and motor neurons in 
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transgenic mice (Canete-Soler et al. 1999). The discovery of disease-linked mutations in 
multiple RNA binding proteins has since highlighted dysfunctional RNA processing as a 
major pathogenic pathway in ALS. Studies of pathology, cellular and animal models have 
provided evidence of abnormalities in multiple steps of RNA processing, including 
transcription, splicing, translation and decay. 
A recent study investigating the mechanism of C9ORF72-mediated toxicity found 
that the hexanucleotide repeat expansion leads to the formation of stable DNA and RNA 
quadruplexes (Haeusler et al. 2014). The DNA G-quadruplex affected the ratio of C9ORF72 
transcripts, such that longer GGGGCC hexanucleotide repeats produced increasing 
amounts of truncated transcripts, which caused a concomitant decrease in full-length 
transcripts (Haeusler et al. 2014). The authors postulated that the change in this ratio is 
due to the inability of cellular transcription machinery to access the transcript within the 
quadruplex structure. Cellular studies have shown that the hexanucleotide is transcribed 
bi-directionally, which generates an antisense transcript containing a CCCCGG-repeat that 
will also be expanded in patients carrying the mutation (Zu et al. 2013). Furthermore, 
pathologically expanded sense and antisense transcripts can be retained in neuronal 
nuclei forming RNA foci in the brains of C9ORF72 expansion-positive patients. Some 
expanded transcripts are exported and are RAN translated to generate GP, GA, GR, PR and 
PA dipeptides which form p62-labeled inclusions (Mori et al. 2013). 
TDP-43 and FUS mutations have also been shown to affect several RNA processing 
steps, such as splicing, mRNA transport and translation.  Using genome-wide approaches, 
several studies have shown that TDP-43 and FUS have thousands of RNA targets, and that 
disease-linked mutations alter the RNA targets bound by these proteins (Hoell et al. 2011; 
Tollervey et al. 2011; Tollervey et al. 2011; Lagier-Tourenne et al. 2012; Rogelj et al. 
2012). These studies also show that both proteins are involved in the maturation of RNA 
and splicing, as knockdown of TDP-43 and FUS altered the levels and splicing of hundreds 
of RNAs. In addition, both TDP-43 and FUS are present in cytoplasmic RNA granules, and 
mutant TDP-43 and mutant FUS have been shown to alter the transport of these granules 
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(Alami et al. 2014) or affect the translation of RNA present in these granules (Yasuda et al. 
2013). 
 
1.1.4.3 Axon failure 
Motor neurons are characterised by a unique morphology. These cells are highly 
polarised, typified by axonal projections that can reach a meter in length in adult humans. 
This morphology requires active axonal transport of organelles, cytoskeletal, synaptic 
components, and trophic factors to maintain normal cellular function. Axonal defects have 
been shown to occur in pre-symptomatic stages of disease in animal models of motor 
neuron disease, and the selective loss of neuromuscular synapse subtypes are believed to 
precede motor neuron degeneration (Frey et al. 2000).  
Changes in the number of neurofilaments or destruction of neurofilaments along 
with thinning of the axonal diameter have been reported in SALS cases (Atsumi 1981). In 
addition, there is accumulation of neurofilaments in spinal cord motor neurons in ALS 
(Hirano et al. 1984). Early evidence of involvement of neurofilament proteins in motor 
neuron degeneration came from studies of mice overexpressing neurofilament proteins 
which impaired the axonal transport of cytoskeletal components and mitochondria, 
accompanied by the degeneration loss of enteric and motor neurons (Collard et al. 1995; 
Canete-Soler et al. 1999). 
Other components of axonal transport have also been shown to contribute 
neurodegeneration. In particular, several studies have found a role for microtubule-
dependent motors proteins kinesin and dynein in the molecular biology of ALS. Landers et 
al. (2009) identified a single nucleotide polymorphism within the KIFAP3 gene. This was 
associated with reduced expression of the encoded kinesin-associated protein, KIFAP3, 
and longer survival in sporadic ALS cases (Landers et al. 2009). Tateno et al. (2009) 
reported the localisation of KIFAP3 in SOD1 aggregates in human ALS cases. This study 
further demonstrated that the association between KIFAP3 and mutant SOD1 impairs the 
transport of choline acetyltransferase and release of acetylcholine before the onset of 
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motor symptoms in transgenic SOD1 mice (Tateno et al. 2009). Finally, a mutation in a 
subunit of the axonal transport protein, dynactin, was identified in a family with a lower 
motor neuron disease (Puls et al. 2003). This mutation occurs within a domain involved in 
microtubule binding and impairs binding of dynactin to microtubules (Puls et al. 2003). 
These features suggest neurofilament alterations and accumulation impair the transport 
of vesicles and organelles along microtubules to contribute axonal defects and subsequent 
motor neuron degeneration. 
 
1.1.4.4 Mitochondrial dysfunction 
  Evidence for mitochondrial involvement in ALS was first observed in 
ultrastructural studies of patient tissues. Atsumi (1981) reported changes in mitochondria 
in the axons of remaining myelinated fibers in ALS muscles, which are considered to show 
axonal degeneration of motor neurons or a disturbance of the slower components of 
axonal transport (Atsumi 1981). Similarly, Hirano et al. (1984) reported morphological 
abnormalities of mitochondria in skeletal muscle, intramuscular nerves and proximal 
axons of SALS patients (Hirano et al. 1984). In addition, the levels of mitochondrial DNA 
deletion mutation are increased in the motor cortex and spinal cord of ALS patients, and 
this was associated with decrease in respiratory chain enzyme activities (Dhaliwal and 
Grewal 2000; Wiedemann et al. 2002).  
Findings from animal and cellular models also implicate mitochondrial dysfunction 
in ALS. Mutant SOD1 transgenic mice develop motor neuron degeneration and show 
vacuolisation and swollen mitochondria (Dal Canto and Gurney 1995; Wong et al. 1995). 
At the end stage, mitochondrial structure was completely unravelled and transformed into 
a series of membranes (Dal Canto and Gurney 1995). Mitochondrial degeneration was 
specific to motor neurons, as the majority of mitochondria in non-motor neurons and 
adjacent non-neuronal cells remained unaffected and indistinguishable from normal mice 
and transgenic mice expressing WT SOD1 (Wong et al. 1995). Transgenic mice expressing 
TDP-43 also display mitochondrial abnormalities and develop impaired motor function 
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(Xu et al. 2010) . They showed that expression of human TDP-43 resulted in aggregation of 
mitochondria and reduced expression of mitofusin 1, a protein essential for mitochondrial 
fusion. Mitochondrial fusion is critical for the maintenance of mitochondrial morphology, 
as inhibition of fusion results in loss of mitochondrial DNA and mitochondrial 
fragmentation (Rapaport et al., 1998).  
Mitochondrial dysfunction is also observed in cellular models of ALS. 
Neuroblastoma cells expressing mutant SOD1 demonstrate a significant decrease of 
mitochondrial membrane potential and impaired long-term storage of calcium (Carrì et al. 
1997). Mitochondrial impairment has also very recently been recapitulated in patient-
derived iPSCs. Kiskinis et al., (2014) showed that human motor neurons generated from 
patient-specific iPSC with the SOD1 A4V mutation have reduced long-term survival and 
deranged mitochondria with a vacuolar appearance. SOD1 motor neurons showed 
differential expression of several mitochondrial proteins, along with mitochondrial 
transportation deficiencies compared to control motor neurons (Kiskinis et al. 2014). 
These findings show that mitochondrial dysfunction is an important feature of motor 
neuron degeneration. 
  
1.1.4.5 Oxidative stress 
Oxidative stress occurs in a cell when there is an imbalance between the 
production of reactive oxygen species (ROS) and the ability of the cell to restore the 
homeostatic environment and reduce the toxic reactive intermediates. There is evidence 
of increased oxidative stress in postmortem tissue from ALS patients. Spinal cord samples 
from FALS and SALS patients contain higher levels of several markers of oxidative damage, 
such as protein carbonyl levels and 3-nitrotyrosine (Shaw et al. 1995; Ferrante et al. 
1997). Elevated levels of lipid oxidation markers and free radicals have been detected in 
the cerebrospinal fluid of ALS patients in the earlier stages of disease (Ihara et al. 2005). 
The same markers of oxidative stress are also found in animal and cellular models 
of ALS. Elevated levels of protein carbonyl and 3-nitrotyrosine have been reported in the 
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spinal cord and cortex of mutant SOD1 transgenic mice (Ferrante et al. 1997; Andrus et al. 
1998). Furthermore, Liu et al. (1999) showed that mutant SOD1 mice have higher levels of 
several ROS and oxidation products (Liu et al. 1999). These observations suggest that 
there is an impairment of detoxification pathways in ALS. 
 
1.1.4.6 Neuroinflammation 
Neuroinflammation is another pathological hallmark of ALS. The presence of 
microglia and infiltrating lymphocytes is often observed at sites of motor neuron loss, such 
as the motor cortex and spinal cord, as well as regions of mild degeneration (Kawamata et 
al. 1992; Henkel et al. 2004). Microglial activation, as measured by [11C](R)-PK11195 
positron emission tomography, occurs throughout the disease (Turner et al. 2004). These 
findings suggest that neuroinflammation is an active process during ALS disease 
progression. It is believed that microglia present two phenotypes, a protective M2 
phenotype and the neurotoxic M1 phenotype and it remains unclear whether the 
inflammation responses protect motor neurons or contribute to neuronal injury (Henkel 
et al. 2009).  
 Evidence from mutant SOD1 transgenic mice has shown a protective role of T cells 
by mediating a beneficial inflammatory response. The infiltration of T cells in the CNS of 
mutant SOD1 mice has been shown to occur early in the disease and stabilizes disease 
progression (Beers et al. 2008; Chiu et al. 2008). It is believed that T cells serve a 
protective role by reducing the pro-inflammatory response and by increasing the release 
of trophic factors (Beers et al. 2008). The transplantation of T cells can also delay motor 
neuron loss, improve neurological function and prolong the survival of mutant SOD1 mice 
(Banerjee et al. 2008). 
Conversely, during the later stages of disease, microglia in the mutant SOD1 
transgenic mice switch from the protective M2 phenotype to the toxic M1 phenotype. This 
change is associated with increased expression of reactive oxygen species and pro-
inflammatory cytokines, along with accelerated disease progression (Alexianu et al. 2001; 
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Hensley et al. 2002; Henkel et al. 2004; Beers et al. 2008). Nguyen et al. (2004) further 
demonstrated a positive correlation between the degree of M1 microglial activation and 
the severity of the disease (Nguyen et al. 2004). These results indicate non-cell 
autonomous involvement in ALS pathogenesis. 
 
1.1.4.7 Glutamate excitotoxicity 
 Finally, there is much evidence that excitotoxicity plays a role in the pathogenesis 
of ALS. Excitotoxicity occurs when extracellular concentrations of excitatory 
neurotransmitters lead to excess ion influx, energy depletion and calcium accumulation, 
resulting in neuronal damage and degeneration. A key argument for a role of excititoxicity 
in ALS is the fact that gabapentin and riluzole, the sole available drug for ALS, both 
interfere with excitatory neurotransmission, and have proven neuroprotective effects in 
patients and animal models.  
 Abnormalities in glutamate metabolism have been observed in ALS patients. For 
instance, the concentration of excitatory amino acids are highly elevated in the 
cerebrospinal fluid of ALS patients (Rothstein et al., 1990), whereas glutamate levels are 
significantly decreased in the brain and spinal cord of ALS patients (Plaitakis et al., 1988). 
In addition, there is a selective loss of excitatory amino acid transporter 2 (EAAT2) in the 
brain and spinal cord of ALS patients (Rothstein et al., 1995). There is also a selective 
defect in sodium-dependent glutamate transport in the brain and spinal cord of ALS 
patient, with a dramatic reduction in glutamate uptake (Rothstein et al., 1992).  
In addition to these abnormalities, in vivo and in vitro studies have shown that 
motor neurons demonstrate a selective vulnerability to glutamate receptor agonists. 
Selective excitotoxic degeneration has previously been reported in mature cultures of rat 
spinal neurons. Following addition of kainic acid, a glutamate receptor agonist, distal 
axonal swellings consistent with excitotoxic injury was observed in mature motor 
neurons, but not observed in immature motor neurons or cortical neurons (King et al., 
2007). Excitotoxicity appears to be mediated by non-N-methyl-D-aspartate (NMDA) 
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receptors, as kainic acid-induced excitotoxicity was blocked by the addition of non-NMDA 
receptor atagonist CNQX (King et al., 2007). Reductions, to a lesser degree, in kainic acid-
induced excitotoxicity were also observed following the application of MK801, an NMDA 
receptor antagonist, suggesting some involvement of NMDA receptors in glutamate 
excitotoxicity (King et al., 2007). 
 
1.1.5 Treatment 
Currently, no curative or disease modifying therapies exist, despite half a century 
of clinical trials and testing of more than 150 pharmacological agents in models of ALS 
(Thomsen et al. 2014). The sole available drug, Riluzole, only prolongs patient survival by 
approximately 2-3 months. Riluzole’s mechanism of action is not well understood; 
however, it is a small molecule that has been shown to suppress glutamate activity 
(Fumagalli et al. 2008). Other measures are taken to improve the quality of life for ALS 
patients, such as the use of feeding tubes and respiratory assistance devices. 
Several approaches are currently under investigation as potential therapies for ALS. 
These include small molecules involved in macrophage activation, muscle contractility, 
neuronal excitability and cellular stress response, stem cell therapies and antisense 
oligonucleotides (Sreedharan and Brown 2013). 
 
1.2 THE ROLE OF FUS IN ALS 
1.2.1 FUS structure 
FUS is a member of the FET family of DNA and RNA binding proteins, which 
includes EWS and TAF15. FUS, TAF15 and EWS share similar domain architecture (Fig. 
1.3). FUS is a 526-amino acid protein with a molecular mass of 53 kDa (Crozat et al. 1993). 
The N-terminal 165 amino acids form a transactivating domain that is enriched for serine, 
tyrosine, glycine and glutamine. This domain is considered as a low complexity region and 
is predicted to contribute to exaggerated protein aggregation (Kato et al. 2012). Next to 
this is an arginine-glycine-glycine domain (RGG) consisting of 102 amino acids. This is 
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followed by an RNA-recognition motif (RRM), which contains a nuclear export signal 
(NES) made up of 11 amino acids. The next 130 amino acids contain another two RGG 
domains and a 31-amino acid zinc finger motif (ZnF). 
 
 
Figure 1.3 Schematic diagram showing the domain architecture of the FET family of 
proteins. Figure adapted from (Kaneb et al. 2012). SYGQ-rich, serine, tyrosine, glycine, 
glutamine-rich domain; RGG, arginine-glycine-glycine domain; E, nuclear export signal; 
RRM, RNA recognition motif; ZnF, zinc finger; PY, proline-tyrosine nuclear localisation 
signal. 
 
1.2.2 FUS location 
In cells, FUS normally displays a clear nuclear localization and a diffuse 
distribution in the cytoplasm with some localization in nuclear speckles and cytoplasmic 
granules (Fig. 1.4) (Andersson et al. 2008). The shuttling of FUS between the nucleus and 
cytoplasm is mediated by transportin-1, a subunit of a receptor complex that targets 
nuclear proteins to the nucleus (Dormann et al. 2010). Within the nucleus, FUS exists as a 
nuclear matrix protein and associates with several SR proteins, such as SC35 and SRp75 
(Meissner et al. 2003). FUS is involved in spliceosome assembly and the formation of 
nuclear gems (Hartmuth et al. 2002; Yamazaki et al. 2012). In the cytoplasm, FUS is 
present in punctate structures known as RNA granules. RNA granules are complexes 
composed of RNA and other proteins. In neurons, FUS can be found in the postsynaptic 
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density of synapses (Aoki et al. 2012). Fujii et al. (2005) showed that FUS is specifically 
recruited to dendritic spines upon neuronal activation. 
 
 
Figure 1.4 FUS localization in cultured human cells (figure adapted from Andersson et al., 
2008). HT-1080, fibrosarcoma cells; F470, primary human fibroblasts; HeLa, cervical 
cancer cells; U1242MG, glioblastoma cells. 
 
1.2.3 FUS functions 
FUS is a ubiquitously expressed multifunctional protein that plays a role in 
numerous biological processes, including transcription regulation, multiple levels of RNA 
processing, cell proliferation, differentiation and DNA repair. 
 
1.2.3.1 Transcription regulation 
FUS was initially identified as a fusion oncogene in myxoid liposarcoma (Crozat et 
al. 1993). The N-terminus of FUS was shown to function as a transcriptional activation 
domain to oncogenic fusion proteins (Zinszner et al. 1997). FUS associates with TFIID and 
RNA polymerase II, key components of the transcriptional pre-initiation complex, which is 
essential for transcription induction (Bertolotti et al. 1996). The co-expression of FUS and 
transcription factor NF-κB has been shown to co-activate transcription (Uranishi et al. 
2001). Thus, it has been proposed that FUS is involved in the recruitment of general and 
specific factors for the initiation of transcription and acts as a transcriptional modulator of 




1.2.3.2 Splicing and maturation of RNA 
A number of studies have demonstrated the importance of FUS in splicing and RNA 
maturation. Splicing removes introns from pre-mRNAs and is mediated by the 
spliceosome, a complex composed of ribonucleoproteins (RNPs). FUS associates with the 
spiceosomal complex (Meissner et al. 2003). In particular, specific FUS domains have been 
shown to interact with spliceosome members, such as SF1 and SR proteins (Yang et al. 
1998; Yang et al. 2000). FUS also associates with components of the SMN complex or 
Gems, a structure involved in the regulation of snRNPs (Yamazaki et al. 2012). In fact, FUS 
is necessary for the formation of Gems, and a reduction in Gems is observed in ALS patient 
fibroblasts (Yamazaki et al. 2012).  
FUS has thousands of RNA targets and changes in alternative splicing are observed 
in a minority of these when the levels of FUS are manipulated (Rogelj et al. 2012). Yang et 
al. (1998) showed that overexpression of FUS alters the accumulation of alternatively 
spliced mRNAs. Conversely, knockdown of FUS in mouse cortical neurons leads to 
increases in four-repeat tau isoforms (Orozco et al. 2012). Depletion of FUS in the central 
nervous system of adult mice leads to changes in hundreds of splicing events (Lagier-
Tourenne et al. 2012). This study also showed that FUS binding sites are enriched in 
alternatively excluded or included exons, supporting the view that FUS mediates splicing 
of its RNA targets (Lagier-Tourenne et al. 2012). 
In addition to this, FUS has been observed in a multi-protein complex with Drosha 
and DGCR8, two key proteins that mediate the genesis of microRNAs (Gregory et al. 2004; 
Shiohama et al. 2007). The role of FUS in microRNA biogenesis remains unclear however, 
and Gregory et al. (2004) suggest that this complex likely mediates preribosomal RNA 
processing, rather than microRNA processing.  
 
1.2.3.3 RNA transport and translation 
It is now established that FUS is a nucleic acid-binding protein (Zinszner et al. 
1997; Baechtold et al. 1999). The finding that FUS binds RNA and engages in 
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nucleocytoplasmic shuttling, led to the idea that FUS may function as a chaperone of RNA 
and participate in RNA transport (Zinszner et al. 1997). A later study demonstrated that 
FUS does in fact function in the transport of mRNA transcript in neurons. Fujii and Takumi 
(2005) found that FUS associates with actin-related mRNA transcripts and facilitates their 
transport to dendritic spines following neuronal activation. 
RNP complexes containing FUS have also been implicated in local translation. A 
recent study showed the presence of FUS in an RNP complex containing the tumor 
suppressor protein adenomatous polyposis coli (APC) (Yasuda et al. 2013). It was 
previously shown that APC targets mRNA transcripts to cell protrusions to form APC-RNPs 
(Mili et al. 2008). Yasuda et al. (2013) showed that while FUS is not required for the 
localization of APC-RNPs, nor RNAs, to cell protrusions, it is necessary for efficient 
translation of the associated RNA transcripts in cell protrusions. Thus, in addition to 
splicing and RNA maturation, transport and translation are also important features of FUS-
containing RNP complexes. 
 
1.2.3.4 DNA repair, cell proliferation and differentiation 
A role for FUS in DNA repair was identified by investigating DNA homologous 
pairing (DHP) activity, a central step in homologous recombination and repair in certain 
forms of DNA damage. Bertrand et al. (1999) found that FUS is one of two major 
mammalian nuclear extracts with DHP activity. Kuroda et al. (2000) reported that FUS 
knockout mice demonstrate meiotic defects and enhanced radiation sensitivity, 
demonstrating the functional significance of FUS in DNA repair. Recently, FUS was shown 
to be important for both homologous recombination and non-homologous end joining-
mediated DNA repair (Wang et al. 2013). Importantly, this study showed that FUS is 
recruited to the site of DNA damage at a very early stage of the DNA damage response, and 
that its localization at the site of DNA damage recruits histone deacetylase 1 (HDAC1), a 
protein with a prominent role in DNA repair in neurons (Wang et al. 2013).  
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The DHP activity of FUS also correlates with cell proliferation. Bertrand et al. 
(1999) showed that immortalizing cells leads to stimulation of FUS DHP activity, and that 
DHP activity is stimulated in proliferating cells. Alternatively, inducing differentiation 
resulted in the inhibition of FUS DHP activity, linking FUS DHP activity with cell 
proliferation (Bertrand et al. 1999). A later study also provided support for a role of FUS in 
cell differentiation. Andersson et al. (2008) showed that the expression of FUS and related 
protein TAF15 is down-regulated in differentiating hESCs and neuroblastoma cells.  
FUS has also been implicated in the development of other cell types, Disruption of 
FUS in mice results in neonatal lethality and abnormal lymphocyte development (Hicks et 
al. 2000). In addition, hippocampal neurons from these mice demonstrate abnormal 
morphology, with irregularly branched dendrites, multiple immature axons and reduced 
dendritic spines (Fujii et al. 2005). Whether these developmental phenotypes are 
associated with the DHP activity of FUS remains unknown. Regardless, these data imply a 
key role for FUS in development.  
 
1.2.4 FUS pathology 
Similar to other neurodegenerative conditions, the neuropathology of FUS-
associated ALS is characterized by protein inclusions (Fig. 1.5). Within FALS cases with 
FUS mutations, examinations have revealed a heterogeneous neuropathology. One 
particular feature that appeared to distinguish early from late-onset cases was the 
frequency and anatomical distribution of basophilic inclusions (Mackenzie et al. 2011). 
Basophilic inclusions are sharply defined, single or multiple, round, oval or multilobulated 
bodies, often similar in size to the neuronal nucleus. In late-onset cases, basophilic 
inclusions are rarely observed; most brain regions examined contained no more than a 
single basophilic inclusion. In contrast, basophilic inclusions are a very obvious 
pathological feature of early-onset cases. Multiple inclusions were found in the spinal cord 
and motor cortex, as well as several other neuroanatomical regions. In addition, dense 





Figure 1.5 Immunostaining of FUS in the anterior horn of the spinal cord in patients with 
FUS mutations (A to F), controls (G and H), patients with SOD1 mutations (I and J) and 
SALS patients (K and L) (Figure adapted from Vance et al., 2009). 
 
Another characteristic that differentiated early- from late-onset cases was the 
frequency, anatomical distribution and appearance of FUS-immunoreactive neuronal 
cytoplasmic inclusions (NCIs) (Vance et al. 2009). While NCIs were observed in lower 
motor neurons of all cases, they were more prevalent in early-onset cases. Early-onset 
cases also exhibited numerous NCIs in the motor cortex and cerebellar dentate nucleus, 
whereas late-onset cases were characterized by NCIs in the basal ganglia (Mackenzie et al. 
2011). The appearance of NCIs also differed between early- and late-onset cases. Late-
onset cases displayed NCIs with thick filaments in the perikaryon. This feature was mostly 
absent in early-onset cases, which typically exhibited compact and round NCIs.  
Finally, early- and late-onset cases may be distinguished pathologically by the 
presence of glial cytoplasmic inclusions (Mackenzie et al. 2011). Inclusions in glia are 
rarely seen in early-onset cases. In contrast, glial inclusions are numerous in late-onset 
cases, and correlate well with the anatomical distribution of neuronal cytoplasmic 





1.2.5 Mechanisms of mutant FUS-mediated toxicity 
Since the discovery of ALS-linked mutations in FUS, cellular studies and animal 
models have been used to determine the mechanism through which these mutations lead 
to motor neuron degeneration. Findings from these studies have led to the proposal of 
both toxic gain of function and loss of function models.  
 
1.2.5.1 Loss of function 
Several animal models with reduced levels of FUS have demonstrated that a lack of 
physiological functions of FUS in the nucleus is sufficient to induce abnormal neuronal 
morphology, locomotive dysfunction and motor neuron degeneration. As mentioned 
above, hippocampal neurons from FUS knockout mice show abnormal dendritic 
morphology, with reduced spine density (Fujii et al. 2005). These mice have a perinatal 
lethal phenotype (Hicks et al. 2000), although another study has reported that surviving 
knockout mice exhibit male sterility (Kuroda et al. 2000).  
Several Drosophila models have shown that knockdown of Cabeza (Caz), the 
Drosophila orthologue of human FUS, recapitulates key features of motor neuron disease. 
Sasayama et al. (2012) showed that knockdown of Caz causes reduced mobility, reduced 
length of synaptic branches of motor neurons and decreased number of synaptic boutons. 
However, Caz-knockdown flies had a life span comparable to WT flies (Sasayama et al. 
2012). 
Loss of endogenous fus in zebrafish also causes a motor phenotype. Fus 
knockdown by antisense morpholino oligonucleotide (ASO) resulted in abnormal motor 
behavior characterized by a deficient touch-evoked escape response, as well as reduced 
axonal outgrowth from spinal cord motor neurons (Kabashi et al. 2011). This motor 
phenotype was rescued by the co-injection of ASO and human WT FUS mRNA, but not or 





1.2.5.2 Gain of function 
Conversely, several lines of evidence suggest that FUS mutations cause ALS by a 
gain of function effect related to the mislocalisation or aggregation of mutant FUS in the 
cytoplasm. Murakami et al. (2011) showed that the expression of mutant FUS in 
Caenorhabditis elegans causes cytoplasmic mislocalisation of FUS protein, progressive 
motor dysfunction and reduced lifespan. Importantly, this animal model demonstrated a 
correlation between the degree of mislocalisation and the severity of neuronal 
dysfunction, recapitulating an important feature observed in the human condition. 
Murakami et al. (2011) also showed that the co-expression of WT-FUS does not rescue the 
motor dysfunction caused by the expression of mutant FUS. This finding strongly suggests 
that mutant FUS causes ALS through a gain of function effect. 
The overexpression of mutant FUS R521H mRNA in zebrafish also causes motor 
deficit in zebrafish, resulting in deficient touch-evoked escape response and reduced 
motor neuron axonal outgrowth (Kabashi et al. 2011). This study showed that the 
overexpression of mutant FUS R521C and S57Δ did not lead to the same drastic motor 
phenotype, suggesting FUS mutations contribute to motor neuron degeneration via 
different mechanisms (Kabashi et al. 2011). 
Mice overexpressing human WT FUS show a rapid decline in motor function, 
characterised by the development of a tremor, progressive hind limb paralysis, and death 
by 12 weeks (Mitchell et al. 2013). These mice also show pathological hallmarks of ALS-
FUS, such as ubiquitin-negative FUS-positive inclusions in spinal cord and brain stem 
motor neurons, significant loss of motor neurons in the spinal cord and loss of fast-twitch 
muscle fibres (Mitchell et al. 2013).  
Overexpression of mutant FUS also results in progressive paralysis in transgenic 
rats (Huang et al. 2011). Degenerating axons are observed in the corticospinal tracts of 
mutant FUS transgenic rats at late stages of the disease, resulting in atrophy of skeletal 
muscle cells and denervation without a significant loss of motor neurons, but substantial 
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loss of cortical and hippocampal neurons (Huang et al. 2011). Whereas overexpression of 
mutant FUS in rats was associated with a motor phenotype, overexpression of WT FUS 
caused deficits in learning and memory, along with loss of neurons in the frontal cortex 
and dentate gyrus (Huang et al. 2011). 
These results seem to support a toxic gain of function mechanism associated with 
ALS-FUS. However, the overexpression of human FUS is associated with down-regulation 
of endogenous Fus in transgenic animals (Mitchell et al. 2013). Thus, it is difficult to 
dissect the contribution of loss or gain of function mechanisms in transgenic animal 
models. 
 
1.3 THE NEED FOR NEW CELLULAR MODELS  
One of the biggest impediments to our understanding of disease mechanisms in 
neurological conditions is the inaccessibility of human neural cell types. Studies of animal 
models have circumvented this issue and enable the study of ALS in an intact organism. 
Numerous transgenic models have been created, including yeast, Drosophila, nematode, 
zebrafish, mouse and rat models of SOD1, TDP-43, FUS and C9ORF72 pathology. These 
models have been successful in modelling the degeneration of motor axons and ALS-like 
motor phenotypes. They have provided some insight into the underlying disease 
mechanisms. However, preclinical successes in the treatment of existing animal models 
have not translated well into clinical benefit for patients. This may be due to differences in 
experimental design between the treatment of existing animal models and the treatment 
of patients. For instance, mice are often treated at the pre-symptomatic stage, whereas 
humans are treated at the end stage of disease. Thus, this is an issue that needs to be 
addressed as improvements are made to current ALS diagnostic tools. Another difference 
is the issue of compliance. Whereas studies using animal models have high compliance, 
low or noncompliance in patients may be a significant contributor to the high failure of 
drugs in clinical trials. Therefore, better attempts at analysing patient compliance during 
drug testing may also lead to improvements in clinical trials (Czobor and Skolnick, 2011). 
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Alternatively, this may be due to inherent anatomical and genetic variations between 
animal and man, or complex genetic and environmental interactions that result in disease, 
thus limiting the potential of animal models of ALS.  
Human cellular models can address some of these issues; however, current cellular 
models have severe limitations. For years, studies have used techniques to overexpress 
mutant protein in immortalised cell lines or in non-neuronal cell types to develop a 
cellular model to study fundamental disease mechanisms and screen for drugs that 
reverse these processes. Immortalised cell lines are known to acquire genetic 
abnormalities with prolonged culture. In addition, the ability of these cells to divide 
continuously and the massive overexpression of human protein do not mirror normal 
physiological conditions. Thus, there are significant limitations to the use of these cells as a 
model for ALS. 
An attractive alternative has emerged in the past decade with the discovery that 
human embryonic stem cells (hESCs) and induced pluripotent stem cells can be directed to 
differentiate into motor neurons. hESCs are pluripotent stem cells derived from human 
embryos at the blastocyst stage. They have the ability to proliferate indefinitely in culture 
while maintaining the capacity to differentiate to all cell types. It is possible to study 
genetic disease conditions in hESCs by using genome-editing tools to introduce disease-
causing mutations. An alternative approach is to reprogram adult somatic cells to generate 
induced pluripotent stem cells. 
 
1.4 INDUCED PLURIPOTENT STEM CELLS 
  The method of reprogramming adult somatic cells to pluripotent stem cells was 
reported in 2006 by Takahashi and Yamanaka (Takahashi and Yamanaka 2006). They 
reported that dermal fibroblasts from adult mice can be reprogrammed into a pluripotent 
state by retroviral transduction of four transcription factors, OCT4. KLF4, c-MYC and SOX2 
(Fig. 1.6). The reprogrammed cells were termed induced pluripotent stem cells (iPSCs). 
iPSCs are similar to embryonic stem cells (ESCs) in their morphology, proliferation, 
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surface antigens, gene expression and capacity to differentiate into the cell types of the 
three germ layers. A year later, Takahashi et al. (2007) applied the same technology to 
human adult dermal fibroblasts to generate the first human iPSCs (Takahashi et al. 2007).  
Since this discovery, many others have shown that it is possible to generate iPSCs 
from other adult somatic cell types, including blood cells, urine cells, amniotic cells and 
others (Wang et al. 2013). In addition, a variety of techniques have been developed to 
deliver the four reprogramming transcription factors. These include non-integrating viral 
vectors, small molecules, transduction of proteins and microRNAs (Wang et al. 2013). 
Since the initial discovery, the efficiency of iPSC generation has greatly improved and the 
technology continues to develop. 
 
 
Figure 1.6 Schematic diagram showing the process of iPSC reprogramming and generation 
(Figure reproduced from System Biosciences). 
 
 Yamanaka's seminal studies provided an avenue to generate patient and disease-
specific iPSCs and led to his being rewarded the Nobel Prize in Medicine and Physiology in 
2012. This discovery, combined with protocols for the directed differentiation of neurons, 
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enabled access to these cell types without the ethical issues involved with the use of 
hESCs. Since this discovery, iPSCs have been used to model numerous genetic disorders, 
including neurodegenerative conditions such as Alzheimer's, Huntington’s and 
Parkinson's disease (Zhang et al. 2010; Nguyen et al. 2011; Israel et al. 2012).  
Although iPSCs offer tremendous potential for studies of disease mechanisms and 
drug discovery, there are also some disadvantages to using these cells as a model system. 
Compared to other cellular models, such as immortalised cell lines, iPSC cultures are costly 
to establish and maintain. The generation of iPSCs requires time and the reprogramming 
occurs at relatively low efficiency. In addition, compared to other cell lines, iPSCs exhibit a 
high degree of variance, even within subclones from the same individual. Furthermore, 
iPSCs carry an epigenetic memory, such that they have a bias towards differentiating into 
the cell type from which they were derived. Therefore, there remains a number of caveats 
concerning the use of iPSCs as a model system. 
 
1.4.1 iPSC models of ALS 
The first application of iPSC technology in the study of ALS was in 2008. Dimos et 
al. (2008) showed that fibroblasts from an 82-year old ALS patient could be 
reprogrammed into iPSCs. Furthermore, these patient-specific iPSCs can be directed to 
differentiate into functional motor neurons (Dimos et al. 2008). For the first time, it 
became possible to gain access to the cell types affected in ALS, but they did not describe a 
pathological phenotype. This study was followed by two reports of iPSCs generated from 
patients with pathogenic TDP-43 mutations (Bilican et al. 2012; Egawa et al. 2012). Both 
of these studies showed that patient-derived iPSCs recapitulated cellular and biochemical 
features associated with ALS-TDP and that motor neurons generated from patient-derived 
iPSCs show selective vulnerability to cell stressors (Bilican et al. 2012; Egawa et al. 2012). 
Furthermore, Egawa et al. (2012) identified a compound that reversed some of the ALS 
phenotypes found in mutant motor neurons. 
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Similarly, Almeida et al. (2013) reported that iPSCs derived from patients carrying 
the hexanucleotide repeat expansion in C9ORF72 also recapitulated key features of ALS-
C9ORF72. This was followed closely by another study of iPSC-derived motor neurons from 
C9ORF72 ALS patients that also recapitulated C9ORF72 pathology, which was reversed by 
the use of antisense oligonucleotides (Sareen et al. 2013). Very recently, two elegant 
studies combined iPSC technology, stem cell differentiation approaches and genome 
editing technology to investigate the pathways perturbed as a result of ALS-linked SOD1 
mutations (Chen et al. 2014; Kiskinis et al. 2014). These studies showed that endogenous 
levels of mutant protein were sufficient in recapitulating aspects of ALS pathology. 
Furthermore, they demonstrate the utility of iPSC models for drug screening and provide 
support for their use in mechanistic studies. 
 
 1.5 PROJECT RATIONALE 
When this project was initiated, the exploration of FUS iPSCs was entirely novel. 
There had been only one publication on iPSCs and motor neurons differentiated from an 
ALS patient, without a description of any pathogenic phenotype. Our recent work on iPSCs 
derived from a patient with a TDP-43 mutation was the first to recapitulate aspects of ALS 
pathology (Bilican et al. 2012). We wished to determine whether mutant FUS iPSC lines 
show a similar propensity to protein mislocalisation and aggregation as was seen in the 
mutant TDP-43 iPSC lines.  
This thesis begins by describing the methods used to characterise iPSC lines derived 
from a patient carrying the FUS R521C mutation and the directed differentiation of these 
iPSC lines into neural progenitors and motor neurons. Our prediction was that the FUS 
R521C mutation would not prevent the functional maturation of motor neurons. The next 
part of the thesis illustrates the characterisation of FUS-ALS phenotypes: mislocalisation of 
FUS protein, redistribution into stress granules and cellular toxicity. We predicted that 
neuralised cells would recapitulate the key features observed in ALS patients carrying FUS 
mutations. The last section describes the investigation of neuronal morphology in neurons 
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differentiated from patient-derived iPSCs and demonstrates that compromised dendrite 
and synaptic morphology may represent an underlying pathogenic mechanism. Although 
our study used multiple lines generated from patient fibroblasts, they represented one 
pathogenic mutation and may limit the interpretation of results. We therefore sought to 
investigate the neuronal morphology in a range of ALS-linked FUS mutants which had 
been previously established (Vance et al. 2013). The advantages and limitations of the 
iPSC model are discussed. Finally, the thesis concludes with an outline of future directions 





MATERIALS AND METHODS 
All chemicals and reagents used were purchased from Life Technologies, unless 
otherwise stated.  
 
2.1 CELL CULTURE 
 All cell culture work was carried out in a class II microbiological flow hood under 
sterile conditions. All incubations were undertaken at 37°C in a humidified 5% CO2 
incubator. Fifteen cell lines were used, 6 human iPSC lines, one hESC line (HUES), 6 neural 
progenitor cell lines, Human Embryonic Kidney (HEK-293T) and human neuroblastoma 
(SH-SY5Y) cell lines. 
 
2.1.1 Generation of iPSCs   
Procurement of skin tissue for use in reprogramming experiments was obtained 
via informed consent under a protocol approved by the King’s College Hospital, NHS 
Foundation Trust ethics review committee and the Department of Research and 
Development. Skin biopsies were taken from a 40-year-old female ALS patient carrying the 
FUS R521C mutation. The biopsy was cut into pieces and plated in a T12.5 tissue culture 
flask and grown in human fibroblast derivation media (DMEM, 10% fetal bovine serum 
(FBS), and 1x penicillin-streptomycin). Outgrowth of cells appeared after 1-2 weeks. 
Medium was changed every 2-3 days. Cells were passaged 1:3 with 0.25% trypsin-EDTA 
(TE) upon reaching confluency. Human dermal fibroblasts from a normal male (56 years 
old, CRL-2465) and a normal female (46 years old; CRL-2524) were obtained from ATCC. 
All fibroblasts were maintained in alpha-MEM with 10% inactivated fetal calf serum. 
Fibroblasts were reprogrammed into pluripotent stem cells following transduction by four 
transcription factors OCT4, SOX2 KLF4, and c-MYC, as previously described (Takahashi et 
al., 2007).   
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Reprogramming was performed by In-Hyun Park in George Daley’s laboratory at 
Harvard. cDNA of OCT4, SOX2 KLF4, and c-MYC were generated by RT-PCR and inserted 
into pMIG vector. SV40 large T in the pBABE-puro vector and hTERT in the pBABE-hygro 
vector were obtained from Addgene. HEK-293T cells were plated in 10-cm tissue culture 
plates and transfected with 2.5 μg of retroviral vector, 0.25 μg of VSV-G vector and 2.25 μg 
of Gag-Pol vector using FUGENE 6 reagents. The supernatant was collected and filtered 
through 0.45 μm cellulose acetate filter two days after transfection, then centrifuged at 
23,000 RPM for 90 minutes and stored at -80°C until use. 1 x 105 control and patient 
fibroblasts were plated in one well of a six-well plate and infected with the retrovirus and 
protamine sulphate. Three days post-infection, cells were passaged into plates pre-seeded 
with mouse embryonic fibroblasts (MEFs). Seven days after infection, medium was 
changed to human embryonic stem cell (hESC) medium (Dulbecco’s Modified Eagle 
Medium: Nutrient Mixture F-12 (DMEM/F12) containing 20% Knockout Serum 
Replacement, 10 ng/mL human recombinant basic fibroblast growth factor (bFGF), 1 x 
non-essential amino acids, 5.5 mM β-Mercaptoethanol (Sigma) and 1 x penicillin-
streptomycin), supplemented with 5 μM ROCK inhibitor (Y27632; Calbiochem). 30 days 
after transduction, hESC-like colonies were picked and expanded. Multiple clonal lines 
were generated and 6 of the most stable were chosen for subsequent differentiation. 
 
2.1.2 General maintenance of pluripotent stem cells 
iPSCs and hESCs were maintained in feeder-free conditions on Matrigel (BD 
Biosciences). Matrigel was diluted in a 1 in 30 dilution in chilled DMEM/F12 and used to 
cover the bottom of flasks and plates for pluripotent stem cell culture. Coating was 
prepared at least one day before passaging of pluripotent stem cells and stored at 4°C, 
wrapped in parafilm. Matrigel-coated flasks or plates were washed with DMEM/F12 prior 
to use.   
Pluripotent stem cells were maintained in mTESR1 or TeSR-E8 media (STEMCELL 
Technologies).  iPSCs and hESCs were thawed by warming one vial of cells in a 37°C water 
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bath until an ice drop was seen inside the cryovial (Fisher Scientific). 1 ml of fresh warmed 
medium was added to the vial and cells were transferred into a conical tube and 
centrifuged for 4 minutes at 1000 rpm. The supernatant was removed and the cell pellet 
was resuspended in fresh medium supplemented with 5 μM Y27632 and transferred to a 
Matrigel-coated T-25 flask.   
Medium was changed daily and cells were passaged with Dispase (BD Biosciences) 
or Gentle Cell Dissociation Reagent (STEMCELL Technologies) once a week, when cell 
colonies were big, in contact with other colonies, and when a change in colour in the 
middle of the colony was observed under the microscope in low magnification. To split the 
cells, old medium was removed and the cells were washed once with DMEM/F12. 1ml of 
Dispase or Gentle Cell Dissociation Reagent was added to a T-25 flask. Cells were 
incubated at 37°C until cells at the edge of colonies started to detach. Cells were washed 
again with DMEM/F12 once and fresh medium was added. Cells were split manually using 
a sterile fire sharped glass pipette Pasteur. Cells were transferred to a conical tube and 
centrifuged at 1000 rpm for 4 minutes. The supernatant was removed and the cell pellet 
was resuspended in fresh media in a 1 in 3 dilution. 
To freeze the cells, 5 μM of Rho-associated kinase (ROCK) inhibitor was added to 
the medium two hours before freezing.  The medium was removed and cells were washed 
once with DMEM/F12. 1ml of Dispase or Gentle Cell Dissociation Reagent was added to a 
T-25 flask. Cells were incubated at 37°C until cells at the edge of colonies started to detach. 
Cells were washed again with DMEM/F12 once and Knockout Serum Replacement 
supplemented with 10% dimethyl sulfoxide (DMSO) was added. Cells were scraped 
manually using a sterile fire sharped glass pipette Pasteur and transferred to a cryovial. 
Vials were placed in a Mr. Frosty freezer container (Thermo Scientific) at -80°C overnight. 
Cells were transferred to liquid nitrogen the next day. 
 
2.1.3 Maintenance of other cell lines 
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HEK293T cells were maintained in DMEM with 10% fetal bovine serum (FBS) and 
1% penicillin-streptomycin. SH-SY5Y cells were maintained in DMEM/F12 with 10% FBS 
and 1% penicillin-streptomycin. Cells were split upon reaching 80% confluence. To split 
the cells, old medium was removed and cells were washed with PBS. TE was added to the 
flask and incubated at 37°C until cells detached. Cells were collected in fresh medium and 
centrifuged at 1000 rpm for 4 minutes. The supernatant was removed and the cell pellet 
resuspended in fresh media. An aliquot of this was used in a 1 in 50 dilution in a new flask. 
 
2.1.4 In vitro embryoid body differentiation of induced pluripotent stem cells 
Embryoid bodies were generated from iPSCs using Aggrewell Plates (StemCell 
Technologies) according to the manufacturer’s instructions. Briefly, cells were grown in 
suspension culture in Aggrewell Plates in mTeSR1 or TeSR E8 medium for two days. Cell 
clusters were then collected and cultured on low adherence Poly (2-
hydroxyethylmethacrylate) (polyHEMA)-treated tissue culture dishes (Sigma) in 
differentiation medium consisting of DMEM supplemented with 20% FBS, 0.1 mM β-
Mercaptoethanol and 1 mM L-glutamine.  
PolyHEMA-treated tissue culture dishes were prepared by dissolving 1.25 grams of 
polyHEMA in 10 ml of ethanol in a shaker at 37°C overnight. Once completely dissolved 
the polyHEMA solution was diluted in 100 ml of ethanol and applied to tissue culture 
dishes and dried on a level, vibration-free surface. PolyHEMA-treated tissue culture dishes 
were UV-sterilised prior to use. 
After 7 days of culture in suspension, embryoid bodies were differentiated for a 
further 2 weeks in differentiation medium on 0.1% gelatin-coated plates. 0.1% gelatin 
solution was prepared by dissolving gelatin in endotoxin-free water and sterilisation by 
autoclaving. Tissue culture plates were coated with gelatin solution at room temperature 
for 2 hours, aspirated and dried before use. 
 
2.1.5 In vitro motor neuron differentiation of induced pluripotent stem cells 
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Motor neuron differentiation of iPSCs was performed by using an established 
protocol as described previously (Bilican et al., 2012) (See Figure 2.1 for a schematic for 
the motor neuron differentiation process). iPSC cultures were differentiated into 
neuroectoderm by dual-SMAD signaling inhibition in chemically defined medium (CDM) 




Figure 2.1. Motor neuron differentiation was initiated with dual SMAD inhibition in CDM 
on days 1-7, followed by the addition of 0.1 μM RA in CDM for 7 days, then 0.1 μM RA and 
1 μM purmophamine in neuronal medium for 7 days, and terminally differentiated in 0.1 
μM RA, 0.1 μM purmophamine, 10 ng/ml brain-derived neurotrophic factor (BDNF) and 
glial cell line-derived neurotrophic factor (GDNF) in maturation medium for 3-6 weeks. 
 
Table 2.1. Chemically defined medium 
Component Final concentration 
DMEM:F12 up to 250 ml 
L-glutamine (10X) 1x 
BSA 5mg/ml 
Lipid 100x 1x 
Monothioglycerol 450 μM 
Insulin 7 μg/ml 





Neurospheres were formed by mechanical dissociation of neuroectoderm. 
Neurospheres were grown in suspension in poly-HEMA-treated tissue culture dishes and 
caudalised in CDM with retinoic acid (RA, 0.1 μM; Sigma) for 7-10 days. Caudalised 
neurospheres were collected and washed with DMEM/F12. They were then resuspended 
in neuronal medium (Table 2.2) and grown in suspension the same polyHEMA-treated 
tissue culture dish for 7-9 days to generate motor neuron precursors. 
 
Table 2.2. Neuronal medium 
Component Final concentration 
Neurobasal medium 1x 
L-glutamine 1x 
Retinoic acid 0.1 μM 




Non-essential amino acids 1% 
bFGF 5 ng/ml 
Heparin 5 ng/ml 
 
 Poly-L-ornithine (Sigma), fibronectin (Sigma) and laminin-coated substrate was 
prepared for plating down and maturation of motor neuron cultures. A coating solution 
consisting of PBS with 1% poly-L-ornithine, 3.75 μg/ml fibronectin and 10 μg/ml laminin 
was applied to tissue culture plates or coverslips and incubated at 37°C overnight. The 
coating solution was removed and the substrate was washed with PBS prior to use. 
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 Motor neuron precursors were collected in a 15 ml falcon tube and washed with 
PBS. They were dissociated with Accutase by incubating in a 37°C water bath and gentle 
trituration until most cells had dissociated from the neurosphere clusters. DMEM/F12 was 
added to the cells and cells were centrifuged at 1 000 rpm for 4 minutes. The supernatant 
was removed and the cell pellet resuspended maturation medium (Table 2.3) and plated 
at a seeding density of 0.5 x 105/200 mm2. Medium was changed once or twice a week by 
removing a half volume of old medium and adding a half volume of fresh maturation 
medium. 
 
Table 2.3. Maturation medium 
Component Final concentration 
Neurobasal medium 1x 
L-glutamine 1x 
Retinoic acid 0.1 μM 
Purmorphamine 0.1 μM 
N2 1x 
Penicillin-streptomycin 1x 
Non-essential amino acids 1% 
Ascorbic acid 400 μM 
Forskolin 10 μM 
BDNF 10 ng/ml 
GDNF 10 ng/ml 
 
2.1.6 Neural conversion of induced pluripotent stem cells and neural progenitor cell 
culture 
Neural progenitor cells (NPCs) were maintained on Matrigel. Matrigel was diluted 
in a 1 in 100 dilution in chilled DMEM: Nutrient Mixture F-12 (DMEM/F12) and used to 
cover the bottom of flasks and plates for NPC culture. Coating was prepared at least one 
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day before passaging of NPCs and stored at 4°C, wrapped in parafilm. Matrigel-coated 
flasks or plates were washed with phosphate buffered saline (PBS) prior to use.  
NPCs were generated by differentiating iPSCs into neuroectoderm by dual-SMAD 
signaling inhibition in CDM with SB431542 (10 μM; Tocris) and dorsomorphin (2.5 μM; 
Calbiochem) for 5-7 days. Neurospheres were formed by mechanical dissociation of 
neuroectoderm. Neurospheres were grown in suspension in poly-HEMA-treated tissue 
culture dishes and caudalised in CDM with RA (0.1 μM; Sigma) for 7-10 days. Caudalised 
neurospheres were collected and resuspended in expansion media (Table 2.4) and plated 
on Matrigel. 
 
Table 2.4. Expansion medium 
Component Final concentration 





bFGF 10 ng/ml 
 
Several days after plating, radial arrangement of columnar neuroepithelial cells 
known as neural rosettes emerge, surrounded by “flat” cells (Fig. 2.2).  Neural rosettes 
were selected using the STEMdiff Neural Rosette Selection Reagent (StemCell 
Technologies) following the manufacturer’s protocol. Neural rosette clusters were 
resuspended in expansion media and plated on fresh Matrigel. After two days, NPCs grow 
out and form a monolayer form the clusters. 
Medium was changed every other day and cells were passaged with Accutase one 
day after reaching 100% confluence. To split the cells, old medium was removed and cells 
were washed with PBS. Accutase was added to the flask and incubated at 37°C until cells 
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detached. Cells were collected in fresh medium and centrifuged at 1 000 rpm for 4 
minutes. The supernatant was removed and the cell pellet resuspended in fresh media. An 
aliquot of this was used in a 1 in 2 dilution in a new flask. 
 
 
Figure 2.2. Neural rosettes (arrows) formed two days after plating iPSC-derived 
neurospheres on Matrigel. Neuroepithelial cells derived from (A) FUS1 iPSCs and (B) WT-
1 iPSCs. Scale bar = 10 μm. 
 
2.1.7 Differentiation of neural progenitor cells 
iPSC-derived NPCs were differentiated into cortical neurons by withdrawal of 
bFGF. NPCs were plated at a seeding density of 0.3 x 105/200 mm2 on Matrigel in 
expansion media. The next day, the medium was removed and default medium (Table 2.5) 
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was added. Medium was changed once or twice a week by removing a half volume of old 
medium and adding a half volume of fresh default medium. After 7 days in default 
medium, a half volume of media was removed and a half volume of default maturation 
medium (Table 2.6) was added. 
 
Table 2.5. Default medium 
Component Final concentration 





Heparin 2 μg/ml 
 
Table 2.6. Default maturation medium 
Component Final concentration 





Heparin 2 μg/ml 
BDNF 5 ng/ml 
GDNF 5 ng/ml 
 
 
2.1.8 Cell counting 
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A haemocytometer was used to quantify the number of cells before plating for 
experiments and for transfection of cells. To do this, a cell suspension of 2 μl of cells and 
18 μl of DMEM/F12 was prepared in a polypropylene tube. The cell suspension was added 
to the chamber and the haemocytometer placed under a microscope. 3 sets of 4 square 
groups were counted. Only cells that were within the square and positioned on the left 
hand or bottom boundary lines were counted. Clumps of cells or cells touching the right 
hand or upper boundary lines were omitted. The total cell count was divided by three and 
multiplied by 50,000 (dilution factor x 5000) to obtain the number of cells per ml. 
 
2.1.9 Plasmid miniprep 
Bacterial cultures were prepared by inoculating frozen glycerol stock in Luria-
Bertani (LB) media containing 100 μg/ml of ampicillin and incubating in a shaker 
overnight at 37°C. Plasmids DNA was isolated from bacterial cultures using the NucleoSpin 
Plasmid kit (Macherey-Nagel) following the manufacturer’s instructions. Plasmid DNA was 
eluted with 30 μl of nuclease-free water (Ambion), quantified with microvolume 
spectrophotometer (Nanodrop, Thermo Scientific). Plasmid DNA was stored at -20°C.  
 
2.1.10 Transfection of iPSC-derived neurons 
Approximately 2 x 104 cells neural progenitors were seeded per well in 24-well 
plates in 500 μl of media. On the day of transfection, 250 μl of media was removed from 
each well and kept in sterile polypropylene tubes as conditioned medium. For each 
transfection, 1 μg of the plasmid construct was mixed and incubated with 1 μl of 
Lipofectamine 2000 and 50 μl of OPTIMEM for 50 minutes at room temperature to form 
complexes. The mixture was added to 250 μl of media drop-wise. 24 hours post-
transfection, the medium was replaced with a 1:1 mixture of conditioned medium and 
fresh medium. At 24 hours post-transfection, transfection efficiency was about 10% across 
experimental replicates. Similar transfection efficiencies were also observed for different 
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plasmids (ie. GFP-WT vs. GFP-mutant). However, after 7 days of differentiation, 
transfection efficiency dropped to about 4%.  
 
2.1.11 Treatment of cells 
Arsenite treatment was used as a cellular stressor for the induction of stress 
granules. A 250 mM stock solution was prepared by dissolving the appropriate amount of 
arsenite in endotoxin-free water and sterilisation by autoclaving. Arsenite was added to 
cells at a final concentration of 1 mM for 30 minutes. 
 
2.1.12 Mycoplasma test 
All cell lines were tested every month for mycoplasma infection. 2 ml of medium 
were taken from cell cultures and analysed using the MycoAlert™ Mycoplasma Detection 
Kit (Lonza) following the manufacturer’s instructions. The luminescence generated by the 




2.2.1 Extraction of RNA from cells 
Cells were manually scraped or collected by enzymatic dissociation in 
polypropylene tubes. Cells were centrifuged for 1 minute at 10 000 rpm and cell pellets 
were kept on ice and washed in PBS three times prior to RNA extraction. Total RNA was 
isolated from cultures of cell lines with the RNeasy kit (Qiagen) according to 
manufacturer’s instructions. RNA was quantified using a microvolume spectrophotometer 
(Nanodrop, Thermo Scientific). 
 
2.2.2 Reverse transcription polymerase chain reaction 
cDNA was synthesised by using 1 μg of total RNA with the SuperScript® III First-
Strand Synthesis System in a 20 μl volume. cDNA was diluted to 5 ng/μl and standard 
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polymerase chain reactions (PCR) were performed using Thermophilus aquaticus (Taq 
DNA polymerase). 25 ng of cDNA of each sample was amplified in a 25 μl reaction 
containing 0.2 mM dNTP, PCR primers, 1.5 mM MgCl2, 10x PCR buffer and 0.1 μl Taq DNA 
polymerase. Amplification was performed at 95°C for 30 seconds, 35 cycles of 58°C or 
61°C for 30 seconds and 72°C for 30 seconds, followed by extension at 72°C for 10 
minutes. PCR products were electrophoresed in 1% agarose gels.  
 
2.2.3 Agarose gel electrophoresis 
The agarose gel electrophoresis involved heating the 1% agarose (w/v) with 1x 
TAE buffer using a microwave oven for a few minutes on high power until dissolved. When 
the agarose solution had cooled down to about 50°C, ethidium bromide was added, then 
poured into a levelled gel casting tray. The gel was allowed to set at room temperature for 
about 30 minutes, then placed into a horizontal electrophoresis unit and finally covered 
with 1x TAE buffer. 5x loading buffer was added to each PCR product and the resultant 
mixture loaded onto the gel, along with 2 μl of DNA ladder. Gels were run at 125 V for 
about 1 hour. Gels were removed and placed into the BioDOC-IT Imaging system, an UV 
transilluminator (UVP Inc., San Gabriel, U.S.A.), and photographed digitally under UV 
transillumination. The size of the DNA was determined by a 100 base pair (bp) DNA ladder 
(New England BioLabs). 
 
2.2.4 Immunofluorescence 
Cells were fixed in 4% paraformaldehyde at room temperature for 15 minutes, 
permeabilised in 0.5% Triton-X in PBS at room temperature for 15 minutes and blocked in 
10% donkey serum (Sigma) in PBS at room temperature for 1 hour. Cells were probed 
with the appropriate primary antibodies diluted in 5% donkey serum overnight at 4°C. 
AlexaFluor-488, AlexaFluor-550 and AlexaFluor-650-labelled secondary antibodies 
(ThermoScientific) were diluted 1:400 in PBS and applied for 1 hour at room temperature 
in the dark. DAPI (Sigma) counterstaining (1.25 μg/ml) was then applied for 5 minutes at 
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room temperature in the dark. Coverslips were mounted on microscope slides 
(SuperFrost, VWR) with DAKO mounting medium and dried at 4°C overnight before 
imaging with a Zeiss Axiovert S100 (HB0100) (Carl Zeiss Ltd.) inverted phase contrast 
fluorescent microscope or a Leica laser scanning confocal microscope (TCS-SP5). 
 
2.2.5 Quantitative image analysis 
 MetaMorph Image System 7.5 (v. 7.7, Molecular Devices) and ImageJ (version 
1.45e, NIH, Bethesda, USA, http://rsb.info.nih.gov/ij/) software programs were used for 
quantitative image analysis. For each analysis, 7-12 images were taken with the same 
exposure times as 16-bit images from each biological replicate. Three biological replicates 
were performed. All image analysis was performed in an automated fashion, with the 
exception of the quantification of dendritic protrusions and localization of synaptic 
proteins, which was counted by eye. Detailed description of different analyses will be 
provided in the corresponding chapters. 
 
2.2.6 Protein extraction 
Cells were manually scraped or collected by enzymatic dissociation in 
polypropylene tubes. Cells were centrifuged for 1 minute at 10 000 rpm and cell pellets 
were kept on ice and washed in PBS three times prior to protein extraction. Cells were 
lysed in Radio Immunoprecipitation assay (RIPA) buffer (Table 2.7) supplemented with 1X 
Complete protease inhibitor (Roche) and left on ice for 20 minutes. Samples were 
sonicated for 10 seconds then centrifuged at 4°C for 30 minutes at maximum speed.  
 
Table 2.7 RIPA buffer 
Component Final concentration 




Sodium Deoxycholoate 0.5% 
Tris 20 mM, pH 7.4 
NaCl 150 mM 
EDTA 1 mM 
EGTA 1 mM 
 
 
2.2.7 Protein assay 
Protein concentrations were determined using the DC Protein Assay Kit II 
(BioRad) according to the manufacturer’s instructions. Briefly, 2 μl of bovine serum 
albumin (BSA) standards (0 – 1.5 μg/μl) and samples were used in duplicates and pipetted 
onto a microtiter plate (Corning). 25 μl of a mixture containing 1 mL of Reagent A and 20 
μl of Reagent S were added to each well. 200 μl of Reagent B was then added to each well. 
A clean, dry pipet tip was used to pop any air bubbles. After 15 minutes, absorbance was 
read with a microplate reader set to 750 nm. Protein concentrations were calculated 
based on the mean absorbance of sample duplicates. 
 
2.2.8 Western immunoblotting 
5 – 10 μg of lysates were denatured by boiling with 2X SDS sample buffer (Table 
2.8) for 10 minutes at 100°C. Biological replicates, along with 2 μl of Precision Plus Protein 
Dual Color Standard (BioRad), were run on separate NuPAGE Novex 10% Bis-Tris Midi 
gels in 4Morpholinepropanesulfonic acid (MOPS) buffer for 60 minutes at 170 V. The gels 
were incubated in transfer buffer for 15 minutes and transferred to nitrocellulose 
membranes using iBlot Transfer Stack and the iBlot Gel Transfer Device for 7.5 minutes. 
Membranes were incubated with Ponceau Red (Sigma; 0.1% w/v in 5% acetic acid) at 
room temperature to detect protein bands. Membranes were washed with Tris-buffered 
saline with 0.1% Tween 20 (TBST; Table 2.9) (Sigma) until Ponceau staining was 
completely removed. Membranes were then blocked with 5% non-fat milk solution in 
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TBST for 30 minutes prior to probing with primary antibodies diluted in a 1% milk 
solution in TBST at 4°C overnight. Membranes were then washed three times with TBST 
and probed with the relevant IRDye secondary antibodies (Li-Cor) diluted 1:5000 in 1% 
milk solution in TBST for 1 hour at room temperature in the dark. Membranes were 
washed three times with TBST and the fluorescent signal was detected with the Odyssey 
Infrared Imaging System (Li-Cor Biosciences). Blots were quantitated using ImageJ 
(version 1.45e, NIH, Bethesda, USA, http://rsb.info.nih.gov/ij/). 
 
Table 2.8 2X SDS sample buffer 
Component Final concentration 
Tris 0.2 M, pH 6.8 
SDS 4%  
Glycerol 20% 
Bromophenol blue 2 mg/ml 
Water Up to final volume 
 
Table 2.9 10X TBS Buffer 
Component Final concentration 
Tris 24.2 g/l 
NaCl 80 g/l 
Water 1 l, pH 7.6 
 
 
2.2.9 PE Annexin V Apoptosis detection 
Neural progenitor cell viability was monitored by the Annexin V-PE Apoptosis 
Detection Kit I (BD Bioscience). Apoptosis is characterised by particular morphological 
features, including the loss of plasma membrane. An early feature of apoptosis is the 
translocation of membrane phospholipid phosphatidylserine (PS) from the inside of the 
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plasma membrane to the outside of the plasma membrane. Annexin V is a protein with 
high affinity for (PS). Thus, Annexin V conjugated to fluorochrome such as Phycoerythrin 
(PE) may be used to probe for cells that are undergoing apoptosis. 7-AAD is a fluorescent 
chemical compound with strong affinity for DNA. As 7-AAD cannot pass through intact 
plasma membranes, it may be used as a marker for late apoptosis, when the plasma 
membrane has been compromised. 
  Annexin V and 7-AAD staining of neural progenitors was performed according to 
the manufacturer’s instructions and assessed with a fluorescence activated cell sorting 
(FACS) Canto flow cytometer (BD Biosciences). 10 000 cells were sorted for each 
condition in each experiment. Three biological replicates were performed. Data were 








 In this study, we used molecular biology approaches to validate the pluripotency of 
mutant and WT iPSC lines and their capacity to generate functional motor neurons, the cell 
type affected in Motor Neuron Disease. The seminal papers by Takahashi and Yamanaka 
(Takahashi and Yamanaka 2006; Takahashi et al. 2007) used several methods to 
demonstrate that the novel cell types recapitulate key features of ESCs. We have 
characterised the morphology, karyotype, genotype, expression of ESC markers, and 
differentiation ability of two iPSC lines generated from a patient carrying the FUS R521C 
mutation and two control iPSC lines generated from two different control individuals. To 
confirm that iPSC lines maintained the parental FUS genotype, we have carried out direct 
sequencing of genomic DNA extracted from these iPSC lines. Finally, we assessed the 
neural differentiation potential of the iPSC lines by examining the expression of a number 
of neuronal lineage-specific markers and by electrophysiological characterisation. 
 
3.1.1 Morphology 
hESCs isolated from in vitro fertilised human embryos have an undifferentiated 
morphology consisting of a high ratio of nucleus to cytoplasm, prominent nucleoli, and a 
colony morphology similar to rhesus monkey ESCs (Fig. 3.1; (Thomson et al. 1995; 
Thomson et al. 1998). Undifferentiated pluripotent stem cell colonies typically have clear 
borders and contain small round cells with spaces between them. Any colony with a 
change from this typical morphology can be considered to be differentiating (Fig. 3.1; 
(Aasen et al. 2008)). Colonies remain mostly undifferentiated; however, spontaneous 
differentiation can occur in small areas within colonies. These cells must be removed since 




Figure 3.1. Colony morphology of ESCs. A) Undifferentiated rhesus monkey ESCs (R278.5 
cell line; Thomson et al., 1995). B) Undifferentiated hESCs (H9 cell line; (Thomson et al. 
1998)). C) H9 colony (Thomson et al. 1998). D) An iPSC colony with a cluster of 
differentiated cells on top (Aasen et al. 2008). 
 
3.1.2 Karyotype analysis 
Prolonged culture of pluripotent stem cells has been shown to result in genetic 
abnormalities (Draper et al. 2004). Karyotype analysis is necessary to show that iPSC lines 
have maintained genomic integrity. This is done by staining the DNA in cells in the 
metaphase stage of cell division. Based on cytogenetic characteristics of chromosomes at 





3.1.3 Direct sequencing 
Direct sequencing was performed to confirm that iPSCs are derived from the 
parent fibroblasts rather than cross contamination. Genomic DNA was obtained from 
individual cell lines using the Wizard® Genomic DNA Purification Kit (Promega) according 
to the manufacturer’s instructions. Direct sequencing of exon 15 of FUS was performed on 
all iPSC lines. 
 
3.1.4 Marker gene expression 
A standard step to confirm the pluripotency of newly generated cell lines is to use 
immunocytochemistry and reverse transcriptase- polymerase chain reaction (RT-PCR) to 
examine the expression of stem cell markers. A panel of molecular markers specific to ESC 
physiology has been identified that are fundamental to maintaining the undifferentiated 
state including: nuclear transcription factors OCT4, NANOG, and SOX2, as well as keratin 
sulphate antigens TRA-1-60 and TRA-1-80. Maintenance of pluripotency depends on a 
tight regulation of OCT4, NANOG and SOX2, and the expression of all markers is necessary 
as a definition of pluripotency (Martí et al. 2013).  
 
3.1.5 Embryoid Body formation 
After verifying that newly generated cell lines express pluripotency markers, the 
next step in characterisation is to determine their capacity to differentiate into cells of the 
three primordial germ layers of the embryo (endoderm, mesoderm and ectoderm). This 
may be done by an in vitro or in vivo differentiation test. The in vivo test involves injecting 
newly generated pluripotent cells into severe combined immunodeficient (SCID) mice.  
Pluripotent cells will proliferate and differentiate in the tissues where they have been 
injected and form a teratoma containing tissues from the three germ layers. 
Differentiation may then be confirmed by immunohistochemistry for germ layer markers.  
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The in vitro test involves the differentiation of embryoid bodies (EBs) in culture. 
Newly generated pluripotent cells are first cultured in suspension to form large 
aggregates, called EBs. EBs are then allowed to adhere to a cell surface where they can 
either be guided to differentiate toward a specific cell lineage, or allowed to spontaneously 
differentiate into the cell types derived from the three germ layers. Again, confirmation of 
differentiation may be done by immunocytochemistry and RT-PCR for germ layer 
markers. As the field has evolved fewer laboratories are using an in vivo differentiation 
test (Nestor and Noggle 2013), and we opted to use an in vitro EB formation test. This 
method is reliable and demonstrates the ability of our newly generated iPSC lines to 
differentiate into cells from the three germ layers. Characteristic, tissue-specific markers 
include: endoderm – GATA4, mesoderm – RUNX1 and BRACHYURY, and ectoderm – PAX6 
(Park et al. 2008). 
 
3.1.6 Neural conversion of iPSCs and motor neuron differentiation 
Once the pluripotency of the iPSCs is confirmed, the next step is to direct their 
differentiation into the cell type of interest, for the purpose of this study, motor neurons 
(MNs). The developmental steps involved in the generation of MNs were identified more 
than a decade ago (Jessell, 2000). The first step in MN specification requires neural 
inductive signals to convert primitive ectodermal cells to a rostral neural state. This is 
followed by the caudalisation of rostral neural cells by signaling molecule retinoic acid 
(RA) to generate spinal progenitors. Finally, the activation of Sonic hedgehog (Shh) 
signaling pathway specifies the terminal differentiation of spinal progenitors into MNs.  
Using these signaling factors, Wichterle et al. (2002) showed that it was possible to 
generate MNs from mouse ESCs and that this developmental pathway recapitulated the 
development of MNs in vivo. The first protocol to direct the differentiation of ESCs into 
MNs relied on EB formation. This method was not without its limitations, as the 
differentiation of EBs is often heterogeneous and the yield of neural cells is often very low. 
A recent method of neural differentiation was developed to address these issues. This 
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approach used two factors, Noggin and SB431542, to inhibit the SMAD signaling pathway 
to induce the neural differentiation of monolayer hESCs and hiPSCs (Chambers et al. 
2009). Dual SMAD inhibition yielded 82% neuroepithelial cells that express typical neural 
stem cell markers. Chambers et al. (2009) showed that these cells can be differentiated 
into MNs after two weeks of exposure to BDNF, RA, Shh and ascorbic acid.   
Thus, we chose this approach for the neural conversion of iPSCs and subsequent 
motor neuron differentiation. The use of Noggin was eventually replaced with a small 
molecule, Dorsomorphin, which was recently shown to be more effective in the inhibition 
of the SMAD signaling pathway (Kim et al. 2010). Similarly, we have also used 
purmorphamine, a small molecule that activates the Shh pathway, in the place of Shh. 
Purmorphamine has been shown to induce the differentiation of ventral spinal 
progenitors and motor neurons with similar efficiency to Shh but at a significantly lower 




 Initial characterisation of iPSCs was done using light microscopy. Phase contrast 
images of all iPSC lines were obtained with a Zeiss Axiovert S100 microscope. 
 
3.2.2 Karyotype analysis 
 Intermediate (passage 40 or earlier) and late (passage 50 or more) passage iPSCs 
from all iPSC lines were used for karyotype analysis. iPSCs were washed with PBS three 
times and manually scraped from tissue culture flasks. Samples were centrifuged 1 minute 
at 10 000 rpm and the supernatant removed. Cells were kept at 4°C and sent for G-banding 





 iPSCs were fixed and samples prepared as described in Section 2.2.4. iPSCs were 
probed with primary antibodies (Table 3.1) diluted in 5% donkey serum overnight at 4°C. 
Donkey anti-rabbit or mouse AlexaFluor-488 secondary antibodies diluted 1:400 in PBS 
were then applied for 1 hour at room temperature in the dark. DAPI counterstaining (1.25 
μg/ml) was applied and coverslips mounted as described in Section 2.2.4. Images were 
obtained with a Zeiss Axiovert S100 microscope. 
 
Table 3.1. Primary antibodies 
Antibody Host Company Dilution 
SSEA4 Mouse monoclonal Millipore 1:200 
Tra-1-60 Mouse monoclonal Millipore 1:200 
Nanog Rabbit polyclonal Santa Cruz 1:50 
OCT3/4 Mouse monoclonal Millipore 1:200 
SOX1 Mouse monoclonal BD Pharmingen 1:100 
Nestin Rabbit polyclonal Millipore 1:500 
MAP2 Mouse monoclonal Abcam 1:500 
β3-Tubulin Mouse monoclonal Sigma 1:500 
HB9 Mouse monoclonal Hybridoma Bank 1:20 
Islet1 Mouse monoclonal Hybridoma Bank 1:20 
Synaptophysin Rabbit  polyclonal Synaptic Systems 1:100 
PSD95 Mouse monoclonal Synaptic Systems 1:100 
ChAT Sheep polyclonal Millipore 1:100 
 
3.2.1 RT-PCR 
 iPSCs were washed with PBS three times and manually scraped from tissue culture 
flasks (2500 mm2). iPSC-derived neural progenitors were enzymatically dissociated from 
tissue culture plates with 1 mL of Accutase, then washed with PBS three times. RNA and 
cDNA were extracted and synthesised as previously described (Sections 2.2.1 and 2.2.2). 
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PCR reactions were performed as described in Section 2.2.2. The annealing temperature 
for primers of PAX6, SOX1, HOXB4, NKX6.1, GATA4, RUNX1, AFP and BRACHYURY was 
58°C, and for the rest of the primers, 61°C (Table 3.2). 
 
Table 3.2. PCR primers  
Gene Forward primer Reverse primer 
BETA-ACTIN GTTACAGGAAGTCCCTTGCCATCC CACCTCCCCTGTGTGGACTTGGG 
OCT4 GTACTCCTCGGTCCCTTTCC CAAAAACCCTGGCACAAACT 
NANOG AATACCTCAGCCTCCAGCAGATG TGCGTCACACCATTGCTATTCTTC 
C-MYC CAACAACCGAAAATGCACCAGCCCCAG CGCTCGAGGTTAACGAATT 
KLF4 GATGAACTGACCCAGGCACTA GTGGGTCATATCCACTGTCT 
GATA4 CTAGACCGTGGGTTTTGCAT TGGGTTAAGTGCCCCTGTAG 
RUNX1 CCCTAGGGGATGTTCCAGAT TGAAGCTTTTCCCTCTTCCA 
BRACHYURY ACCCAGTTCATAGCGGTGAC CAATTGTCATGGGATTGCAG 
NESTIN GGCGCACCTCAAGATGTCC CTTGGGGTCCTGAAAGCTG 
SOX1 GGAAACACAATCGCTGAACC ATTATTTTGCCCGTTTTCCC 
PAX6 ATGTGTGAGTAAAATTCTGGGCA GCTTACAACTTCTGGAGTCGCTA 
NKX6.1 CACACGAGACCCACTTTTTCC CCCAACGAATAGGCCAAACG 
HOXB4 GTGAGCACGGTAAACCCCAAT CGAGCGGATCTTGGTGTTG 
  
3.3 RESULTS 
3.3.1 iPSCs exhibit ESC morphology and growth characteristics 
 The morphology of all iPSC lines was evaluated by light microscopy to compare 
with the morphology of ESC line HUES. iPSCs formed tightly packed and flat colonies with 
clear borders (Fig. 3.2). Individual iPSCs exhibited morphological features similar to ESCs, 
including a high nucleus to cytoplasm ratio, notable nucleoli, a round shape and 
spontaneous differentiation in culture. In addition, iPSCs proliferate for more than 80 
passages while maintaining these characteristics, with at least 11 months in culture. The 
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population doubling time of iPSCs were approximately 50 hours. All of the cell lines were 
successfully cryopreserved and thawed. 
 
 
Figure 3.2. Phase contrast images of human pluripotent stem cells. Colonies of iPSCs 
derived from A) FUS fibroblasts and B) WT fibroblasts and C) colonies of hESCs from HUES 
cell line.  D) Undifferentiated iPSCs. Scale bar = 10 μm. 
 
3.3.2 iPSCs maintain normal karyotypes 
 Karyotype analysis was undertaken to examine the chromosomal integrity of iPSC 
lines. All of the iPSC lines generated did not acquire any chromosomal abnormalities 






had a normal karyotype of 46 XX, WT1 iPSC line had a normal karyotype of 46 XY (Fig. 3.3) 
and WT2 iPSC line had a normal karyotype of 46 XX (not shown). On one occasion, WT1 
iPSCs exhibited an abnormal banding pattern, with alteration in the chromosome 22. This 
is a common region of normal variation, and this unusual banding pattern may simply 
reflect a polymorphism. Alternatively, the karyotype alteration may be due to poor 
maintenance of the iPSC culture, as differentiated might show alterations in the karyotype. 
We included this line in our analysis as they did not behave any differently from the other 









Figure 3.3. Representative karyogram of A) FUS iPSCs at passage 52 and B) WT1 iPSCs at 
passage 53. Arrow indicates an unusual banding pattern in the short arm of chromosome 
22 of WT1 iPSCs. 
 
3.3.3 iPSCs maintain parent genotype 
 Direct sequencing of exon 15 of FUS was performed on all iPSC lines to confirm 





cell line. iPSC lines derived from controls maintained the WT genotype (Fig. 3.4). All iPSC 




Figure 3.4. Representative chromatogram of direct sequencing of FUS exon 15 in WT and 
FUS iPSC lines. Arrow indicates the location of the R521C mutation in FUS iPSCs. 
 
3.3.4 Marker gene expression 
 Colonies from FUS and WT1 iPSC lines showed strong protein expression of 
pluripotency markers OCT4, SSEA4, TRA-1-60 and NANOG (Fig. 3.5). All iPSC lines 
expressed OCT4, NANOG, c-MYC and KLF4 by RT-PCR (Fig. 3.6). Relative to hESC lines 
HUES, iPSC lines expressed higher levels of C-MYC. FUS2 iPSCs expressed lower levels of 
KLF4 compared to all other pluripotent stem cell lines. The expression of pluripotency 
markers was also assessed in WT2 iPSC line, which expressed OCT4, NANOG, c-MYC and 








Figure 3.5. Representative images (20x) of A) FUS and B) WT iPSC colonies stained 







Figure 3.6. WT and FUS iPSCs demonstrate expression of pluripotency markers. RT-PCR 
was performed on HUES and iPSC cultures. No cDNA is used as a negative control. Beta-
actin is shown as a positive amplification and loading control. HUES ESCs, WT1, FUS1 and 
FUS2 iPSCs all demonstrate expression of pluripotency transcription factors OCT4, NANOG, 
C-MYC, and KLF4. 
 
3.3.5 iPSCs can differentiate into EBs 
EBs derived from FUS and WT1 iPSCs showed similar gene expression of 
embryonic germ layers: GATA4 (endoderm), RUNX1 and BRACHYURY (mesoderm), PAX6 
(ectoderm) (Fig. 3.7). Some embryoid bodies exhibited spontaneous beating, a feature of 
contractile cardiomyocytes with pacemaker activity (Xu et al. 2002). FUS and WT1 iPSC 
lines demonstrated a similar capacity to differentiate into the three germ layers. EBs were 
derived from WT2 iPSCs at a later time point, and also demonstrated gene expression of 





Figure 3.7. In vitro differentiated WT and FUS iPSCs demonstrate gene expression from 
the three germ layers. Semi-quantitative RT-PCR was performed on undifferentiated 
(undiff) iPSC cultures and differentiated (diff) EBs. No cDNA is used as a negative control. 
Beta-actin is shown as a positive amplification and loading control. FUS1, FUS2 and WT1 
EBs all demonstrate upregulation of characteristic, tissue-specific markers upon 
differentiation relative to the corresponding iPSCs from which they were derived. 
Endoderm – GATA4, ectoderm – PAX6, mesoderm – RUNX1, Brachyury. 
 
3.3.6 Neuronal marker expression 
 During neural induction there is a down-regulation of OCT4 expression and a 
corresponding upregulation of nestin expression (Fig. 3.8). FUS and WT1 iPSCs displayed 
variable rates of neural differentiation. Expression of pluripotency marker OCT4 was 
dramatically reduced by day 7 of neural differentiation in FUS iPSCs, and completely 
down-regulated by day 8, WT1 iPSCs still displayed strong expression of OCT4 by day 7 of 
neural differentiation, and OCT4 expression was still observed in some cells of WT1 iPSC 
colonies by day 8 of neural differentiation (Fig. 3.9). FUS iPSCs were positive for nestin at 
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day 5, whereas expression of nestin was induced in day 6 of neural differentiation in WT 
iPSCs (Fig. 3.10). FUS and WT1 iPSCs differentiated into neuroepithelial cells that 
expressed neuroectoderm markers SOX1 and nestin (Fig. 3.12). The rate of neural 




Figure 3.8. Expression of OCT4 is high on D0 of neural induction. OCT4 expression is 
down-regulated during neural induction. Nestin is not expressed on D0 of neural 





Figure 3.9. Immunocytochemistry of dual SMAD inhibition neuralisation. By day 7 of 
neural differentiation, OCT4 (green) expression was mostly down-regulated. By day 5 of 
neural differentiation, nestin expression was up-regulated in FUS iPSC lines. Nestin (red) 
expression was up-regulated in day 6 of neural differentiation in WT1 iPSC line. Scale bar 






Figure 3.10. Representative images (20x) of a) WT and b) FUS iPSC neural progenitors, 
following two weeks of differentiation, stained positive for neuroectoderm markers SOX1 






FUS and WT neuroepithelial cells were treated with 0.1 μM retinoic acid and 1 μM 
purmorphamine to generate NKX6.1- and HOXB4-positive ventral spinal progenitors (See 
section 2.1.5; Fig. 3.13). By 5 weeks of culture, FUS and WT iPSCs differentiated into 
neurons displaying strong expression of MAP2 (Fig. 3.14) and β3-tubulin (Fig. 3.15). The 
presence of MNs in these cultures was confirmed by expression of Islet1 (Fig. 3.16), HB9 
(Fig. 3.17) and choline acetyltransferase (ChAT) (Fig. 3.18). Using this differentiated 
method, FUS and WT iPSCs differentiated into neuronal cultures with a similar proportion 
of MNs (Fig. 3.17). By 8 weeks of culture, FUS and WT iPSC-derived neurons expressed 










Figure 3.11. In vitro differentiated WT and FUS iPSCs demonstrate gene expression of 
neuroectoderm and spinal progenitor markers. Semi-quantitative RT-PCR was performed 
on neural progenitors differentiated for 3 weeks. cDNA from fibroblasts and no cDNA is 
used as a negative control. Beta-actin is shown as a positive amplification and loading 
control. WT1, WT2, FUS1 and FUS2 neural progenitors all demonstrate upregulation of 





Figure 3.12. Confocal representative images (63x) of a) WT and b) FUS iPSC cortical 
neurons differentiated for 8 weeks stained positive for neuronal dendrite-specific marker 





Figure 3.13. Representative images (20x) of a) WT and b) FUS iPSC motor neuron 
populations differentiated for 5 weeks stained positive for neuron-specific marker β3-





Figure 3.14. Representative images (20x) of a) WT and b) FUS iPSC motor neuron 
populations differentiated for 8 weeks stained positive for Islet1 (green), a marker of 







Figure 3.15. Representative images (20x) of a) WT and b) FUS iPSC motor neuron 
populations differentiated for 8 weeks stained positive for motor neuron-specific marker 
HB9 (green) and DAPI (blue). c) Percentage of cells expressing the motor neuron marker 
HB9 differentiated from WT1 and FUS1 iPSC lines. Error bars represent standard error of 






Figure 3.16. Representative images of WT and FUS iPSC motor neuron populations 
differentiated for 8 weeks stained positive for ChAT (green), the enzyme responsible for 
biosynthesis of acetylcholine, and DAPI (blue). ChAT is a specific indicator for monitoring 
the functional state of cholinergic neurons. (Right panels) Higher magnification images of 





Figure 3.17. Representative images of a) WT and b) FUS iPSC motor neuron populations 
differentiated for 12 weeks stained positive for pre-synaptic marker piccolo (green), post-






After more than 12 weeks in culture, FUS and WT iPSCs differentiated into 
functional neurons that generated single and multiple action potentials following current 
injections of various amplitudes (Fig. 3.20). FUS and WT iPSC-derived neurons also 
exhibited spontaneous excitatory postsynaptic currents (results not shown).  
 
 
Figure 3.18. Representative action potentials evoked in FUS iPSC motor neuron 
populations differentiated for 12 weeks under current clamp conditions by current 
injection. iPSC neurons had a negative resting potential and following injection of current, 
a) repetitive spiking and b) single spiking were recorded. (Experiments and images 





 In this chapter, it was described the characterisation of iPSC lines that were 
generated from one ALS patient fibroblast line carrying the FUS R521C mutation and two 
control fibroblast lines. All iPSC lines exhibited ESC-like morphology, normal karyotypes, 
and pluripotency gene expression. The lines derived from the patient fibroblasts 
maintained the FUS R521C mutation, determined by direct sequencing of exon 15 of FUS. 
All iPSC lines demonstrated the ability to differentiate into EBs and the cells express 
markers of the three germ layers. All iPSCs are capable of differentiating into functional 
motor neurons in vitro. Neurons derived from FUS and WT iPSCs expressed neuronal 
markers, generated action potentials and exhibited spontaneous excitatory postsynaptic 
currents. 
 Although teratoma formation is considered a gold standard of pluripotency, we did 
not have the facilities required to perform this assay. Teratoma formation requires the use 
of animals, and may not necessarily accurately predict differentiation potential in culture. 
Although an in vivo test of differentiation is required for the registration of a cell line, its 
necessity is debated and some argue that in vitro test of differentiation is sufficient (Buta 
et al. 2013). Thus, we opted to use the in vitro test to confirm the capacity of our iPSC lines 
to generate cell types of the three germ layers.  
 Recently, an alternative approach was developed for assessing the pluripotency in 
human cells, including iPSCs. This approach, known as the PluriTest, takes advantage of 
gene expression datasets generated from about 450 genome-wide microarray-based 
transcriptional profiles from diverse stem cell preparations to generate a much larger 
dataset from which to both assess pluripotency and to obtain detailed information on 
features of a sample that deviate from typical pluripotent stem cell lines (Muller et al., 
2011). This test is now commonly used as a method of characterising iPSC lines and 
comparing their features with established human pluripotent stem cell lines. 
 The WT1 iPSC line exhibited an unusual banding pattern in the short arm of 
chromosome 22 in this karyotype analysis (see fig. 3.3). Karyotypic changes are common 
in human embryonic and induced pluripotent stem cells (Taapken et al., 2011), but this 
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particular abnormality has not been published to date. The appearance of this 
chromosome is not typical. It is possible that this aberration pattern may be the result of 
segment duplications. However, this is a common region of normal variation, and this 
unusual banding pattern may simply reflect a polymorphism. Spectral karyotyping is 
another technique that improves the resolution of the traditional karyotype analysis, 
where chromosome-specific DNA sequences are labeled with different fluorophores. The 
coloured chromosomes are then visualized to detect any genomic changes. This technique 
is more expensive and has a higher resolution for identification of translocations. 
Alternatively, array-based analyses of genomic integrity, such as array-comparative 
genomic hybridization and single nucleotide polymorphism arrays, enable the detection of 
copy number changes along the genome and allow for much higher resolution, albeit at 
much higher costs. Finally, whole genome sequencing of iPSCs may be done to examine 
genomic integrity at the single-base resolution. The cost of this approach is much higher 
than the other techniques, and unlikely to be used as a routine stem cell integrity analysis 
currently. 
We have assessed the expression of pluripotency markers and embryonic germ 
layer markers using RT-PCR in this study. The negative control used for both of these 
experiments was no cDNA. Another negative control that may have been used for 
assessing the expression of pluripotency markers is cDNA from fibroblasts or other 
somatic cell types. Alternatively, cDNA from tissue corresponding to each of the three 
germ layer may have been used as a positive control for assessing the expression of 
embryonic germ layer markers.  
All iPSC lines were successfully differentiated into functional MNs as shown by 
detailed cell-lineage and electrophysiology studies. iPSC lines from the patient and 
controls were induced to differentiate into neuroectoderm and spinal progenitor cells, and 
subsequently into similar proportions of HB9+ cultures. In our cultures, 17-24% of 
neuronal populations were HB9-positive. However, as HB9 and ISLET1 expression are 
variable, we rely on ChAT expression to represent mature MNs.  All iPSC lines 
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demonstrated strong expression of ChAT as shown by immunocytochemistry. However, 
the specificity of the antibody used in this study was not assessed, and may lead to 
unspecific staining. Problems with antibody specificity may be addressed by using the 
antibody for immunoblotting of tissue with and without the protein of interest. 
Patient iPSC lines showed an earlier neural induction relative to control iPSC lines. 
It has been reported that human iPSCs differentiate into neuroepithelia with variable rates 
and efficiency (Hu et al. 2010). Whether this variability is a consequence of the R521C 
mutation or inherent variability between iPSC lines merits further investigation. It would 
be of interest to determine whether iPSC lines derived from patients carrying other ALS-
associated FUS mutations demonstrate a similar propensity to differentiate into 
neuroepithelia earlier. 
In summary, we have carried out extensive characterisation of patient and control-
derived iPSC lines to show that all iPSC lines demonstrate the hallmarks of pluripotency. 
These iPSC lines can be differentiated into functional motor neurons using 
developmentally relevant signaling factors. Thus, the FUS R521C mutation does not 
prevent differentiation and functional maturation of motor neurons. In the next chapter, I 
describe the characterisation of FUS-associated ALS phenotypes in neural cells derived 





CHARACTERISATION OF FUS-ASSOCIATED ALS PHENOTYPES 
4.1 BACKGROUND 
 In this study, we used molecular and cellular biology techniques to determine 
whether neural populations derived from FUS iPSCs recapitulate the key pathological 
features of FUS-associated ALS. Several studies have reported that ALS patient-derived 
iPSCs can be differentiated into neural populations that reveal mutation-specific 
phenotypes. MN cultures derived from mutant TDP-43 iPSCs have elevated levels of 
insoluble TDP-43 protein, perturbed RNA metabolism, abnormal morphology and 
decreased survival (Bilican et al. 2012; Egawa et al. 2012). Neurons derived from iPSC 
lines containing the hexanucleotide repeat in C9ORF72 have RNA foci containing the 
GGGGCC repeat, repeat-associated non-ATG (RAN) translation products, elevated p62 
levels and increased sensitivity to cellular stress (Almeida et al. 2013). We therefore 
sought to assess three well-defined phenotypes specific to FUS mutations, the 
mislocalisation of mutant FUS protein, the redistribution of mutant FUS in stress granules 
and cell death and increased vulnerability to cellular stress as have been reported in cell 
line transfection studies (Vance et al. 2009; Bosco et al. 2010; Dormann et al. 2010; Vance 
et al. 2013). 
 
4.1.1 Mislocalisation of FUS protein 
In cultured human cells, FUS protein displays a diffuse nuclear localisation with 
infrequent nuclear granules, and a diffuse distribution in the cytoplasm, with some 
localisation in small cytoplasmic granules (Andersson et al. 2008). An assessment of the 
distribution of FUS protein in post-mortem tissue of patients with FUS mutations revealed 
occasional very large FUS immunoreactive inclusions in the cytoplasm in lower MNs 
(Kwiatkowski et al. 2009; Vance et al. 2009).  
Functional studies have shown that ALS-associated FUS mutations result in an 
increase in the cytoplasmic localisation of FUS protein compared to the WT protein 
108 
 
(Kwiatkowski et al. 2009; Vance et al. 2009). It was subsequently revealed that the 
majority of ALS-associated FUS mutations occur within a non-classical proline-tyrosine 
(PY) nuclear localisation signal which is necessary for Transportin-mediated nuclear 
import of FUS protein (Dormann et al. 2010). Interference with this transport pathway 
resulted in the redistribution of FUS to the cytoplasm and reduction of nuclear levels of 
FUS. 
 
4.1.2 Redistribution of mutant FUS in stress granules 
Protein aggregates are a key pathological hallmark of ALS. In the initial reports of 
FUS mutations in FALS patients, neuropathological exams of individuals with FUS 
mutations revealed large globular and elongated cytoplasmic inclusions labelled positively 
by FUS antibodies in spinal cord MNs and dystrophic neurites (Fig. 4.1; (Kwiatkowski et al. 
2009; Vance et al. 2009). A detailed analysis of six ALS-FUS cases later showed that FUS-
immunoreactive neuronal and glial inclusions are a consistent feature in multiple 







Figure 4.1. Immunostaining of FUS in dystrophic neurites from the basal ganglia in a 
patient with FUS R514G mutation (Image generated by Andrew King, unpublished). 
 
Subsequently, several independent groups reported that ALS-linked FUS mutants 
are redistributed into cytoplasmic stress granules under conditions of cellular stress, such 
as strong inhibition of transportin-dependent import, oxidative stress or heat shock 
cellular insults (Bosco et al. 2010; Dormann et al. 2010; Vance et al. 2013). Dormann et al. 
(2010) also showed that pathological inclusions in ALS-FUS patients label positively for 
stress granule marker proteins such as poly(A)-binding protein 1 (PABP-1) and eIF4G. As 
its name suggests, PABP-1 binds the poly(A) tail of mRNA and regulates mRNA translation 
and stability by functioning in miRNA-mediated gene expression regulation and nonsense-
mediated decay. PABP-1 is a central component of stress granules, and are recruited to 
stress granules during stress granule assembly and disassembly (Kedersha et al., 2001). 
These findings suggest that stress granule formation may be involved in the formation of 
protein aggregates observed in ALS-FUS. 
 
4.1.3 Neuronal susceptibility 
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  ALS is a neurodegenerative disorder characterised by the progressive loss of 
upper and lower motor neurons. It is believed that various initiating triggers, such as gene 
mutations, protein damage by oxidation or protein seeding, lead to the aggregation of 
specific proteins that results in neuronal toxicity. Animal models of FUS-related 
proteinopathy have demonstrated that expression of wild type or mutant human FUS 
protein leads to the formation of FUS aggregates and progressive neurodegeneration such 
as axonal loss and loss of neurons in the brain (Lanson Jr and Pandey 2012).  
Several iPSC models of ALS have also revealed selective cellular vulnerability in 
ALS. ALS neurons with pathogenic TDP-43 mutations and C9ORF72 hexanucleotide repeat 
expansion show increased spontaneous cell death in long term cell culture and greater 
sensitivity to a variety of cell stressors (Bilican et al. 2012; Almeida et al. 2013). Several 
cellular models of ALS indicate that cells expressing mutant proteins (SOD1, TDP-43 and 
the G4C2 expansion in C9ORF72) are likely to die by apoptosis, a process of programmed 
cell death. However, a very recent study provided evidence of necroptosis, a programmed 




 iPSC-derived neural progenitors and neurons were cultured, fixed processed for 
immunocytochemistry as described in Section 2.2.4. iPSC-derived neural progenitors and 
neurons were probed with primary antibodies (Table 4.1) diluted in 5% donkey serum 
overnight at 4°C. Donkey anti-rabbit or mouse AlexaFluor-488 secondary antibodies 
diluted 1:400 in PBS were then applied for 1 hour at room temperature in the dark. DAPI 
counterstaining (1.25 μg/ml) was applied and coverslips mounted as described in Section 
2.2.4. Images were obtained with a Zeiss Axiovert S100 microscope and a Leica TCS-SP5 
laser scanning confocal microscope. 
 
Table 4.1. Primary antibodies 
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Antibody Host Company Dilution 
FUS Rabbit polyclonal Novus Biologicals 1:400 
PABP1 Mouse monoclonal Millipore 1:500 
 
 
4.2.2 Quantitative image analysis - Metamorph 
 To assess the subcellular distribution of FUS protein in iPSC-derived neurons, 
quantitative image analysis was performed using MetaMorph Microscopy Automation & 
Image Analysis Software 7.5 (Molecular Devices).  Fields based on uniform DAPI staining 
were selected and imaged in two channels. 7-12 images of each cell line were obtained 
with the Zeiss Axiovert S100 microscope. The exposure time for capturing the images was 
maintained and all images were taken on the same day.  
Images were first converted to grayscale and the DAPI and FUS channels were 
used to define the thresholds. The number of cells in each image was determined using the 
“Count nuclei” app and the DAPI images. Nuclear FUS was also determined using the 
“Count nuclei” app, but using FUS images; the integrated intensity of each image was 
divided by the number of cells in that image to determine the amount of nuclear FUS per 
cell. To quantify cytoplasmic FUS, the DAPI image was first used to mask the nucleus of the 
corresponding FUS image.  The integrated intensity of each image was then obtained and 
divided by the number of cells in that image to determine the amount of cytoplasmic FUS 
per cell. Total FUS per cell was calculated by adding the integrated intensity of nuclear and 
cytoplasmic FUS.  
 
4.2.3 Quantitative image analysis - ImageJ 
 To quantify the colocalisation of FUS protein with stress granule marker PABP1 in 
iPSC-derived neural progenitors, quantitative image analysis was performed using Image J 
(version 1.48p). Fields based on uniform DAPI staining were selected and imaged in two 
channels. 7-12 images of each cell line were obtained with the Leica TCS-SP5 laser 
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scanning confocal microscope. The exposure time for capturing the images was 
maintained and all images were taken on the same day. 
Images were first converted to greyscale and the FUS and PABP1 channels were 
used to define the thresholds. The number of cells in each image was quantified with the 
ImageJ plug-in “analyse particles” using DAPI images. The ImageJ plug-in “analyse 
particles” was used to filter the granule size (0-50 pixels2) and to quantify the number of 
FUS and PABP1 granules. The total number of FUS or PABP1 granules was divided by the 
number of cells in that image to determine the average number of granules per cell. The 
ImageJ plug-in “colocalisation” was used to determine colocalised particles in 
corresponding FUS and PABP1 images. The “analyse particles” plug-in was then used to 
quantify the number of colocalised particles. The total number of colocalised particles was 
divided by the number of cells in that image to determine the average number of 
colocalised granules per cell. Data were normalised to the mean number of FUS, PABP1 
and colocalised granules in control WT1 neural progenitors. 
 
4.2.4 PE Annexin V and 7AAD profiling 
 Apoptotic cell death in iPSC-derived neural progenitors was assessed by 
fluorescence activated cytometric sorting (FACS) analysis of Annexin V and 7AAD staining. 
Neural progenitors were chosen as more mature neurons have complex processes and 
were not suitable for FACS anslysis. iPSC-derived neural progenitors were plated on 
Matrigel-coated 6-well tissue culture plates at a density of 200,000 cells per well. One day 
before FACS analysis, one well was treated with 1 μM staurosporine (Cell Signaling 
Technology) to induce apoptosis as a positive control. Unstained cells were used as a 
negative control. On the day of FACS analysis, culture medium was collected into separate 
conical tubes for each sample. Neural progenitors were enzymatically dissociated from 
tissue culture plate with Accutase (1.5 ml per 25 cm2). Cells were transferred to the 
corresponding conical tube and centrifuged at 1000 rpm for 4 minutes. The supernatant 
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4.3.1 R521C neurons have increased cytoplasmic FUS protein levels 
 To determine whether FUS neurons recapitulate the mislocalisation of FUS protein 
observed in post-mortem tissue in patients carrying FUS mutations, the subcellular 
distribution of FUS protein was analysed in neurons differentiated for 6 weeks by 
quantitative image analysis (Fig. 4.2). MN-containing neural populations derived from two 
independent FUS iPSC clones had significantly higher levels of cytoplasmic FUS than WT1 
MN-containing neural populations following identical differentiation protocols (Fig. 4.3). 
Some clonal variation was observed between the FUS lines, but a 1.3 fold or more of 
cytoplasmic FUS expression was consistently found in FUS neurons than in WT neurons 
(levels of cytoplasmic FUS normalised to WT1: FUS1 = 1.33 ± 0.1; FUS2 = 1.61 ± 0.1; FUS1 
vs WT1, P < 0.05; FUS2 vs WT1, P < 0.001; FUS1 vs FUS2, not significant).  
FUS2 motor neuron-containing neural populations had significantly lower levels of 
nuclear FUS than WT1 motor neuron-containing neural populations (Fig. 4.3; FUS2 
normalised to WT1 = 0.80 ± 0.05, FUS2 vs WT1, P < 0.05). FUS1 motor neuron-containing 
neural populations also had lower levels of nuclear FUS than WT motor neuron-containing 
neural populations; however, this did not quite reach statistical significance (FUS1 
normalised to WT1 = 0.90 ± 0.05; FUS1 vs WT1, not significant; FUS1 vs FUS2, not 
significant). FUS and WT neurons had similar levels of total FUS (Fig. 4.3; levels of total 
FUS normalised to WT1: FUS1 = 1.03 ± 0.06; FUS2 = 0.92 ± 0.05; FUS1 vs WT1, not 
significant; FUS2 vs WT1, not significant; FUS1 vs FUS2, not significant). 
Quantification of the subcellular distribution of FUS was also performed in WT2 
motor neuron-containing neural populations in an independent set of experiments (data 












Figure 4.3. Quantitative image analysis of subcellular distribution of FUS in WT1, FUS1 and 
FUS2 iPSC neurons. Mean intensity of FUS staining in samples were normalised to mean 
intensity of FUS staining in WT1 neurons. Data represent means ± SEM. Significance levels 
were determined by one-way ANOVA and post-hoc Tukey test. Significance of difference 
between iPSC lines (* P < 0.05; *** P < 0.001; n = 2000+ cells per line from 3 independent 
experiments). 
 
4.3.2 R521C FUS protein is redistributed into cytoplasmic stress granules 
 A second feature of FUS-associated ALS is the redistribution of mutant FUS protein 
into cytoplasmic stress granules. This experiment was initially attempted on iPSC-derived 
neurons; however, due to problems with adherence of iPSC-derived neurons on coverslips 
following treatment with arsenite, we opted to use iPSC-derived neural progenitors. To 
assess whether FUS neural progenitors recapitulate this feature, iPSC-derived neural 
progenitors were treated with 1 mM arsenite for 30 minutes, and colocalisation of FUS and 
stress granule marker PABP1 was determined with quantitative image analysis(Fig. 4.4 
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and 4.5). FUS neural progenitors exhibited FUS-positive, PABP1-positive granules after 
treatment with 1 mM arsenite (Fig. 4.5). WT neural progenitors also exhibited PABP1-
positive granules after treatment with 1 mM arsenite, but they did not colocalise with FUS 
(Fig. 4.5).  
 
 
Figure 4.4. Representative images (40x) of untreated WT and FUS iPSC neural progenitors 





Figure 4.5. Representative images (40x) of WT and FUS iPSC neural progenitors treated 
with 1mM arsenite for 30 minutes, stained for FUS (red), PABP1 (green) and DAPI (blue). 
Colocalisation of FUS and PABP1 is indicated by arrowheads. 
 
FUS neural progenitors had more FUS-positive granules per cell than WT neural 
progenitors (Fig. 4.7). Some clonal variability was observed between FUS and WT lines, 
but FUS neural progenitors consistently had 4-fold (or more) FUS-positive granules in 
each cell than WT neural progenitors (Fig. 4.6; WT1 = 0.79 ± 0.10; WT2 = 1.30 ± 0.23; 
FUS1 = 5.56 ± 1.07; FUS2 = 5.02 ± 0.77. WT1 vs WT2, not significant; FUS1 vs WT1, P < 
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0.001; FUS2 vs WT1, P < 0.001; FUS1 vs WT2, P < 0.001; FUS2 vs WT2, P < 0.001; FUS1 vs 
FUS2, not significant).  
FUS neural progenitors also had significantly more stress granules per cell than 
WT neural progenitors (Fig. 4.8). Again, clonal variability was observed between both FUS 
and WT lines, but FUS neural progenitors consistently had approximately double the 
number of stress granules per cell than WT neural progenitors (Fig. 4.6; WT1 = 4.50 ± 
0.51; WT2 = 4.07 ± 0.38; FUS1 = 10.3 ± 1.69; FUS2 = 8.59 ± 1.33. WT1 vs WT2, not 
significant; FUS1 vs WT1, P = 0.006; FUS2 vs WT1, P = 0.04; FUS1 vs WT2, P < 0.001; FUS2 




Figure 4.6. Quantitative image analysis of FUS-, PABP1-positive and colocalised particles in 
WT1, WT2, FUS1 and FUS2 neural progenitors following treatment with 1mM arsenite. 
Data represent means ± SEM. Significance levels were determined by one-way ANOVA and 
post-hoc Tukey test. Significance of difference between iPSC lines (* P<0.05; ** P<0.005; n 




There was variability in the number of FUS particles that colocalised with PABP1 
particles between the lines, but FUS neural progenitors had at least 3.7-fold (or more) 
colocalised particles in each cell compared to WT neural progenitors (Fig. 4.6; WT1 = 0.47 
± 0.07; WT2 = 0.27 ± 0.06; FUS1 = 2.41 ± 0.15; FUS2 = 3.06 ± 0.14. WT1 vs WT2, not 
significant; FUS1 vs WT1, P < 0.001; FUS2 vs WT1, P < 0.001; FUS1 vs WT2, P < 0.001; 
FUS2 vs WT2, P < 0.001). FUS2 neural progenitors also had significantly more colocalised 
particles than FUS1 neural progenitors (Fig. 4.6; FUS1 vs FUS2, P = 0.007). 
  
4.3.3 FUS neural progenitors have increased apoptotic cell death 
 Finally, to determine whether the R521C mutation confers a selective cellular 
vulnerability, we performed Annexin V and 7-AAD profiling using flow cytometry. We 
decided against the use of iPSC-derived neurons for this experiment due to the nature of 
the experimental protocol. Enzymatic dissociation is required to collect cells for flow 
cytometry and FACS analysis. In a mature neuronal culture, enzymatic dissociation may 
damage cells and induce apoptosis. Therefore, we opted to perform this analysis on iPSC-
derived neural progenitors.  iPSC-derived neural progenitors in untreated culture or 
treated with 1 mM arsenite for 30 minutes were stained for PE Annexin V and 7-AAD (Fig. 
4.9). FACS analysis showed that in untreated cultures, FUS neural progenitors have 
significantly greater percentages of PE Annexin V-positive cells (Fig. 4.10; WT1 = 6.39 ± 
2.01; FUS1 = 13.7 ± 1.56; FUS2 = 13.8 ± 1.12; FUS1 vs WT1, P = 0.04; FUS2 vs WT2, P = 
0.03; FUS1 vs FUS2, not significant). In untreated cultures, FUS neural progenitors also 
have significantly greater percentages of 7-AAD-positive cells (Fig. 4.11; WT1 = 5.9 ± 0.35; 
FUS1 = 14.4 ± 0.13; FUS2 = 10.02 ± 2.12; FUS1 vs WT1, P = 0.01; FUS2 vs WT1, P < 0.005; 









Figure 4.9. Representative dot plots of PE Annexin V and 7AAD of WT and FUS neural 
progenitors in untreated cultures (top) and of WT and FUS neural progenitors treated 





Figure 4.10. Representative gate of PE Annexin V (left) and 7AAD (right) of A) WT and B) 
FUS neural progenitors in untreated cultures and of C) WT and D) FUS neural progenitors 
treated with 1mM arsenite for 30 minutes. Gating was performed manually to avoid bleed-
through staining of PE Annexin V in 7AAD channel and to ensure that only cells positive 




Figure 4.11. FACS analysis of PE Annexin V and 7-AAD in untreated WT1, FUS1 and FUS2 
neural progenitors. Data represent means ± SEM. Significance levels were determined by 
one-way ANOVA and post-hoc Tukey test between lines in the same treatment condition. 
Significance of difference between iPSC lines (*P<0.05; **P<0.005; n = 30,000 cells per line 
from 3 independent experiments). 
 
FACS analysis also showed that in cultures treated with 1 mM arsenite for 30 
minutes, FUS neural progenitors have greater percentages of PE Annexin V-positive cells 
(Fig. 4.12; WT1 = 7.11 ± 2.96; FUS1 = 17.9 ± 1.82; FUS2 = 16.2 ± 1.61). However, FUS 
neural progenitors showed clonal variability, as only FUS1 neural progenitors had 
significantly higher percentages of PE Annexin V-positive cells than WT1 neural 
progenitors (FUS1 vs WT1, P = 0.03; FUS2 vs WT2, P = 0.054; FUS1 vs FUS2, not 
significant). Arsenite-treated FUS neural progenitors also have greater percentages of 7-
AAD-positive cells (Fig. 4.13; WT1 = 7.96 ± 1.49; FUS1 = 11.23 ± 1.65; FUS2 = 10.24 ± 





Figure 4.12. FACS analysis of PE Annexin V and 7-AAD in WT1, FUS1 and FUS2 neural 
progenitors treated with 1 mM arsenite for 30 minutes. Data represent means ± SEM. 
Significance levels were determined by one-way ANOVA and post-hoc Tukey test between 
lines in the same treatment condition. Significance of difference between iPSC lines 
(*P<0.05; n = 30,000 cells per line from 3 independent experiments). 
 
4.4 DISCUSSION 
 In this chapter, I explored three ALS-associated phenotypes in neural progenitors 
and neurons derived from FUS mutant ALS patient and WT iPSC lines, including 
cytoplasmic mislocalisation of FUS protein, recruitment of FUS protein in stress granules 
and spontaneous apoptotic cell death and vulnerability to cellular stress.   
FUS neurons show a significant increase in FUS protein levels in the cytoplasm and 
decreased levels in the nucleus compared to WT neurons. Although FUS protein levels in 
WT and FUS lines were largely similar, some variability in the subcellular distribution of 
FUS protein was observed between neurons derived from the two FUS iPSC lines. While 
both lines showed a decrease in the levels of FUS protein in the nucleus, only FUS2 
reached statistical significance. FUS2 also had higher levels of FUS protein in the 
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cytoplasm, relative to FUS1, although this difference did not reach significance. Line to line 
variation in transcript and protein abundance is common in iPSCs, even those derived 
from the same individual, and could arise from the reprogramming of clonal selection. It 
may be useful to use subcellular fractionation and immunoblotting to quantify any 
differences. Because of low cell numbers and mixed cell populations, we elected to use 
quantitative image analysis as very large numbers of neurons are required to obtain 
enough protein for immunoblotting and information on cell specificity is lost. 
Following acute treatment with the oxidative stressor arsenite, cytoplasmic stress 
granules were observed in both WT and mutant FUS neural progenitors. Relative to 
mutant FUS neurons, mutant FUS neural progenitors only showed modest staining of FUS 
in the cytosol in the untreated condition. This may be attributed to alterations in gene 
expression levels in different cell types. FET proteins have been reported to demonstrate 
some differences in localization in cultured cells (Andersson et al., 2008). Different cell 
types may also have variable rates of mRNA translation and protein degradation, which 
could contribute to the decreased levels of cytosolic FUS observed in mutant FUS neural 
progenitors.  
Quantitative image analysis revealed that cytoplasmic FUS protein was recruited 
to stress granules in neural progenitors from both FUS mutant lines, but not WT. Neural 
progenitors from both lines expressing the R521C mutant had a >3.7-fold increase in the 
number of PABP1 and FUS-positive stress granules per cell compared to WT neural 
progenitors. Interestingly, neural progenitors derived from the FUS2 line have a greater 
number of FUS-positive stress granules per cell than those derived from the FUS1 line. 
Dormann et al. (2010) had shown that the FUS mutations associated with the most severe 
nuclear import defect and the greatest levels of mislocalised cytoplasmic FUS (P525L and 
R522G) were most readily recruited into stress granules upon heat shock. Similarly, Bosco 
et al. (2010) also showed that mutant FUS assembled into stress granules in proportion to 
their cytoplasmic expression levels. The increase in cytoplasmic FUS may affect the 
assembly or dynamics of stress granules to result in differences in their composition.  
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The dramatic increase in the number of FUS-positive granules in mutant lines is 
consistent with previous reports from our laboratory in mutant FUS patient fibroblasts 
following oxidative stress (Vance et al. 2013). FUS neural progenitors also have 
approximately double the number of stress granules per cell compared to WT neural 
progenitors. This finding is consistent with a previous report showing that expression of 
mutant FUS is associated with increased stress granule size and number in HEK 293 cells 
(Baron et al. 2013). 
Neural progenitors from both lines expressing the R521C mutations showed an 
increase in spontaneous apoptotic cell death compared to WT1 neural progenitors, as 
demonstrated by a greater portion of PE Annexin V- and 7AAD-positive cells. Following 
acute treatment with arsenite, all neural progenitors showed a modest increase in the 
expression of Annexin V and 7AAD, however, a statistical difference between mutant and 
controls was only detected in neural progenitors from the FUS1 line. The FUS2 neural 
progenitors also showed an increase in PE Annexin V-positive cells, but this did not reach 
significance. Interestingly, differences in levels of late-apoptotic cell death marker 7-AAD 
were more striking in the untreated mutant FUS lines than following arsenite treatment.  
These results suggest that the R521C mutation is associated with higher levels of 
spontaneous and acute oxidative stress induced apoptotic cell death. It would be 
interesting to assess cell death in the neural progenitors following a period of recovery 
from acute arsenite treatment or low dose arsenite over a longer period to determine 
whether mutant FUS progenitors have an increased sensitivity to chronic oxidative stress. 
The expression of mutant FUS that is resistant to proteasome-dependent 
degradation has been shown to induce apoptosis (Perrotti et al., 2000). It is not known 
whether the FUS R521C mutation is resistant to proteasome-dependent degradation. 
However, the presence of pathological FUS protein aggregates in disease tissue and the 
increased insolubility associated with mutant FUS protein suggests that mutant FUS 
protein may be resistant to proteasomal degradation. Alternatively, the expression of 
mutant FUS has been shown to induce endoplasmic reticulum stress (Farg et al., 2012). 
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One downstream pathway triggered by ER stress is the induction of cell death. It would be 
of interest to investigate the turnover of FUS protein and endoplasmic reticulum 
homeostasis in iPSC-derived neural progenitors to determine its possible association with 
apoptotic cell death. 
In summary, we have attempted to quantify three relevant phenotypes to 
determine whether neural populations derived from mutant FUS iPSCs recapitulate key 
features of FUS-associated ALS. Neural populations derived from mutant FUS iPSCs 
demonstrated greater mislocalisation of FUS protein to the cytoplasm, recruitment into 
stress granules and spontaneous and oxidative stress induced apoptotic cell death. The 
fact that these results were consistent in two independently-derived human stem cell lines 
from an ALS patient suggest that these events are due to the presence of the R521C mutant 
protein which is expressed at physiological levels. They provide an important validation of 
data derived from transfected cell lines (Bosco et al. 2010; Dormann et al. 2010), human 
fibroblasts (Vance et al. 2013) and transgenic zebrafish (Armstrong and Drapeau 2013), 
which is consistent with the findings of human pathology (Mackenzie et al. 2011). In the 






INVESTIGATING NEURONAL MORPHOLOGY AND SYNAPSES IN IPSCS 
5.1 BACKGROUND 
In this study, we used molecular biology approaches and quantitative image 
analysis to investigate the morphology and synapses of neurons derived from control WT 
and FUS mutant patient iPSC lines. Studies have previously shown that pathological 
changes in motor neuron axons and synapses occur prior to motor neuron degeneration in 
SOD1 mouse models (Frey et al. 2000; Pun et al. 2006). In support of these findings, recent 
cellular and animal models have provided evidence that FUS may play a role in 
determining peripheral neuronal structure and function, particularly at the synapse. We 
therefore sought to explore any differences in neuronal architecture and subcellular 
structures in neurons derived from mutant FUS and control iPSC lines by measuring: 
neurite outgrowth, density of dendritic protrusions and the expression and location of 
selected synaptic proteins. 
 
5.1.1 Neurite outgrowth 
Neurons are the most polarized cells in the body and motor neurons are the 
largest with an axo-dendritic volume that is 1 million times greater than the cell body. 
Outgrowth of axons and dendrites occurs rapidly during early neuronal differentiation and 
continues until adulthood, but remodeling of axons and dendrites occurs throughout life. 
As axons grow outward, they make contact with the dendritic spines of thousands of 
neurons, close contacts with astroglia and oligodendroglia and form synapses with 
neurons centrally and with peripheral target cells such as myocytes and sensory 
receptors. The axo-dendritic tree is the outcome of a complex, multi-stage process that 
involves multiple molecular components to achieve an optimal structure and function. A 
complex and dynamic network of synapses must be made to connect the billions of 
neurons in the human brain for the nervous system to function properly. Dendritic and 
synaptic loss and distal axonal degeneration are early and consistent features of all 
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neurodegenerative disorders, affecting predominantly, but not exclusively, the motor 
neurons in ALS. In several animal models of ALS, progressive denervation and 
reinnervation of motor endplates occurs through a process of motor neuron axonal 
dieback and leads to progressive muscular paralysis (Schaefer et al. 2005).  
FUS appears to play a role in the regulation of neuronal morphology. Fujii et al. 
(2005) showed that in hippocampal neurons from FUS-deficient mice have irregularly 
branched dendrites and abnormal axonal processes. Similarly, the knockdown of FUS in 
hippocampal neurons results in reduced axon length and abnormal growth cone 
morphology (Orozco et al. 2012). The expression of ALS-associated FUS mutations in 
primary mouse cortical neurons has also been shown to alter axonal morphology, 
resulting in reduced axon length, decreased axon branches and the area of the growth 
cone (Groen et al. 2013). These findings suggest that FUS has an important role in 
cytoskeletal organisation, in axons and dendrites. 
 
5.1.2 Dendritic spine morphology 
Dendritic spines are small protrusions that receive synaptic input from axons and 
dendrites. Changes in dendritic spine morphology and function are associated with 
synaptic plasticity (Engert and Bonhoeffer 1999) and may be an early feature of 
neurodegeneration. Neurons from FUS knockout mice have abnormal dendritic spine 
morphology. WT hippocampal neurons have spines with a mushroom-like shape, whereas 
FUS-deficient hippocampal neurons have reduced spine density, or spines that were 
transformed into abnormally thin filopodia-like protrusions (Fujii et al. 2005). This study 
implies that FUS regulates the stability of dendritic spines, possibly by transporting RNA 
transcripts and translocating to spines upon glutamate activation (Fujii et al. 2005). Thus, 
FUS may regulate dendritic spine morphology by transporting transcripts for local 





5.1.3 Alterations in synaptic proteins 
As mentioned, pathological changes at the NMJ are thought to precede 
degeneration of the motor neuron cell body, a dying back axonopathy. Animal and cellular 
models of ALS demonstrate several features of synaptic abnormalities prior to onset of 
motor symptoms, including increased excitability, reduced NMJ synaptic fidelity and 
susceptibility to excitotoxicity (Kuo et al. 2004; Armstrong and Drapeau 2013). Recently, 
iPSC-derived motor neurons from ALS patients with SOD1, C9orf72 and FUS mutations 
were shown to recapitulate the hyperexcitability detected in ALS patients and that a 
pharmacological agent that reduces excitability increases survival of MNs (Wainger et al. 
2014).  
Alterations in motor neuron excitability may reflect changes in the 
compartmentalisation or expression of synaptic proteins. Interestingly, FUS binds to, or 
regulates mRNA that encodes multiple components of the synapse, including receptors, 
channel subunits and neurofilaments (Lagier-Tourenne et al. 2012; Rogelj et al. 2012). 
Furthermore, FUS is associated with adenomatous polyposis coli ribonucleoprotein 
complexes (APC-RNPs), a type of granule that targets RNAs to cell protrusions. Yasuda et 
al. (2013) showed that transcripts within APC-RNPs are translated and that the expression 
of FUS mutants preferentially recruits APC-RNPs. These findings prompted us to 
investigate whether neurons derived from patient iPSCs carrying mutant FUS display 
altered abundance and density of selected synaptic proteins.  
We chose four different synaptic proteins for this analysis: postsynaptic density 
protein 95 (PSD 95), piccolo, vesicular glutamate transporter 1 (VGLUT1) and synapsin I. 
These proteins were selected based on their key location and functions. PSD95 is a 
membrane associated guanylate kinase scaffolding protein within the postsynaptic 
density. It is a component of a scaffold for the clustering of receptors, ion channels and 
associated signaling proteins. Piccolo is a multidomain scaffold protein that has a role in 
the clustering of synaptic vesicles in nerve terminals at the presynaptic active zone 
(Mukherjee et al. 2010). VGLUT1 mediates the uptake of glutamate into synaptic vesicles 
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at the presynaptic terminal of glutamatergic neurons. Synapsin I is a phosphoprotein in 
the coating of synaptic vesicles that functions to accelerate synaptic vesicle traffic to 
contribute to short-term synaptic plasticity (Rosahl et al. 1995). Although our analysis is 
limited to only four synaptic proteins, our selection covers the presynaptic and the 
postsynaptic compartments with roles in axo-dendritic transport and neurotransmitter 





 Frozen glycerol stocks of hemagglutinin (HA)-tagged FUS WT or FUS mutants 
(Q519E, R514G, K510X and R521G) and EGFP-transformed cells generated previously 
(Vance et al. 2013; Scotter et al. 2014) were cultured in Luria-Bertani (LB) media 
containing 100 μg/ml of ampicillin, then incubated on an orbital shaker overnight at 37°C. 
Extraction of plasmid DNA from bacteria was prepared using plasmid DNA purification kit 
(Machery-Nagel) following the manufacturer’s instructions. Plasmid DNA were eluted 
using nuclease-free water (Ambion), quantified using a microvolume spectrophotometer 
(Nanodrop, Thermo Scientific), then stored at -20°C. iPSC-derived neural progenitors or 
neurons were transfected with plasmids as described in Section 2.1.9. 
 
5.2.2 Immunofluorescence 
 iPSC-derived neurons were fixed and samples prepared as described in Section 
2.2.4. iPSC-derived neurons were probed with primary antibodies (Table 5.1) diluted in 
5% donkey serum overnight at 4°C. Donkey anti-rabbit or mouse AlexaFluor-
488/550/650 secondary antibodies (1:400) were then applied for 1 hour at room 
temperature in the dark. DAPI counterstaining (1.25 μg/ml) was applied and coverslips 
mounted as described in Section 2.2.4. Images were obtained with a Zeiss Axiovert S100 




Table 5.1. Primary antibodies 
Antibody Host Company Dilution 
VGLUT1 Rabbit polyclonal Synaptic Systems 1:100 
Piccolo Rabbit polyclonal Synaptic Systems 1:100 
PSD95 Mouse monoclonal Synaptic Systems 1:100 
Synapsin Rabbit polyclonal Millipore 1:500 
Map2 Mouse monoclonal Abcam 1:500 
Map2 Rabbit polyclonal Abcam 1:500 
HA-tag Rabbit monoclonal Cell Signaling 1:1000 
 
5.2.3 Quantitative image analysis of dendrite outgrowth - Metamorph 
 Motor neuron-containing populations were differentiated for 5 weeks, then 
prepared for immunofluorescence as described above. Cortical neurons were 
differentiated from iPSC-derived neural progenitors for 7 days, then prepared for 
immunofluorescence as described above. To quantify dendrite outgrowth in iPSC-derived 
MNs, quantitative image analysis was performed using MetaMorph Microscopy 
Automation & Image Analysis Software 7.5 (Molecular Devices).  Fields based on uniform 
DAPI staining or EGFP-positive cells were selected and imaged in two or three channels. 7-
12 images of each cell line were obtained with the Zeiss Axiovert S100 microscope. The 
exposure time for capturing the images was maintained and all images were taken on the 
same day.  
Images were first converted to grayscale and the DAPI, MAP2 and EGFP channels 
were used to define the thresholds. The number of cells in each image was determined 
using the “Count nuclei” app and the DAPI images, or in the case of transfected cells, the 
“Count nuclei” app and the HA images. Dendrite outgrowth was determined using the 
“Neurite Outgrowth” app, using MAP2 or EGFP images. The outgrowth, processes and 
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branches of iPSC-derived neurons were analysed (Fig. 5.1). These measurements are 
defined by the MetaMorph Application Module as follows: 
 Cells – number of cells in a field 
 Total outgrowth – total length of skeletonised outgrowth in μm (corrected for 
diagonal lengths) 
 Mean outgrowth – average skeletonised outgrowth in μm corrected for diagonal 
length divided by the number of cells 
 Total processes – number of outgrowths that connect to the cell body 
 Total branches – number of branching junctions 
 Mean processes – number of processes divided by number of cells 
 Mean branches – number of branching junctions divided by number of cells 
 
For dendrite outgrowth analysis of iPSC lines, data were obtained from three 
independent differentiation experiments and at least 500 cells from MN-containing 
populations in each line. For neurite outgrowth analysis of iPSC cortical neurons 
transfected with FUS mutants, data were obtained from two independent differentiation 
experiments and 30-50 cortical neurons differentiated from iPSC-derived neural 
progenitor cells for each mutation. 
 
 





5.2.4 Quantitative image analysis of dendritic protrusions - ImageJ 
 To quantify dendritic protrusions, FUS and WT motor neurons were differentiated 
for 8 weeks then prepared for immunofluorescence as described in Section 5.2.2. 
Quantitative image analysis was performed using ImageJ plug-in NeuronJ (Meijering et al. 
2004). Fields based on uniform MAP2 staining were selected and imaged in two channels.  
7-12 images of each cell line were obtained with the Zeiss Axiovert S100 microscope. The 
exposure time for capturing the images was maintained and all images were taken on the 
same day. 
Images were first converted to grayscale 8-bit. Dendrites were manually traced 
and the length of dendrites was measured using MAP2 images. The density of dendritic 
protrusions was measured by manually counting the number of clearly evident dendritic 
protrusions on primary dendrites. Dendritic protrusions between 0.5 and 8 μm were 
included in this analysis.  
 
5.2.5 Quantitative image analysis of synaptic puncta - ImageJ 
Synaptic puncta were quantified as described previously, with slight modifications 
(Marchetto et al. 2010).To quantify pre- and post-synaptic markers, quantitative image 
analysis was performed using Image J (version 1.48p). Fields based on uniform MAP2 
staining were selected and imaged in four channels. 5-7 z-series of each cell line with 0.5-
μm increments were obtained with a 63x objective on the Leica TCS-SP5 laser scanning 
confocal microscope. The exposure time for capturing the images was maintained and all 
images of the same marker were taken on the same day. A collapsed maximum Z 
projection of images was generated for each channel within a z-series. For pre- and post-
synaptic puncta, maximum projections were converted to grayscale and individual marker 
channels were used to define the thresholds. The thresholded images were then combined 
with the MAP2 channel to quantify the density of puncta. To quantify the length of a 
dendrite, maximum projections of the MAP2 channel were converted to 8-bit images. 
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NeuronJ was used to add tracings for each Z projection. Data were obtained from two 




5.3.1 FUS neurons have reduced dendrite outgrowth 
 To assess neuronal morphology, the dendrite outgrowth of FUS and WT motor 
neurons was analysed by quantitative image analysis using Metamorph software. MN-
containing neural populations derived from two independent R521C mutant FUS iPSC 
clones had significantly less outgrowths compared to control neural populations (Fig. 5.2). 
Mutant FUS neurons had ~50% decrease in the mean outgrowth per cell (Fig. 5.3; WT1 = 
420.2 ± 14.7; WT2 = 407.9 ± 41.1; FUS1 = 217.98 ± 27.9; FUS2 = 221.5 ±12.7; WT1 vs WT2, 
not significant; WT1 vs FUS1, P < 0.001; WT1 vs FUS2, P < 0.001; WT2 vs FUS1, P < 0.001; 





Figure 5.2. Mutant FUS iPSC neurons in motor neuron-containing populations have 
reduced dendrite outgrowth, processes and branches. Confocal images (40x) of WT and 
mutant FUS iPSC neurons stained for neuronal dendrite-specific marker, MAP2 (red). 
(Right panels) Representative images of WT and FUS iPSC neurons. Processes are 





Figure 5.3. Quantitative image analysis of total length of dendrite outgrowth in WT1, WT2, 
FUS2 and FUS2 motor neurons. Data represent mean outgrowth length per cell ± SEM. 
Significance levels were determined by one-way ANOVA and post-hoc Tukey test. 
Significance of difference between iPSC lines (*** P < 0.001). n = 400+ cells from 3 
independent experiments. 
 
Analysis of the complexity of dendritic arborisation revealed that FUS neurons had 
a reduction in the number of dendrite processes compared to WT neurons (Fig. 5.4). MN-
containing neural populations derived from two independent mutant FUS iPSC clones had 
significantly less dendritic processes compared to WT MN-containing neural populations 
(WT1 = 5.44 ± 0.38; WT2 = 6.33 ± 0.56; FUS1 = 3.06 ± 0.28; FUS2 = 3.56 ± 0.30; WT1 vs 
WT2, not significant; WT1 vs FUS1, P < 0.001; WT1 vs FUS2, P < 0.001; WT2 vs FUS1, P < 





Figure 5.4. Quantitative image analysis of dendritic processes in WT1, WT2, FUS1 and 
FUS2 neurons. Data represent mean processes per cell ± SEM. Significance levels were 
determined by one-way ANOVA and post-hoc Tukey test. Significance of difference 
between iPSC lines (*** P < 0.001). n = 400+ cells from 3 independent experiments. 
 
Furthermore, FUS neurons showed reduced branching compared to WT neurons 
(Fig. 5.5). MN-containing neural populations derived from two independent FUS iPSC 
clones had significantly fewer dendritic branches compared to WT MN-containing neural 
populations (WT1 = 2.27 ± 0.21; WT2 = 2.60 ± 0.38; FUS1 = 0.70 ± 0.19; FUS2 = 1.20 ± 0.12 
WT1 vs WT2, not significant; WT1 vs FUS1, P < 0.0001; WT1 vs FUS2, P < 0.001; WT2 vs 
FUS1, P < 0.001; WT2 vs FUS2, P < 0.001). FUS1 MN-containing neural populations also 
had significantly less dendritic branches compared to FUS2 MN-containing neural 





Figure 5.5. Quantitative image analysis of the number of dendritic branches in WT1, WT2, 
FUS2 and FUS2 neurons. Data represent mean branches per cell ± SEM. Significance levels 
were determined by one-way ANOVA and post-hoc Tukey test. Significance of difference 
between iPSC lines (* P < 0.05; *** P < 0.001). n = 400+ cells from 3 independent 
experiments. 
 
5.3.2 ALS-associated FUS mutations are associated with reduced neurite outgrowth 
 To determine whether other ALS-linked FUS mutations also affect neurite 
morphology, HA-tagged FUS construct (WT, Q519E, R514G, K510X or R521G) and EGFP 
construct were expressed in WT2 neural progenitors, which were then differentiated into 






Figure 5.6. Confocal representative images of iPSC cortical neurons transfected with EGFP 
only, HA-FUS-WT and EGFP, HA-FUS-Q519E and EGFP, HA-FUS-R514G and EGFP, and HA-
FUS-K510X and EGFP,stained for HA (magenta) and green fluorescence from EGFP. 
 
Neurons expressing Q519E, R514G, K510X and R521G had significantly less 
neurite outgrowth compared to neurons expressing EGFP only (Fig. 5.7; EGFP only = 
598.08 ± 26.7; WT = 533.7 ± 35.6; Q519E = 264.8 ± 18.6; R514G = 268.4 ± 29.0; K510X = 
437.8 ± 51.6; R521G = 257.1 ±19.2; EGFP only vs WT, not significant; EGFP only vs Q519E, 
P < 0.001; EGFP only vs R514G, P < 0.001; EGFP only vs K510X, P = 0.006; EGFP only vs 
R521G, P < 0.001). Compared to neurons expressing WT FUS, neurons expressing Q519E, 
R514G and R521G had significantly less neurite outgrowth (WT vs Q519E, P < 0.001; WT 
vs R514G, P < 0.001; WT vs R521G, P < 0.001). Interestingly, the truncation mutant K510X, 
which shows a greatest degree of cytoplasmic mislocalisation in cell line transfection 
studies (Vance et al., 2013), showed only a modest reduction in the mean neurite 








Figure 5.7. Quantitative image analysis of neurite outgrowth in WT cortical neurons 
transfected with EGFP only, HA-FUS-WT, HA-FUS-Q519E HA-FUS-R514G, HA-FUS-K510X, 
HA-FUS-R521G All HA-FUS transfected cells were co-transfected with EGFP plasmid. Data 
represent mean outgrowth per cell ± SEM. Significance levels were determined by one-
way ANOVA and post-hoc Tukey test. Significance of difference between EGFPonly and 
HA-FUS constructs (∆ P < 0.05; ∆∆∆ P < 0.001). Significance of difference between HA-FUS-
WT and HA-FUS mutant constructs (*** P < 0.001). n = 40+ cells from 2 independent 
experiments. 
 
5.3.3 FUS neurons have reduced dendritic protrusions 
Dendritic protrusions are filopodia-like processes along dendritic shafts and 
dendritic growth cones. Protrusions along dendritic shafts appear to initiate synaptogenic 
contacts with axons and to function in the development and stabilisation of mature 
dendritic spines (Portera-Cailliau et al., 2003; Ziv and Smith, 1996). Alternatively, 
protrusions in dendritic growth cones are involved in activity-dependent dendritic growth 
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and branching (Portera-Cailliau et al., 2003). Dendritic protrusions have also been shown 
to function as channels for activity-dependent retrograde translocation of postsynaptic 
molecular complexes to parental dendrites (Kawabata et al., 2011).   
In order to evaluate the architecture of dendritic protrusion in motor neurons 
derived from iPSCs, we analysed the dendritic morphology of each line using ImageJ. 
Mutant FUS neurons differentiated for 8 weeks showed a reduction in the number of 
dendritic protrusions compared to WT neurons (Fig. 5.8). MN-containing neural 
populations derived from two independent FUS iPSC clones had significantly less dendritic 
protrusions compared to WT MN-containing neural populations (Fig. 5.9; WT1 = 1.46 ± 
0.07; WT2 = 1.22 ± 0.06; FUS1 = 0.38 ± 0.04; FUS2 = 0.29 ± 0.04; WT1 vs FUS1, P < 0.001; 
WT1 vs FUS2, P < 0.001; WT2 vs FUS1, P < 0.001; WT2 vs FUS2, P < 0.001; FUS1 vs FUS2, 
not significant). WT1 MN-containing neural populations also had significantly more 





Figure 5.8. Representative images (63x) of a) WT and b) FUS iPSC neurons stained for 
neuronal dendrite-specific marker, MAP2. Dendritic protrusions are indicated by arrows.  





Figure 5.9. Quantitative image analysis of the number of dendritic protrusions in WT1, 
WT2, FUS2 and FUS2 neurons. Data represent mean number of protrusions per 10 μm 
length of dendrite ± SEM. Significance levels were determined by one-way ANOVA and 
post-hoc Tukey test. Significance of difference between iPSC lines (* P < 0.05; *** P < 
0.001). n = 3 neurites per cell from 30+ cells and 2 independent experiments. 
 
5.3.4 Altered synapse number in FUS neurons 
In order to determine whether the abnormal dendritic morphology is associated 
with changes at the synapse, the localisation of synaptic proteins was analysed by 
quantitative image analysis using ImageJ. The density of piccolo, VGLUT1, synapsin I and 
PSD 95 puncta within neurites were analysed in cortical neurons differentiated from iPSC-
derived neural progenitors for 40+ days. 
The expression of piccolo, a component of the presynaptic cytoskeletal matrix, was 
assessed in FUS and WT neurons (Fig. 5.10). FUS and WT neurons showed comparable 
density of piccolo puncta (WT1 = 1.05 ± 0.06; WT2 = 0.95 ± 0.05; FUS1 = 0.93 ± 0.08; FUS2 





Figure 5.10. Confocal images of A) WT and B) FUS cortical neurons stained for MAP2 (red) 
and piccolo (green). Quantitative image analysis of piccolo puncta in WT1, WT2, FUS1 and 
FUS2 neurons. Data represent mean piccolo puncta per 10 μm ± SEM. Significance levels 
were determined by one-way ANOVA. n = 5 neurites per cell from > 10 cells in 2 
independent experiments. 
 
In order to verify whether FUS mutant neurons show alterations in the number of 
glutamatergic synapses, the expression of VGLUT1 was assessed. VGLUT1 is a glutamate 
transporter in the membrane of synaptic vesicles and a marker of glutamatergic neurons. 
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FUS and WT neurons displayed comparable density of VGLUT1 puncta (Fig. 5.11). (WT1 = 




Figure 5.11. Confocal images of A) WT and B) FUS cortical neurons stained for MAP2 (red) 
and VGLUT1 (green). Quantitative image analysis of VGLUT1 puncta in WT1, WT2, FUS2 
and FUS2 neurons. Data represent mean VGLUT1 puncta per 10 μm ± SEM. Significance 





The expression of synapsin 1, a phosphoprotein associated with small synaptic 
vesicles and involved in binding presynaptic vesicles to components of the cytoskeleton, 
was assessed in mutant FUS and WT neurons (Fig. 5.12). Mutant FUS neurons had an 
increased density of synapsin puncta when compared to WT neurons (WT1 = 1.35 ± 0.12; 
WT2 = 1.12 ± 0.10; FUS1 = 2.50 ± 0.16; FUS2 = 3.17 ± 0.21; WT1 vs WT2, not significant; 
WT1 vs FUS1, P < 0.001; WT1 vs FUS2, P < 0.001; WT2 vs FUS1, P < 0.001; WT2 vs FUS2, P 




Figure 5.12. Confocal images of A) WT and B) FUS cortical neurons stained for MAP2 (red) 
and synapsin (green). Quantitative image analysis of synapsin puncta in WT1, WT2, FUS2 
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and FUS2 cortical neurons. Data represent mean synapsin puncta per 10 μm ± SEM. 
Significance levels were determined by one-way ANOVA and post-hoc Tukey test. 
Significance of difference between iPSC lines (* P < 0.05; ** P < 0.0001). n = 5 neurites per 
cell from > 10 cells in 2 independent experiments. 
 
Finally, the expression of postsynaptic marker PSD95 was also assessed in FUS and 
WT neurons (Fig. 5.13). FUS neurons had an increased density of PSD95 puncta compared 
to WT neurons (WT1 = 1.11 ± 0.09; WT2 = 1.44 ± 0.10; FUS1 = 2.10 ± 0.11; FUS2 = 2.11 ± 
0.14; WT1 vs FUS1, P < 0.001; WT1 vs FUS2, P < 0.001; WT2 vs FUS1, P < 0.001; WT2 vs 
FUS2, P < 0.001; FUS1 vs FUS2, not significant). WT2 neurons also had an increased 






Figure 5.13. Confocal images of Confocal images of A) WT and B) FUS cortical neurons 
MAP2 (red) and PSD95 (green). Quantitative image analysis of PSD95 puncta in WT1, 
WT2, FUS2 and FUS2 neurons. Data represent mean PSD95 puncta per 10 μm ± SEM. 
Significance levels were determined by one-way ANOVA and post-hoc Tukey test. 
Significance of difference between iPSC lines (* P < 0.05; *** P < 0.001). n = 5 neurites per 
cell from > 10 cells in 2 independent experiments. 
 
5.4 DISCUSSION 
In this chapter, I described the investigation of neurite and synapse morphology in 
neurons derived from mutant FUS patient and control WT iPSC lines. We first assessed the 
dendritic morphology in iPSC neurons by analyzing the total length of dendrite outgrowth, 
the number of processes and their branches, and quantifying the density of dendritic 
protrusions. In order to validate these findings, we explored the effect of expressing other 
ALS-associated FUS mutations on neurite outgrowth of transiently transfected WT iPSC-
derived neurons. Lastly, we investigated the abundance and distribution of several pre- 
and post-synaptic proteins. 
Mutant FUS neurons demonstrate a reduction in total number and length of 
dendrites and the complexity of their dendritic arbor compared to WT neurons. FUS 
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neurons also show a reduction in the number of dendritic protrusions compared to WT 
neurons. Interestingly, mild variability in the neuronal morphology between the two cell 
lines derived from both the control and mutant FUS case. WT1 neurons had a greater 
number of dendritic protrusions compared to WT2 neurons. While both FUS iPSC lines 
had comparable mean outgrowth and processes, FUS2 neurons had more dendritic 
branches than FUS1 neurons. As discussed in Chapter 4, the FUS iPSC lines also showed 
variability in the cytoplasmic distribution of FUS protein. Since FUS regulates neuronal 
morphology, variation in the levels of FUS protein may lead to changes in dendritic 
morphology, but in this instance it is impossible to draw a causal connection. 
While we have shown that the expression of endogenous mutant FUS protein is 
associated with abnormal dendrite outgrowth and complexity, it is not known whether 
axonal morphology is equally affected in our iPSC-derived motor neurons. Previous 
studies have shown that not all neurite processes in iPSC-derived neurons are MAP2-
positive, with some overlap between MAP2 and TuJ1-positive neurites, but also some 
neurites staining exclusively for MAP2 or TuJ1 (Ricciardi et al., 2012). It would be of 
interest to carry out a more detailed neurite outgrowth analysis with combined MAP2 and 
TuJ1 staining, to determine whether expression of endogenous mutant FUS in iPSC-
derived motor neurons has a general effect on neuronal cytoskeleton, or whether it is 
specific to dendritic outgrowth. 
The expression of several other ALS-associated FUS mutants (Q519E, R514G and 
R521G) in neurons derived from the WT2 iPSC line also showed a 50% reduction in the 
total length of neurites. Interestingly, while the expression of FUS K510X leads to reduced 
neurite outgrowth compared to the expression of EGFP only, the amount of neurite 
outgrowth was not significantly different from the amount of neurite outgrowth in 
neurons expressing FUS WT. The K510X mutation generates truncated FUS protein lacking 
the nuclear localisation signal and is associated with almost exclusive cytoplasmic 
localisation (Vance et al. 2013). This observation suggests that the abnormal neuronal 
morphology associated with mutant FUS may be mediated by the nuclear localisation of 
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the mutant protein. Intriguingly, a recent genetic study discovered a novel mutation in 
CREST, a gene that encodes a neuronal chromatin remodeling complex component (Chesi 
et al. 2013). This study showed that CREST mutations inhibit activity-dependent neurite 
outgrowth and that CREST and FUS physically interact in mouse cortical neurons (Chesi et 
al. 2013). These findings and our observations suggest that mutations in CREST or FUS 
may impair interaction with other transcriptional regulators, resulting in transcriptional 
dysregulation, abnormal neurite outgrowth and subsequent motor neuron degeneration. 
It should be noted that there are limitations to studies involving the transient 
expression of proteins. The constructs used in this thesis have been published previously, 
and have shown similar levels of expression in primary cortical neurons and cell lines 
(Vance et al., 2009). We have not used immunoblotting to quantify the levels of transiently 
expressed wild-type and mutant HA-FUS protein here due to the low transfection 
efficiency and the large amount of protein required; therefore, we cannot confirm that WT 
and mutant protein are expressed at the same levels in the iPSC-derived neurons used in 
this study. Another issue to address is that in the Vance et al. (2009) study, all cells were 
used for experiments 1-2 days after transfection. As such, it is not known whether WT and 
mutant proteins have similar levels of stability. Despite these issues, we have observed a 
similar neurite outgrowth defect in iPSC neurons overexpressing ALS-associated FUS 
mutations. It would be of interest to confirm these data in other iPSC lines derived from 
patients with these mutations or to use genome editing technology to generate iPSC lines 
with these mutations, so as to study the effects of endogenous protein.   
Both mutant FUS and WT neurons demonstrate strong expression of the four pre- 
and postsynaptic proteins assessed in this study. This data indicate that iPSC-derived 
neurons exhibit a clustering of synaptic molecules and imply that these neurons are 
functionally mature and capable of synaptic activity. FUS and WT neurons show 
differences in the morphology of specific synaptic markers. The density of piccolo puncta 
and VGLUT1 puncta were comparable between WT and FUS neurons indicating that the 
synaptic active zone may be intact and the transport of glutamate vesicles are normal in 
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both lines.  In contrast, FUS neurons have a greater density of synapsin puncta compared 
to WT neurons. Synapsins are neuron-specific phosphoproteins that interact with synaptic 
vesicles and cytoskeletal proteins, regulating the neurotransmitter release in presynaptic 
neurons. Alterations in synapsin function result in abnormal neuronal activity and 
synaptic transmission (Llinás et al. 1991). Thus, FUS R521C-mediated alterations in the 
density of synapsin puncta may, in turn lead to aberrant synaptic transmission and 
contribute to the hyperexcitability observed in ALS patients and in FUS iPSC-derived 
neurons (Wainger et al. 2014). 
Mutant FUS neurons also have a greater density of PSD-95 puncta along their 
neurites compared to WT neurons. PSD-95 has previously been shown to play a role in 
regulating dendrite outgrowth and branching, in addition to its role in dendritic spine 
formation and the anchoring of synaptic signaling molecules. Charych et al. (2006) showed 
that overexpression of PSD-95 leads to a decrease in the number of secondary dendrites, 
whereas knockdown of PSD-95 resulted in an increase of primary and secondary 
dendrites (Charych et al. 2006). Thus, the change in the density of PSD-95 puncta in FUS 
neurons may be associated with the reduced neurite outgrowth observed in mutant FUS 
neurons.  
Increased immunoreactivity in PSD95 has previously been reported in 
postmortem brain samples from Alzheimer’s disease patients (Leuba et al. 2008). This 
study showed that the increased expression of PSD95 was specific, as expression of other 
pre- and postsynaptic proteins were unchanged. The change in PSD95 expression was 
accompanied by an increase in MAP2 expression (Leuba et al. 2008). Similarly, reductions 
in several pre- and postsynaptic markers are also observed in brain tissue from dementia 
patients (Kramer and Schulz-Schaeffer 2007). These results suggest that neurite and 
synaptic reorganisation may be a common feature of neurodegenerative disorders. 
It has previously been shown that in Alzheimer’s disease, the widespread loss of 
synapses is associated with enlargement of synaptic size, suggesting a compensatory 
response (Scheff et al. 1990). In this study, we have observed an increase in the density of 
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PSD95 puncta in mutant FUS neurons compared to WT neurons, which may reflect a 
compensatory response. Since mutant FUS neurons are also characterised by fewer 
dendritic processes than WT neurons, the few remaining dendrites may express more 
PSD95 or show increased clustering of PSD95 to compensate for the overall loss of 
synaptic contacts. A similar compensatory effect has been reported in hippocampal CA3 
pyramidal neurons of stressed rats, where increased density of spines were associated 
with decreased number of dendritic branches (Rao and Raju 1995). 
It is also possible that the increased density of synapsin I and PSD95 puncta in FUS 
neurons may reflect impaired degradation of these proteins. The degradation of PSD95 is 
mediated by the ubiquitin-proteasome system (UPS) (Colledge et al. 2003). Impairment in 
this protein degradation system as a result of toxic aggregation of SOD1 has been 
previously described in a SOD1 mouse model of ALS (Cheroni et al. 2005). It is possible 
that mutant FUS also impairs UPS function and that increased levels of PSD95 are due to 
impaired degradation.  Synapsin I expression is regulated by fucose-α(1-2)-galactose 
carbohydrates, as the binding of these carbohydrates to synapsin I inhibits degradation by 
calcium-dependent protease calpain (Murrey et al. 2006). A role for calpain-dependent 
cleavage has previously been implicated in several neurodegenerative disorders. Higher 
levels of calpains are observed in the motor neuron degeneration (mnd) mutant mouse, 
which exhibits progressive dysfunction of the spinal cord and brain (Li et al. 1998). In 
addition, calcium influx and the activation of calpain are involved in axonal degeneration 
(George et al. 1995). Alterations in the calpain system may affect expression levels of 
synapsin I, alter synaptic activity and could therefore contribute motor neuron 
degeneration. 
In summary, we have investigated the effects of mutant FUS on of neurite 
outgrowth, arborisation, dendritic protrusion and synapse morphology in neurons derived 
from patient iPSC lines. iPSC-derived neurons expressing R521C mutant FUS show a 
reduction in the length and complexity of neurites and dendritic protrusions. This effect 
was also seen following the expression of several other ALS-associated FUS mutations in 
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neurons derived from the WT iPSC line which confirms that this phenotype is associated 
with mutant FUS. In addition, mutant FUS neurons display abnormal synapses and 
significant alterations in the abundance and localisation of PSD-95 and synapsin. 
Therefore, the FUS R521C mutation is associated with abnormal neuronal and synaptic 
morphology which may well have a detrimental effect on neuronal health in motor 







6.1 SUMMARY  
The experiments described in this thesis used human stem cells derived from ALS 
patients to explore the effects of ALS causing FUS mutations on neurons as a model of 
disease and to investigate the mechanisms underlying disease pathogenesis (Fig. 6.1). I 
have shown that differentiated motor neurons expressing mutant FUS at physiological 
levels recapitulate several key features of FUS-associated ALS pathology. 
 
 
Figure 6.1 Schematic of patient-specific iPS cellular model of FUS-associated ALS (Figure 
adapted from Kiskinis et al., 2014). 
 
Our initial hypothesis for the project was to determine whether mutant FUS 
protein in iPSC-derived neurons would show a similar propensity to mislocalise and 
aggregate as had previously been shown in transfected cell lines and primary neurons 
(Vance et al. 2013). Neurons and neural progenitors derived from mutant FUS iPSCs show 
a shift in FUS protein abundance from the nucleus to the cytoplasm and the recruitment of 
FUS protein into cytoplasmic stress granules following oxidative stress. Neural 
progenitors derived from mutant FUS iPSCs have an increased propensity to undergo 
spontaneous apoptotic cell death compared to those derived from WT iPSCs. Furthermore, 
mature neurons expressing mutant FUS exhibited an abnormal axo-dendritic morphology 
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and differences in localization of certain synaptic proteins, which may contribute to 
neurodegeneration in ALS. 
 
6.2 FUS MISLOCALISATION AND AGGREGATION 
I have shown that neurons differentiated from mutant FUS iPSC lines show a 
significant increase in FUS protein levels in the cytoplasm and decreased levels in the 
nucleus compared to neurons differentiated from control WT iPSC lines. A 1.3 fold or more 
of cytoplasmic FUS expression was consistently found in mutant FUS neurons than in WT 
neurons. Mutant FUS neurons also had lower levels of nuclear FUS than WT neurons, 
although one mutant FUS line did not quite reach statistical significance. I have also shown 
that mutant FUS protein is redistributed into cytoplasmic stress granule in neural 
progenitors differentiated from mutant FUS iPSC lines following acute oxidative stress. 
Mutant FUS neural progenitors had at least 3.7-fold or more FUS particles that colocalised 
with PABP1 particles compared to WT neural progenitors. In addition, mutant FUS neural 
progenitors consistently had 4-fold more FUS-positive granules and double the number of 
stress granules than WT neural progenitors. 
These findings are consistent with studies using transfected cell lines, primary 
neurons and patient fibroblasts (Bosco et al. 2010; Dormann et al. 2010; Vance et al. 
2013). These studies demonstrated that ALS-linked FUS mutations disrupt the nuclear 
localizing signal to impair nuclear import, resulting in increased cytoplasmic localization 
of FUS protein and decreased nuclear FUS. Furthermore, they showed that oxidative stress 
recruits mutant FUS to cytoplasmic stress granules (Bosco et al. 2010; Dormann et al. 
2010; Vance et al. 2013).  Pathologic inclusions in ALS patients with FUS mutations and 
FTD-FUS patients also contain marker proteins of stress granules (Dormann et al. 2010), 
providing support for its relevance to ALS pathology. It is believed that these two 
pathological hits, nuclear import defects and cellular stress, are involved in the 
pathogenesis of ALS through the formation of cytoplasmic aggregates, which sequester 
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FUS, disrupt RNA processing and initiate motor neuron degeneration (Dormann et al. 
2010; Vance et al. 2013). 
Our findings show that mutant FUS protein in iPSC-derived neurons and neural 
progenitors also mislocalise and aggregate in a similar manner to transfected cells. We 
also found that mutant iPSC-derived neural progenitors show differences in the 
abundance of stress granules compared to WT iPSC-derived neural progenitors following 
oxidative stress. This observation is in line with a previous report showing that expression 
of mutant FUS is associated with increased stress granule size and number and a toxic gain 
of function mechanism of mutant FUS in stress granule dynamics and cellular stress 
response (Baron et al. 2013) 
 
6.3 CELLULAR TOXICITY AND VULNERABILITY 
I have found that mutant FUS neural progenitors showed an increase in 
spontaneous and acute oxidative stress induced apoptotic cell death. In untreated cultures, 
mutant FUS neural progenitors had more than double the percentage of cells undergoing 
early apoptotic cell death and approximately double the percentage of cells undergoing 
late apoptotic cell death compared to WT neural progenitors. After acute treatment with 
arsenite, mutant FUS neural progenitors also had greater percentages of cells undergoing 
early apoptotic cell death, although only one mutant FUS line reached statistical 
significance. Mutant FUS neural progenitors also had greater percentages of cells 
undergoing late apoptotic cell death compared to WT neural progenitors following acute 
arsenite treatment, but this difference was not significant. 
The toxicity of FUS-related neurodegeneration has been reported in a number of 
animal models. Expression of human FUS in yeast causes the formation of FUS 
immunoreactive aggregates and cytotoxicity (Fushimi et al. 2011; Sun et al. 2011). 
Similarly, transgenic models of FUS expression in the fruit fly, nematode, zebrafish, rat and 
mouse have established that elevated levels of WT and mutant FUS results in motor 
defects and neurodegeneration (Chen et al. 2011; Huang et al. 2011; Kabashi et al. 2011; 
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Lanson et al. 2011; Murakami et al. 2011; Mitchell et al. 2013). Although some suggest that 
the toxic aggregation of FUS protein is necessary to confer toxicity, others have found that 
knockdown of FUS also leads to neurodegeneration (Kabashi et al. 2011; Wang et al. 
2011). Thus, there is evidence for both gain of toxic function and loss of function 
mechanisms underlying FUS-mediated neurodegeneration. 
As shown by FACS analysis, mutant FUS neural progenitors exhibited increased 
spontaneous and acute oxidative stress induced apoptotic cell death, suggesting selective 
cellular toxicity of the mutation in neural progenitors. It is not known how physiological 
levels of mutant FUS leads to cellular toxicity. Apoptosis of neural progenitors is regulated 
by pro- and anti-apoptotic signaling factors, including an inhibitor of atypical PKCζ, 
prostate apoptosis response 4 (PAR-4) (Bieberich et al. 2003). Overexpression of FUS has 
previously been shown to promote growth inhibition and apoptosis of prostate cancer cell 
by altering the levels of proliferative and anti-proliferative factors (Brooke et al. 2011). 
Whether this finding translates to neuronal cell types is not known. An understanding of 
the effect of mutant FUS on pro- and anti-apoptotic signaling factors might be relevant to 
ALS since cellular models of ALS indicate that cells expressing mutant proteins are likely 
to die by apoptosis (Lee et al. 2013). 
 It may also be of interest to investigate the consequences of increased spontaneous 
cell death in mutant FUS neural progenitors. In human cortical development, neurons are 
produced temporally by the sequential generation of preplate neurons, deep layer 
neurons, followed by the superficial layers. In order to generate these diverse neuronal 
cell types, a pool of cortical progenitors are maintained during development by 
asymmetric divisions. The spinal cord also consists of diverse neuronal cell types, which 
differentiate from progenitor cells according to inductive signals (Ericson et al., 1997). 
Increases in spontaneous cell death may affect the maintenance of the pool of progenitors, 
subsequently altering the generation of different neuronal subtypes and neural circuits to 




 6.4 NEURITE OUTGROWTH 
I have shown that mutant FUS neurons demonstrate a reduction in total length and 
number of neurites compared to WT neurons. Motor neuron-containing neural 
populations derived from mutant FUS iPSC lines had ~50% decrease in the mean 
outgrowth per cell, ~40% decrease in the number of dendritic processes and ~50% 
decrease in the number of dendritic branches compared to WT motor neuron-containing 
neural populations. In addition, the expression of several other ALS-associated FUS 
mutants (Q519E, R514G and R521G) in WT neurons also showed a 50% reduction in the 
total length of neurites.  
An important next step is to understand the role of mutant FUS in mediating these 
structural differences and the functional consequences of such abnormalities. Defects in 
neurite outgrowth have previously been reported in several FUS and TDP-43 animal and 
iPSC models of ALS (Kabashi et al. 2011; Egawa et al. 2012). Reduced axonal outgrowth 
and branching in zebrafish is associated with a deficient touch-evoked escape response 
(Kabashi et al. 2011). Thus, reduced neurite outgrowth may impair the strength and 
stability of connections between neurons in the central nervous system and at the NMJ, 
which may in turn contribute to ALS. 
Neurite outgrowth depends on a complex interplay between extracellular guiding 
cues and intracellular signaling pathways. Extracellular cues are detected by molecules 
expressed on the surface of neurons, and transduced to activate cell signaling and gene 
transcription inside the cell (Hansen et al. 2008). This interplay results in alterations in 
cytoskeletal dynamics and membrane trafficking that generates neurite outgrowth. There 
are several ways by which mutant FUS could affect neurite outgrowth. Based on its role in 
RNA transport and local translation, FUS could alter the normal expression of cell surface 
molecules or signal transduction components and thereby impair the detection and 
transduction of extracellular cues. Alternatively, it could reduce the transcription of 
cytoskeletal molecules to reduce the scaffolding required for neurite outgrowth.  
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FUS depletion has been shown to down-regulate a number of genes involved in cell 
surface receptor linked signal transduction, including the cadherins and neuroligins 
(Lagier-Tourenne et al. 2012). They also showed that FUS binding is enriched for mRNA 
encoding structural components in neuronal projections, such as neurofilaments and 
microtubule-associated protein tau (Lagier-Tourenne et al. 2012). Whether ALS-linked 
FUS mutants impact the expression of these proteins in the same way is unknown. 
However, Hoell et al. (2011) showed that the RNA binding pattern of FUS reflects its 
subcellular localization. While mutant FUS proteins maintained their RNA-binding 
capability and specificity, mutant FUS proteins had an increased interaction with 
cytoplasmic RNA targets compared to WT FUS (Hoell et al. 2011). These findings suggest 
that ALS-linked FUS mutants that lead to a decrease in nuclear FUS and an increase in 
cytoplasmic FUS might alter RNA transcription, editing, trafficking and translation of 
genes involved in regulating neurite outgrowth. We have not investigated this hypothesis 
in this thesis due to time limitations; however, it is an important question to address and 
may explain the specific vulnerability of motor neurons to FUS mutations. 
Altered neuronal microRNA biogenesis may be another mechanism through which 
mutant FUS gives rise to abnormal neuronal morphology. MicroRNAs are small non-coding 
RNAs that function in translational regulation. MicroRNAs are brain-enriched and have a 
key role in neuronal development and neurodegeneration (Nelson et al. 2008). FUS was 
recently shown to participate in the biogenesis of a specific subset of neuronal microRNAs 
(Morlando et al. 2012). The reduction of FUS in the nucleus would inhibit the association 
of FUS and target microRNAs, as well as the association of FUS and Drosha, a protein 
necessary for the processing of microRNAs (Morlando et al. 2012). Reduced nuclear FUS, 
due to mutations affecting the nuclear localisation signal, could affect the processing of 
microRNAs, leading to translational dysregulation and abnormal neurite outgrowth. 
It must also be noted that other ALS-linked mutants have been implicated in 
neuronal morphology. Mutations in the neuronal chromatin remodeling complex 
component CREST, which inhibits activity-dependent neurite outgrowth, were recently 
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identified in ALS patients, (Chesi et al. 2013). Similarly, mutant TDP-43 iPSC-derived 
motor neurons show reduced neurite outgrowth and a decrease in expression of genes 
encoding components of cytoskeletal intermediate filaments and neurofilaments (Egawa 
et al. 2012). Both TDP-43 and CREST are known to interact with FUS. Taken together, 
these studies suggest a link between reduced neurite outgrowth and ALS-linked genetic 
mutations. Alterations in the cytoskeleton may have a tremendous impact on a cell such as 
the motor neuron, due to its highly polarised morphology and vast axonal length. 
Therefore, an important avenue to explore is the impact of genetic mutations on the 
factors that regulate neurite outgrowth, in order to find the mechanistic basis responsible 
for this abnormal neuronal morphology. 
 In this study, we have found that neurons derived from mutant FUS iPSCs show 
reduction in the number and length of neurites, and that the expression of other ALS-
associated FUS mutants in WT neurons also leads to a reduction in the length of neurites. 
These abnormalities might be expected to impair the strength and stability of connections 
between neurons in the central nervous system and at the NMJ. Several lines of evidence 
provide support for a role of FUS in the regulation of neuronal morphology. Hippocampal 
neurons from FUS-deficient mice have irregularly branched dendrites and abnormal 
axonal processes (Fujii et al. 2005). Similarly, knockdown of FUS in hippocampal neurons 
also results in reduced axon length and abnormal growth cone morphology (Orozco et al. 
2012).  Defects in neurite outgrowth have previously been reported in several FUS and 
TDP-43 animal and iPSC models of ALS, as well as primary mouse cortical neurons 
(Kabashi et al. 2011; Egawa et al. 2012; Groen et al. 2013). Since motor neurons are the 
most polarized cells in the body, with some axons reaching a meter in length, abnormal 
neuronal morphology might be especially relevant to ALS.   
 
 6.5 SYNAPTIC MORPHOLOGY AND TRANSMISSION 
Another observation I made was that neurons differentiated from mutant FUS iPSC 
lines exhibited abnormal synaptic spine abundance and morphology. Mature neurons 
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derived from mutant FUS iPSC lines showed a decrease in the density of dendritic 
protrusions compared to mature neurons derived from WT iPSC lines. They also show an 
alteration in the abundance of two of the synaptic proteins investigated in this study. In 
particular, mature neurons derived from mutant FUS iPSC lines showed a greater density 
of synapsin and PSD95 puncta along dendrites compared to mature neurons derived from 
WT iPSC lines. Such alterations are likely to affect synaptic transmission For instance, an 
increase in numbers of synaptic puncta is observed in late phase long-term potentiation, a 
strengthening of synaptic efficacy is believed to be an important cellular mechanism for 
memory formation (Bozdagi et al. 2000).   
There is strong evidence for disturbances in synaptic physiology in ALS. 
Fasciculations, which are spontaneous involuntary muscle fibre contractions are a key 
diagnostic sign of lower motor neuron dysfunction in ALS and indicate that there are 
major disturbances in membrane excitability. Ultrastructural examination of muscle 
biopsies from ALS patients shows increased calcium and increased numbers of synaptic 
vesicles (Siklos et al. 1996). Aggregated synaptic vesicles are also observed in the motor 
cortex of ALS patients (Sasaki and Iwata 1996). These significant synaptic changes occur 
throughout the motor system and imply major synaptic dysfunction in the central and 
peripheral nervous system. 
There is further evidence from animal models that disturbed physiology plays an 
important part in the disease process. Slice preparations from transgenic SOD1 mice 
exhibit motor neuron hyperexcitability, enhanced spontaneous excitatory and inhibitory 
transmission (van Zundert et al. 2008). Hyperexcitability, along with reduced synaptic 
fidelity has also been shown in transgenic TDP-43 zebrafish (Armstrong and Drapeau 
2013). Similarly, transgenic FUS zebrafish exhibit a motor phenotype with reduced 
synaptic fidelity and reduced NMJ transmission (Armstrong and Drapeau 2013). These 
data have recently been recapitulated in iPSC models of ALS. Wainger et al. (2014) 
reported that motor neurons from iPSC lines derived from patients with SOD1, FUS and 
C9ORF72 mutations exhibit hyperexcitability, possibly due to altered ratios of ion 
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channels. Patient-specific iPSC-derived neurons could provide an important opportunity 
to investigate how defects in synaptic transmission may contribute to motor neuron 
degeneration. 
One way by which mutant FUS could contribute to alterations in the density of 
PSD95 and synapsin puncta is by impairing transport and localised translation of mRNA. 
FUS has previously been implicated in the activity-dependent transport of mRNA to 
dendritic spines, which are the major sites of synaptic transmission. Upon glutamatergic 
activation, there is an increase in the dendritic localisation of the ND1-L mRNA transcript, 
which encodes an actin-stabilising protein (Fujii and Takumi 2005). FUS-deficient 
hippocampal neurons show a reduction in the ND1-L transcript the dendrites following 
glutamatergic activation, and may regulate neuronal actin cytoskeleton by supplying Nd1-
L mRNA to the local translational machinery in dendrites (Fujii and Takumi 2005).  
It is not known whether this activity-dependent transport is transcript-specific or 
a general mechanism for local translation. Since FUS has been shown to bind to thousands 
of mRNA species, it may be that FUS participates in the general transport of synaptic 
mRNA to dendritic spines. An important question to address is whether FUS mutations 
may affect the transport of transcripts critical for synaptic function. It has recently been 
shown that ALS-linked TARDBP mutations lead to impaired transport of RNA granules in 
motor neuron axons (Alami et al. 2014). It is therefore possible, that FUS mutations also 
impact the transport of RNA granules in motor neuron dendrites to alter local translation 
of synaptic components. 
Another way that mutant FUS could contribute to alterations in the density of 
synaptic puncta is by promoting the translation of their transcript. Components of the 
translation machinery are located in dendritic spines, and local protein synthesis in 
dendrites is required for the rapid enhancement of synaptic transmission induced by 
exposure to the growth factor BDNF (Santos et al. 2010). FUS is localized in APC-RNP 
granules in cellular protrusions (Yasuda et al. 2013). These granules target RNA to cell 
protrusions for the translation of associated transcripts. The expression of FUS mutations 
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facilitated the formation of granules, which were also the sites for local translation 
(Yasuda et al. 2013). Another question to address is the effect of FUS mutations in a 
neuronal context, whether the local translation of transcripts is impaired in neurite 
protrusions of ALS motor neurons. 
In this study, we have found that mature neurons derived from mutant FUS iPSCs 
show alterations in the density of synapsin and PSD95 puncta. These abnormalities might 
be expected to perturb synaptic physiology and neuronal transmission. Wainger et al. 
(2014) recently reported that motor neurons derived from mutant FUS iPSCs, as well as 
mutant SOD1 and C9ORF72 iPSC lines, were hyperexcitable compared to motor neurons 
derived from WT iPSCs. They further described sensitivity to potassium channel agonists 
across these mutant iPSC lines (Wainger et al. 2014). It is not known how these different 
genetic mutations converge to give rise to hyperexcitability. However, this phenotype 
appears to be broadly relevant to familial ALS, and may also relate to the major 
disturbances in membrane excitability found in ALS patients. 
 
6.6 IPSCS AS A TOOL FOR DISEASE MODELLING 
This study used human stem cells derived from an ALS patient and age-matched 
control individuals to explore the effects of ALS causing FUS mutations on neuronal 
populations as a model of disease and to explore underlying disease mechanisms. I have 
shown that differentiated motor neurons and neural progenitors expressing mutant FUS 
at physiological levels recapitulated several key features of FUS-associated ALS pathology. 
Neurons and neural progenitors derived from mutant FUS iPSCs show a shift in FUS 
protein abundance from the nucleus to the cytoplasm and the recruitment of FUS protein 
into cytoplasmic stress granules following oxidative stress. Neural progenitors derived 
from mutant FUS iPSCs have an increased propensity to undergo spontaneous and 
oxidative stress induced apoptotic cell death compared to those derived from WT iPSCs. 
Furthermore, neurons expressing mutant FUS exhibited a reduction in total number and 
length of neurite outgrowth and dendritic protrusions. Mature neurons derived from 
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mutant FUS iPSCs also show abnormal synaptic morphology, with alterations in the 
density of PSD95 and synapsin puncta along dendrites. 
Since the initiation of this project, several studies have described iPSC models of 
ALS, using fibroblasts from patients with mutations in TARDBP, C9ORF72 and SOD1. We 
have previously shown that motor neurons derived from an ALS patient carrying a TDP-43 
mutation recapitulated several cellular and molecular abnormalities associated with ALS 
pathology, including mislocalisation from the nucleus to the cytoplasm, protein 
fragmentation, the formation of insoluble TDP-43 aggregates and spontaneous cell death 
in prolonged culture (Bilican et al. 2012). Subsequently, Egawa et al. (2012) reported the 
same cellular phenotypes in iPSC lines derived from multiple patients with TDP-43 
mutations and identified a compound that rescued the abnormal ALS phenotype.  
Almeida et al. (2013) was the first to report an iPSC model of C9ORF72 ALS and 
showed that perturbation in autophagy may contribute to pathogenesis. Another study 
quickly followed and reported abnormal electrophysiology in motor neurons 
differentiated from C9ORF72 iPSCs and the use of antisense oligonucleotides to rescue the 
motor neuron phenotype (Sareen et al. 2013).  
Recently, two independent groups combined iPSC technology with genome editing 
to study SOD1 iPSCs and determine the pathogenicity of the mutation. Chen et al. (2014) 
identified abnormal dysregulation of neurofilament and neurite degeneration due to SOD1 
mutations; whereas Kiskinis et al. (2014) found mitochondrial defects, along with 
induction of ER stress and unfolded protein response pathways. Importantly, both showed 
the prevention of these phenotypes by the genetic correction of the SOD1 mutation (Chen 
et al. 2014; Kiskinis et al. 2014). For the first time, this enabled the demonstration of 
causal connections between mutations and functional phenotypes. 
 To our knowledge, this study is the first to describe an iPSC model of ALS using 
fibroblasts from a patient with FUS mutation. Similar to the aforementioned studies, our 
iPSC model of FUS ALS also recapitulated several cellular abnormalities associated with 
ALS pathology, namely mislocalisation and aggregation of FUS protein and spontaneous 
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apoptotic cell death. Our finding that mature neurons derived from mutant FUS iPSCs 
exhibited abnormal axo-dendritic and synaptic morphology suggests that FUS mutations 




The current study was limited by the cellular resource as we had access to two 
iPSC lines derived from a single patient carrying the FUS R521C mutation and two iPSC 
lines from unrelated age-matched control individuals. All lines were generated from 
fibroblasts and reprogrammed in the same laboratory at the same time using an identical 
methodology. Despite these limitations, we were able to identify FUS-specific disease 
phenotypes in the FUS R521C lines and undertake an early exploration of pathogenic 
mechanisms. We have now generated three subclones of another iPSC line from a patient 
with the FUS R514G mutation and have recently begun to carry out cell-lineage and 
functional studies, as well as characterizing ALS-associated phenotypes in these lines. 
Unfortunately time constraints do not permit the generation of sufficient replicated data 
to be included in this thesis. 
Another limitation of this project is phenotypic variability arising from in vitro 
differentiation. We and others working in the field consistently observe heterogeneity of 
cellular populations through all stages of differentiation. It is possible that subtle 
differences in the percentage of cells at different stages of maturation could result in non-
cell autonomous effects that are not accounted for. When this study began, we used an 
established protocol for differentiation of iPSCs to motor neurons that eliminated the use 
of stromal feeders or embryoid bodies (Bilican et al. 2012). In all of our experiments, we 
observed that HB9-positive motor neurons comprised 20-30% of the population after 
differentiation. One way to enrich for motor neurons is to transfect or transduce neuronal 
cultures with a reporter containing a fluorescent protein under the control of a motor 
neuron-specific promoter (such as HB9), then using FACS to purify motor neurons.  We 
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decided against this strategy due to the time, costs and small number of surviving cells left 
to conduct experiments. Alternatively, a recent study reported a highly efficient motor 
neuron differentiation of iPSCs, which uses three small molecule inhibitors of BMP type I 
receptors ALK2 and ALK3, ALK5, ALK4, ALK7 and GSK-3, to differentiate pluripotent stem 
cells to neuroepithelia, which were then treated with retinoic acid and purmorphamine to 
generate a population of differentiated cells in which ~90% were post-mitotic motor 
neurons (Chen et al. 2014). Thus, recent advances in motor neuron differentiation will 
enable the derivation of more homogenous cultures and may further reduce the source of 
variability. 
It must be mentioned that this study aimed to model a neurodegenerative disorder 
with an average age of onset of 50 years. Clearly, the few months of cell culture do not 
compare to 50 years of aging in the adult nervous system. A potential strategy to address 
this limitation is to promote premature aging in cell culture. Hutchinson-Gilford progeria 
syndrome (HGPS) is a human premature ageing disease that is caused by a single point 
mutation in the lamin A gene (LMNA) (Eriksson et al. 2003). Mutations in LMNA result in 
the production of a shorter transcript known as progerin. Miller et al. (2013) showed that 
the overexpression of progerin RNA induces multiple aging-related processes and 
characteristics in iPSC-derived neurons. Furthermore, this study reported multiple 
progerin-induced neurodegenerative phenotypes in Parkinson’s disease patient iPSC-
derived neurons that were not observed otherwise (Miller et al. 2013). In a similar 
manner, overexpression of progerin RNA in mutant FUS iPSC-derived neurons could be 
used to accentuate ageing-related processes and provide a model of FUS-ALS with 
premature ageing. This would allow us to interrogate the contributions of mutant FUS and 
age-related processes to neurodegeneration and provide additional insights into the 
molecular mechanisms underlying ALS. 
 
 6.8 FUTURE DIRECTIONS 
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The cellular model presented in this thesis provides a novel tool to study the 
pathogenesis of ALS that is associated with FUS mutation. An important and obvious 
application of this resource is in its use for therapeutic discovery and drug toxicity studies. 
The identification of disease-specific phenotypes in neurons derived from FUS R521C iPSC 
lines could be used for compound screening assays for the reversal of ALS phenotypes 
such as cytoplasmic mislocalisation and FUS aggregation. These could be used in parallel 
with neurons derived from other mutant iPSC lines and from SALS patients to enable the 
identification of compounds that could be effective across a spectrum of ALS pathologies. 
In addition to the discovery of drugs that will reverse disease phenotypes, it is also 
important to evaluate the toxicity of potential compounds. This may be addressed by 
combining patient-specific iPSC lines with methods of directed differentiation of iPSCs to 
cardiomyocytes and hepatocytes, which are clinically important cell types for studies of 
drug toxicity (Dick et al. 2010). Failures in clinical trials as a result of imperfect models, 
such as the animal models which differ genetically and anatomically from humans, would 
be avoided. These efforts would reduce the time and costs of clinical trials. 
Another avenue that merits further investigation is the electrophysiological 
properties of neurons derived from mutant FUS iPSC lines. In this thesis, we have 
described several synaptic morphological differences between neurons derived from 
mutant FUS and WT iPSC lines, namely increased density of PSD95 and synapsin puncta. 
We were unable to analyse the functional consequences, if any, of these differences due to 
time constraints. Neurophysiological recordings would enable the evaluation of a number 
of basic physiological characteristics of FUS mutant expressing neurons, such as action 
potential firing rate and spike morphology. Whole-cell patch clamp recordings would 
allow for a more in-depth investigation of electrophysiological properties and health, such 
as membrane potential, action potential threshold, as well as specific currents which 
determine neuronal membrane excitability. In addition, calcium imaging may also be used 
as a measure of neuronal electrical activity. Changes in neuronal calcium concentrations 
may reflect changes in a number of ion channels and neurotransmitter receptors. These 
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measures may then be combined with molecular biology techniques to verify whether 
particular channels or receptors are differentially expressed in mutant and WT neurons to 
contribute to perturbed synaptic morphology. 
An interesting observation is the increase in the number of stress granules 
following arsenite treatment in FUS R521C neural progenitors. Mutant FUS has been 
shown to affect the dynamics of stress granules, such as the time required for assembly 
and resolution, the number and size of granules, and the binding affinity of stress granule 
proteins TIA1 and G3BP (Baron et al. 2013). The formation of stress granules is triggered 
by environmental stressors. These foci are composed of a number of ribonucleoproteins, 
including initiation factors, RNA-binding proteins, transcription factors and other 
molecules. Thus, another direction that warrants attention is the properties of stress 
granules in FUS R521C and WT neurons. It could be useful to assess the size of stress 
granules and to study the assembly and disassembly of stress granules in FUS R521C and 
WT neural progenitors. Differences in these properties may reflect changes in the binding 
affinity of mutant FUS for stress granule components. A comparison of stress granule-
associated proteins, especially those implicated in ALS and other neurodegenerative 
disorders, in FUS R521C and WT neural progenitors could provide insight into how FUS 
mutations contribute to neurodegeneration by altering the dynamics of the stress 
granules. 
FUS R521C iPSC lines may also be of value in the study of neurodegenerative 
conditions with FUS pathology, including FTD, Huntington’s disease and spinocerebellar 
ataxia. The differentiation of these iPSC lines into the neuronal cell types affected in these 
conditions may allow us to gain insight into the cellular processes underlying these 
disorders. Comparisons of cortical neurons and motor neurons differentiated from these 
lines may also shed light on the link between FTD and ALS and how FUS contributes to the 





In this thesis we have shown that mutant FUS iPSCs recapitulate key aspects of 
FUS-ALS pathology, including mislocalisation of FUS protein, redistribution of FUS protein 
into stress granules and a propensity to undergo apoptotic cell death. Furthermore, 
neurons differentiated from mutant FUS iPSCs exhibit abnormal neuronal and synaptic 
morphology, such as reduced neurite outgrowth and altered density of selective synaptic 
molecules. We acknowledge the limitations of studying one mutation in iPSCs derived 
from a single patient and similar studies in iPSCs from patients with other FUS mutations 
combined with genome editing technology to reverse the genomic mutation would 
provide further support for the pathogenicity of these mutations. The study of the factors 
that regulate neurite outgrowth and synaptic transmission in neurons differentiated from 
patient-derived iPSCs could help to elucidate the exact role that they have in the 
pathogenesis of ALS. This model may also be used for drug screening and the discovery of 
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